1	Physical activity and kinesiophobia: A systematic review and meta-analysis
2	
3	Miriam Goubran, PhDc ¹ , Ata Farajzadeh, OT, PhDc ¹ , Ian M. Lahart, PhD ² , Martin Bilodeau, PT,
4	PhD ^{1,3} , Matthieu P. Boisgontier, PT, PhD ^{1,4,*}
5	
6	¹ School of Rehabilitation Sciences and ² Human Kinetics, Faculty of Health Sciences, University
7	of Ottawa, Canada
8	³ Faculty of Education, Health and Wellbeing, Institute of Human Sciences, University of
9	Wolverhampton, Wolverhampton, UK
10	⁴ Perley Health Centre of Excellence in Frailty-Informed Care, Ottawa, Canada
11	*Corresponding author: matthieu.boisgontier@uOttawa.ca

1	2

Kinesiophobia and Physical Activity: A Systematic Review and Meta-Analysis

- 13
- 14

ABSTRACT

Objective. Physical activity contributes to the primary, secondary, and tertiary prevention of multiple diseases. However, in some patients, an excessive, irrational, and debilitating fear of movement (i.e., kinesiophobia) is thought to induce avoidance behaviors, contributing to decreased engagement in physical activity. The aim of this study was to examine whether kinesiophobia is negatively associated with physical activity in several health conditions and what factors may influence this relationship.

Methods. Five databases were searched for studies including both a measure of kinesiophobia and physical activity. Two reviewers screened articles for inclusion, assessed risk of bias, and extracted data from each study. Pearson product-moment correlations were pooled from eligible studies using the generic inverse pooling and random effects method to examine the relationship between kinesiophobia and physical activity.

Results. Seventy-four studies were included in the systematic review and 63 studies (83 estimates, 26 27 12,278 participants) in the main meta-analysis. Results showed a small-to-moderate negative 28 correlation between kinesiophobia and physical activity (r = -0.19; 95% confidence interval: -0.26 to -0.13; $I^2 = 85.5\%$; p < 0.0001). Funnel plot analysis showed evidence of publication bias, but p-29 30 curve analysis suggested that our results could not be caused by selective reporting. A subgroup 31 meta-analysis showed that the correlation was statistically significant in patients with cardiac, 32 rheumatologic, neurologic, or pulmonary conditions, but not in patients with chronic or acute pain. 33 Conclusion. Our results suggest that higher levels of kinesiophobia are associated with lower 34 levels of physical activity in several health conditions that are not necessarily painful.

35	Impact. Kinesiophobia should be dissociated from pain and considered in relation to specific
36	health conditions when implementing interventions to promote physical activity. Kinesiophobia
37	may have prognostic implications in patients for whom physical activity contributes to prevent
38	recurrence or worsening of their condition.
39	
40	Keywords. Exercise, Health Status; Pain; Prevention; Psychology; Rehabilitation

- 41
- 42 **Disclosures:** None

43

Kinesiophobia and Physical Activity: A Systematic Review and Meta-Analysis

- 44
- 45

INTRODUCTION

Seven decades ago, the seminal work of Morris et al. (1953)¹ showed that conductors on London 46 double-decker buses, who were responsible for checking tickets, assisting passengers with 47 48 luggage, and supervising the loading and unloading of passengers, had a lower incidence and less severe coronary heart disease than bus drivers. Since then, the scientific literature demonstrating 49 the health benefits of physical activity has grown exponentially and expanded to include multiple 50 health conditions². These benefits include reduced risk of disability, disease, and mortality^{2,3}. 51 Specifically, higher levels of physical activity have been shown to contribute to a reduced risk of 52 cardiovascular disease⁴, obesity⁵, depression⁶, hypertension⁷, cancer⁸, and dementia⁹. Yet, one in 53 four adults worldwide does not meet the recommendations for physical activity¹⁰. Physical activity 54 also plays an important role in secondary and tertiary prevention by reducing the impact, slowing 55 56 the progression, and preventing the recurrence of multiple health conditions, including cardiovascular disease^{11,12}, osteoarthritis¹³, stroke^{14,15}, and cancer¹⁶. 57

Several factors may explain physical inactivity¹⁷, including environmental, interpersonal, and 58 intrapersonal factors¹⁸. Environmental factors include lack of access, weather conditions, and 59 safety concerns¹⁹. Interpersonal factors include family responsibilities, lack of support, and lack 60 of a gym partner²⁰. Intrapersonal factors include gender²¹, age²², cognitive function^{23,24}, and 61 62 socioeconomic circumstances²⁵. Another intrapersonal factor of interest is kinesiophobia, which 63 can be defined as an excessive, irrational, and debilitating fear of movement and activity resulting from a sense of vulnerability to pain, injury, or a medical condition²⁶. Kinesiophobia is typically 64 65 measured using self-administered questionnaires, such as the Tampa Scale of Kinesiophobia

(TSK)^{27,28}, which assesses an individual's belief that physical activity can lead to injury or pain and that the severity of their medical condition is underestimated. While kinesiophobia is often observed in the context of pain or a clinical condition, its presence in otherwise healthy adults is also possible²⁹ due to the irrational nature of this phobic condition. The irrational fear that characterizes kinesiophobia is likely to influence the desires and impulses for movement and rest³⁰, as well as affective determinants of physical activity in general³¹.

The relationship between kinesiophobia and physical activity can be explained by theories 72 suggesting that the perception of a cue related to physical activity automatically activates the 73 74 concept of physical activity as well as the unpleasant (or pleasant) affective memories associated with this concept³²⁻³⁵. This activation results in an impulse that favors the tendency to avoid (or 75 approach) physical activity³⁶. Thus, negative affective associations are likely to hinder physical 76 activity. Accordingly, an aversive fear of pain, injury, or aggravation of a medical condition that 77 has been associated with the concept of movement may result in the development of automatic 78 79 avoidance behaviors that contribute to the maintenance and exacerbation of this fear, and ultimately lead to a phobic state (i.e., kinesiophobia) that diminishes the ability to engage in regular 80 physical activity. 81

Previous systematic syntheses of the literature on this topic include a meta-analysis³⁷ and two systematic reviews^{38,39}. The main results of these reviews suggest that exercise interventions may reduce kinesiophobia in individuals with back pain. While back pain is one condition that may contribute to kinesiophobia, it is not the only one. The relationship between physical activity and kinesiophobia should be investigated in other conditions such as cardiac, neurological, and rheumatologic conditions.

The main objective of this study was to systematically review and meta-analyze the direct 88 relationship between kinesiophobia and physical activity. We hypothesized that levels of 89 kinesiophobia would be negatively associated with levels of physical activity. In addition, we 90 examined the moderating effect of health status, physical activity measurement instruments (i.e., 91 accelerometers, pedometers, questionnaires), physical activity outcomes (e.g., total physical 92 93 activity, moderate or vigorous physical activity, steps per day), and kinesiophobia measurement instruments. Finally, because kinesiophobia and physical activity can vary with age, sex, and 94 pain^{40,41}, we explored the influence of these factors on the association between kinesiophobia and 95 96 physical activity.

- 97
- 98

METHODS

99 Search Strategy

100 This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines⁴². Potential studies were identified by searching the 101 MEDLINE (via PubMed), PsychInfo, CINAHL, EMBASE, and SPORTDiscus databases. In 102 October 2023, two reviewers (MG and AF) searched for all available records using the following 103 104 combination of keywords in the title or abstract of the article: ("kinesiophobia" OR "fear 105 avoidance" OR "fear of movement" OR "movement phobia" OR "movement fear") AND ("physical activity" OR "exercise" OR "walking"). In PsychInfo the limits "clinical trial", 106 107 "quantitative study", "peer-reviewed journal", "English", and "human" were used. In PubMed the limits "clinical trial", "observational study", "RCT", "English" were used. In SPORTDiscus the 108 limits "peer-reviewed", "English", "academic journal", and "article" were used. In CINAHL the 109

110	limits "peer-reviewed", "English", "research article", "journal article", and "humans" were used.
111	To reduce literature bias ^{43,44} , this systematic review was pre-registered in PROSPERO ⁴⁵ .
112	

113 Eligibility Criteria and Study Selection

114 Inclusion Criteria

To be included in this systematic review, articles had to be published in a peer-reviewed journal, be written in English, report original data collected from human participants, include at least one self-reported measure of kinesiophobia and one measure of physical activity, and formally test the association between these two variables, be it a univariate or multivariate test. The physical activity measure could be derived from a self-reported measure of the level of physical activity or from a device (e.g., accelerometer, pedometer) worn while participants are engaged in their normal daily activities.

122

123 *Exclusion Criteria*

Studies were excluded if they were published as a book chapter, study protocol, conference abstract, or were based on laboratory-based measures of physical fitness (e.g., maximal muscle force, $\dot{V}O_2$ max) and not on a measure of physical activity.

127

128 Study Selection

Article screening was performed in Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia; www.covidence.org), a web-based collaborative software platform that streamlines the production of systematic reviews. After removing duplicates, titles and abstracts were independently reviewed by two reviewers (MG, AF) according to the inclusion

and exclusion criteria using a systematic 5-step process. If there was any doubt at any step, the full 133 text was further reviewed. Step 1: Articles not written in English were excluded. Step 2: Articles 134 135 that did not report original empirical data were excluded (e.g., reviews, meta-analyses, commentaries, technical reports, case studies). Step 3: Articles that did not involve human 136 137 participants were excluded. Step 4: Articles that did not assess both kinesiophobia and physical 138 activity were excluded. Step 5: Articles that did not formally test the association between kinesiophobia and physical activity were excluded. In addition, we performed reference screening 139 and forward citation tracking on the articles remaining after step 5. Any disagreements between 140 the two reviewers were resolved by consensus among three reviewers (MG, AF, MPB). 141

142

143 **Data Extraction**

Data extracted from selected articles included first author's name, article title, publication year, digital object identifier (DOI), number of participants, number of men and women, age range, mean age, mean weight, mean height, mean body mass index, health status, mean pain intensity, type of kinesiophobia measure, level of kinesiophobia, type of physical activity measure, type of physical activity outcome, level of physical activity (continuous or categorical), as well as statistical estimates and significance of the association between kinesiophobia and physical activity.

151

152 Methodological Quality and Risk of Bias Assessment

The risk of bias of the studies included in the systematic review was estimated using the National
Institutes of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional
Studies⁴⁶, the Transparent Reporting of Evaluations with Non-Randomized Designs (TREND)

reporting checklist⁴⁷, and the Consolidated Standards of Reporting Trials (CONSORT) reporting checklist for randomized trials⁴⁸. All scores were normalized to a 0-10 scale to make them comparable across assessment instruments (Table 1).

159

160 Meta-Analysis

All analyses were performed in R Studio integrated development environment (IDE)
(2023.06.1+524, "Mountain Hydrangea" release) for R software environment⁴⁹ using the {meta}⁵⁰
and {metafor}^{51,52} R packages⁵³.

164

165 *Main Meta-Analysis*

We pooled Pearson product-moment correlations from eligible studies to examine the relationship 166 between kinesiophobia and physical activity. Correlations were pooled using the generic inverse 167 pooling method via the 'metacor' function in the {meta} R package⁵⁰. This function automatically 168 performs a necessary Fisher's z-transformation on the original, untransformed correlations prior 169 to pooling. The 'metacor' function also reconverts the pooled association back to its original form 170 for ease of interpretation. Correlation estimates were nested within studies using the 'cluster' 171 172 argument to account for the dependencies between these estimates, resulting in a three-level metaanalysis (level 1: participants, level 2: correlation estimates, level 3: studies). The distribution of 173 variance across levels was assessed using the multilevel version of I²⁵⁴. The performance of the 2-174 level and 3-level meta-analyses was assessed and compared using the {metafor} R package^{51,52}. 175

We anticipated considerable between-study heterogeneity, and therefore used a random-effects model to pool correlations. The restricted maximum likelihood (RML) estimator⁵⁵ was used to calculate the heterogeneity variance Tau². In addition to Tau², to quantify between-study

heterogeneity, we report the I^2 statistic, which provides the percentage of variability in the 179 correlations that is not caused by sampling error⁵⁶. The I² statistic was interpreted as follows: 0-180 40%, may not be important; 30-60%, may represent moderate heterogeneity; 50-90%, may 181 represent substantial heterogeneity; and 75-100%, may represent considerable heterogeneity. To 182 reduce the risk of false positives, we used a Knapp-Hartung adjustment⁵⁷ to calculate the 183 184 confidence interval around the pooled association. We also report the prediction interval, which provides a range within which we can expect the associations of future studies to fall based on the 185 current evidence. The pooled correlation was interpreted using Cohen's conventions⁵⁸: $r \approx -0.10$, 186 187 small negative correlation; $r \approx -0.30$, moderate negative correlation; $r \approx -0.50$, large negative correlation. 188

189

190 *Publication Bias Assessment*

Publication bias was assessed using a funnel plot, which is a scatter plot of the studies' effect size 191 192 expressed as the Fisher's z transformed correlation on the x-axis against a measure of their standard error (which is indicative of precision of the study's effect size) on the y-axis. When there is no 193 publication bias, the data points in a funnel plot should form a roughly symmetrical, upside-down 194 195 funnel. Studies in the top part of the plot, which have lower standard errors, are expected to lie closely together, and not far away from the pooled effect size. In the lower part of the plot, studies 196 197 have higher standard errors, the funnel "opens up", and effect sizes are expected to scatter more heavily to the left and right of the pooled effect. Egger's regression⁵⁹ can be used to formally test 198 199 funnel plot's asymmetry. However, since there is no direct function to conduct Egger's test for 3-200 level models, we calculated it by using the standard errors of the effect size estimates as a predictor 201 in the meta-regression⁶⁰.

P-curve analysis⁶¹ was conducted to assess whether the distribution of the statistically significant 202 results was consistent with what would be expected if only true effects were present. When the 203 null hypothesis is true (i.e., there is no true effect), p-values are assumed to follow a uniform 204 distribution: highly significant effects (e.g., p = 0.01) are as likely as barely significant effects 205 (e.g., p = 0.049). However, when the null hypothesis is false (i.e., there is a true effect in our data), 206 207 p-values are assumed to follow a right-skewed distribution: highly significant effects are more likely than barely significant effects. A left-skewed distribution would suggest that some studies 208 used statistical tests to find significant results in ways that may not be reproducible or generalizable 209 210 (i.e., p-hacking).

211

212 Secondary Meta-Analysis

A secondary meta-analysis was conducted using the same approach, but based on Spearman's rho
values, to further test the relationship between kinesiophobia and physical activity.

215

216 Subgroup analyses and meta-regressions

Subgroup analyses were conducted to examine the differences in correlations between studies including participants with different health conditions and using different types of physical activity measures (i.e., device-based versus self-reported), physical activity measurement instruments (i.e., type of questionnaires, type of devices), physical activity outcomes, and kinesiophobia measures. Exploratory meta-regressions were conducted to examine if the average age of participants, the proportion of women, and pain in a study predicted the reported correlation between kinesiophobia and physical activity. Pain was normalized to a 0-100 scale to make the data comparable across

pain scales. A sensitivity analysis was conducted to examine whether the quality of the studiesaffected the results.

- 226
- 227

RESULTS

228 Literature Search

229 The primary search identified 3.015 potentially relevant articles from the five databases (Figure 1), including 912 duplicates. Of the 2,103 articles screened, disagreement occurred in 210 cases 230 (10%), all of which were resolved by consensus. All articles remained after step 1 as they were all 231 232 written in English. 1,133 articles were excluded in step 2 because they were irrelevant (n = 710) 233 or did not report original data (n = 423). No articles were excluded in step 3 because they all involved human participants. Eight hundred and fifty-two articles were excluded in step 4 because 234 they did not assess kinesiophobia (n = 117) or physical activity (n = 735). Seventy-seven articles 235 were initially excluded at step 5 because they did not formally test the correlation between 236 237 kinesiophobia and physical activity or did not report the estimate of this correlation. However, the corresponding authors of these articles were contacted by email to request the Pearson correlation 238 estimate of this association and the sample size used to calculate it. Nineteen authors replied to our 239 email: Eight authors provided raw data for 10 studies⁶²⁻⁷¹ and 11 authors provided the Pearson's 240 correlation estimate^{29,72-81}. In addition, the Pearson's correlation estimate of two articles were 241 calculated based on information reported in the article^{82,83}. This process reduced the number of 242 243 studies excluded at step 5 to 54, resulting in a total of 64 articles included from the databases.

Using reference screening and forward citation tracking, the authors identified 27 studies that assessed both physical activity and kinesiophobia, of which 8 reported an estimate of their relationship⁸⁴⁻⁹¹ and 19 did not⁹²⁻¹¹⁰. The corresponding authors of these 19 studies were asked by

- email to provide this estimate or their data. Two authors sent the estimate^{104,107}. Seventeen emails
 remained unanswered^{92-103,105,106,108-110}.
- 249

250 **Descriptive Results**

251 *Participants*

The 74 articles identified by the systematic review included a total of 13388 participants aged 11 to 85 years, including 7308 women, 4729 men, and 1351 participants whose gender and sex was not reported. The studies investigated populations with pain $(n = 37)^{62,64-71,73,76-81,83,88,89,111-128}$ cardiac conditions $(n = 6)^{86,87,104,129-131}$, surgery $(n = 8)^{63,131-137}$, arthritis $(n = 10)^{75,82,84,85,91,138-142}$, neurologic conditions $(n = 3)^{90,143,144}$, pulmonary conditions $(n = 3)^{145-147}$, cancer $(n = 1)^{74}$, women health conditions $(n = 2)^{72,148}$, as well as healthy adults $(n = 6)^{29,85,107,149-151}$ (Table 1).

258

259 Kinesiophobia

In 54 of the 74 studies, kinesiophobia was assessed using the 17-item TSK (TSK-17; n =260 38)^{29,62,64,65,68,72,73,77,84,85,90,91,111-114,117-120,122-125,130,133-135,138-144,146,148,150} shorter versions of the TSK 261 $[(TSK-11^{152}; n = 10)^{63,81,88,116,121,122,128,131,136,151}, (TSK-14; n = 1)^{74}, (TSK-13^{153}; n = 2)^{115,137}, (TSK-14; n = 1)^{74}, (TSK-13^{153}; n = 2)^{115,137}, (TSK-14; n = 1)^{74}, (TSK-14; n = 1)^{74},$ 262 7; n = 1)¹⁴⁵], or its adaptation for patients with coronary artery disease (TSK-Heart¹⁵⁴; n = 2)^{86,87}. 263 The TSK is a questionnaire that assesses the belief that movements can lead to (re)injury, pain, or 264 aggravation of an underlying and serious medical condition²⁸. Each item is rated on a Likert scale 265 266 ranging from 1 (strongly disagree) to 4 (strongly agree). On the TSK-17, a score of 37 is used to distinguish between low (\leq 37) and high (> 37) levels of kinesiophobia²⁷. On the TSK-13, scores 267 inferior to 23 are considered sub-clinical¹⁵⁵. The other measures that were used are the Fear-268 Avoidance Belief Questionnaire¹⁵⁶ (FABQ; n = 15)^{66,67,69-71,76,78-80,82,83,104,126,127,132}, Kinesiophobia 269

Causes Scale¹⁵⁷ (KCS; n = 2)^{107,149}, the Fear of Activities in Situations scale (FActS; n = 1)¹²⁹, the Brief Fear of Movement Scale for Osteoarthritis¹⁵⁸ (BFMSO; n = 1)⁷⁵, and Breathlessness Beliefs Questionnaire (BBQ; n = 1)¹⁴⁷.

Sixty-four studies reported mean levels of kinesiophobia (Table 1). The studies based on the TSK17 or TSK-Heart (mean range: 17 to 68) reporting the highest levels of kinesiophobia were those
involving participants with a cardiovascular condition (41.4 to 49.7), followed by studies testing
participants with arthritis (31.8 to 45.27) or chronic pain (30.5 to 44.6). Levels of kinesiophobia
were lower in participants with a neurological (36.6 to 41), pulmonary (20.7 to 39.6), women
health (36), or surgical condition (32.9 to 35.9), and in healthy adults (18.9 to 39.0).

279

280 *Physical Activity*

Fifty-one studies assessed physical activity using a self-reported measure (Table 1). Most of these 281 questionnaire-based studies used the short form of the International Physical Activity 282 Ouestionnaire (IPAO-SF; n = 20)^{29,73,76,78,79,82,85,86,112,114,116,130,131,133,138-141,146,147} which consists of 283 6 items assessing time spent in light (i.e., walking), moderate (e.g., carrying light loads, cycling at 284 moderate speed, doubles tennis), and vigorous physical activity (e.g., digging, fast cycling, heavy 285 lifting, aerobics) over the last 7 days¹⁵⁹. Other questionnaires were used to assess physical activity, 286 such as the Baecke Habitual Physical Activity Questionnaire¹⁶⁰ (BHPAQ; n = 5)^{64,89,90,107,113}, 287 Saltin-Grimby Physical Activity Level Scale¹⁶¹ (SGPALS; n = 5)^{80,104,115,125,135}, Godin-Shephard 288 Leisure-Time Exercise Questionnaire¹⁶² (GLTEQ; n = 2)^{121,134}, Minnesota Leisure Time Physical 289 Activity Questionnaire¹⁶³ (MLTPAQ; n = 1)¹³⁶, Physical Activity Scale for the Elderly¹⁶⁴ (PASE; 290 $n = 2)^{123,149}$, Physical Activity Questionnaire for the Elderly¹⁶⁴ (PAQE; $n = 1)^{72}$, Short 291 Questionnaire to Assess Health Enhancing Physical Activity¹⁶⁵ (SQUASH; n = 1)¹⁴², the Tegner 292

Assessment Scale¹⁶⁶ (TAS; n = 1)⁶³, University of California Los Angeles (UCLA) activity score¹⁶⁷ (n = 1)⁸⁴, Leisure Time Physical Activity Index¹⁶⁸ (LTPAI; n = 1)⁶⁷, Global Physical Activity Questionnaire¹⁶⁹ (GPAQ; n = 2)^{77,83}, Freiburger Questionnaire on Physical Activity¹⁷⁰ (FQPA; n = 1)¹²⁷, Jurka Physical Activity Scale¹⁷¹ (JPAS; n = 1)⁸¹, Rapid Assessment of Physical Activity questionnaire¹⁷² (RAPAQ; n = 1)⁶⁸, Tecumseh Occupational Activity Questionnaire¹⁷³ (TOAQ; n = 1)¹³⁶, and Australian Health Survey-derived questions (AHS; n = 1)⁷¹.

Physical activity was also assessed with devices such as accelerometers measuring accelerations 299 in 3 dimensions $(n = 23)^{65,66,74,75,78,91,110,113,117,118,120,122,124,126,129,132,137,143-145,148,150,151}$ and 300 pedometers measuring the number of steps $(n = 3)^{63,88,128}$ (Table 1). In most studies, the device 301 was worn at the hip $(n = 10)^{63,91,113,117,124,129,137,148,150,151}$. Other positions included wrist $(n = 10)^{63,91,113,117,124,129,137,148,150,151}$ 302 $5^{65,111,126,132,143}$, arm $(n = 3)^{74,144,145}$, trunk $(n = 2)^{118,122}$, and thigh $(n = 1)^{75}$, with five studies not 303 reporting where the device was worn^{66,78,88,120,128}. Most studies that employed accelerometer-based 304 measures used the ActiGraph (Actigraph, LLC, Pensacola, FL, USA) $GT3X+(n = 4)^{120,137,150,151}$, 305 wGT3X-BT $(n = 2)^{138,148}$ or GT9X Link $(n = 2)^{78,132}$. The other accelerometers were the RT3 306 (Stayhealthy Inc., Monrovia, CA, USA; n = 3)^{117,118,124}, the SenseWear Pro3 Armband 307 (BodyMedia, Pittsburgh, PA, USA; n = 3)^{74,144,146}, the Activity Sensory Move II (movisens GmbH, 308 Karlsruhe, Germany; n = 1)¹²⁹, the LifeShirt (Vivometrics, Inc., Ventura, CA, USA; n = 1)¹²², the 309 ActiWatch (Mini Mitter Co., Inc., Bend, OR, USA; n = 1)¹¹¹, AX3 (Axtivity, Newcastle upon 310 Tyne, UK; n = 1)⁶⁵, FitBit (FitBit Inc., San Francisco, CA) Charge HR (n = 1)¹²⁶, Charge 3 (n = 1) 311 1)¹⁴³, and the Activ8 (2M Engineering, North Brabant, Netherland, n = 1)⁶⁶. The type of 312 accelerometer was not reported in one study¹¹³. The pedometers were the Digi-Walker SW-200 313 (New Lifestyles Inc., Lees Summit, MO, USA; n = 1)⁶³, the Active Style Pro HJA-350IT (Omron 314 Heathcare, Kyoto, Japan; n = 1)⁸⁸ and Yamax Power-Walker EX-510 3D (Pedometer Express, 315

Minnesota, USA; n = 1)¹²⁸. These devices were worn for 5 days (n = 1)¹¹¹, 6 days (n = 1¹²⁹), 7 days 316 $(n = 16)^{63,65,75,88,91,113,117,118,120,124,132,137,144,148,150,151}$, or 14 days $(n = 1)^{126}$. The remaining 7 studies 317 did not specify the number of days the device was worn^{66,74,78,122,128,143,145}. All studies provided the 318 kinesiophobia 319 accelerometer or pedometer the day was assessed on (n = 18)^{63,65,66,75,78,88,89,111,113,120,122,126,132,137,143,148,150}. The remaining studies did not specify whether 320 321 kinesiophobia was measured the day the device was provide or the last day of physical activity assessment $(n = 7)^{74,118,124,128,144,146,151}$. 322

To assess physical activity, the studies used the following outcomes: Score from a questionnaire 323 TAS, PAQE, BHPAQ, SGPALS, 324 (e.g., LTPAQ, n = 24)^{63,64,67,68,72,80,81,84,87,89,90,104,107,113,115,119,121,123,125,127,134,137,149}, MET-min/week (n = 23)^{31,73,76,77-10,104,107,113,115,119,121,123,125,127,134,137,149} 325 79,83,85,86,112,114,116,130,131,133,136,138-142,146,147, steps per day (n = 14)63,65,75,78,88,113,120,126,128,132,143-145,150, 326 hours per day or week $(n = 12)^{62,65,69-71,74,91,113,120,138,143,145}$, counts per minute $(n = 4)^{111,113,117,137}$. 327 kilocalories per day $(n = 2)^{129,144}$, or percentage of active time $(n = 1)^{122}$. Nine studies used multiple 328 physical activity outcomes^{63,65,78,91,113,120,143-145}. 329

330

331 Association Between Physical Activity and Kinesiophobia

Among the 74 articles included in the systematic review, 42 reported correlation coefficients of the association between physical activity and kinesiophobia. Specifically, 32 articles reported at least one Pearson's r correlation coefficient and 12 articles reported at least one Spearman's rho^{87,89,91,113,116,124,127,132,135,143,149,151}. When a correlation coefficient was not reported, but the exact p-value (or t value) and sample size were available and it was possible to know the sign of the correlation, which was the case for 7 studies^{83,111,115,120,125,133,144}, the Pearson's r estimate was computed using an ad-hoc R code (Supplemental Code 1A). For the studies that reported a relative

339 p-value < 0.001 instead of an exact p-value, we used a p-value of 0.0009 to estimate an 340 approximate r value⁸².

Through email correspondence with the authors, we obtained 23 additional Pearson's r estimates^{29,62-81,104,107}. In total, 83 Pearson's r estimates from 63 studies and 21 Spearman's rho estimates from 12 studies were used in the meta-analysis (Table 1). The remaining study did not report a correlation coefficient and was therefore not included in the meta-analysis¹¹⁷. This study reported a non-statistically significant positive association between physical activity and kinesiophobia based on a standardized beta coefficient.

- 347
- 348 *Pain*

Mean pain intensity at rest was reported in 45 out of the 74 articles included in the systematic 349 the Visual Analog Scale¹⁷⁴ (VAS; n = 21)^{65,69-} Most studies used 350 review. 71,76,78,82,85,89,90,112,114,117,119,120,122,124,126,138,139,141 or the Numeric Rating Scale¹⁷⁵ (NRS; n = 351 15)^{29,62,66,68,75,79,80,83,88,111,113,116,127,128,137}. Other studies used the Knee Injury Osteoarthritis 352 Outcome Score pain subscale¹⁷⁶ (KOOS-P; n = 3)^{63,84,134}, Brief Pain Inventory¹⁷⁷ (n = 1)⁶⁴, Oxford 353 Knee Score¹⁷⁸ (OKS; n = 1)¹⁴⁰, the Quality of Well-Being Scale – Self-administered Pain Scale¹⁷⁹ 354 (OWBS-P; n = 1)¹⁵⁰, the Short Form 36 bodily pain¹⁸⁰ (SF-36; n = 1)¹³⁰, the Graphic Rating 355 Scale¹⁸¹ (GRS; n = 1)¹³³, Fibromvalgia Impact Questionnaire-Pain¹⁸² (FIQ-Pain, n = 1)⁶⁷ and the 356 Verbal Rating Scale¹⁸³ (VRS; n = 1)¹⁰⁴. In the meta-analysis, scores that were not on a 0-100 scale 357 358 in the initial measure were scaled to that range.

359

360 Meta-Analysis

361 *Main Meta-Analysis*

Our main meta-analysis of 63 studies, 83 Pearson's r correlation estimates, and 12278 participants revealed a statistically significant small-to-moderate negative correlation between kinesiophobia and physical activity (r = -0.19; 95% confidence interval [95CI]: -0.26 to -0.13; p < 0.0001) (Table 2; Figure 2). However, we observed substantial-to-considerable between-study statistical heterogeneity (Tau² = 0.06, 95CI: 0.02 to 0.09; I² = 85.5%, 95CI: 82.6 to 87.9%), and the prediction interval ranged from r = -0.61 to 0.30, indicating that a moderate positive correlation cannot be ruled out for future studies.

The sampling error variance on level 1 and the value of I^2 on level 2, i.e., the amount of heterogeneity variance within studies, were small (10.3% and 8.2%, respectively). The largest share of heterogeneity variance was from level 3, with between-study heterogeneity making up 81.5% of the total variation in our data (Supplemental Figure 1). Overall, this indicates that there is considerable between-study heterogeneity, and less than one tenth of the variance can be explained by differences within studies.

The 3-level model showed a better fit than the 2-level model with lower Akaike's information criterion (AIC) (28.4 vs. 39.0) and Bayesian information criterion (BIC) (35.6 vs. 43.8), indicating better performance. These lower AIC and BIC are consistent with the significant likelihood ratio test (LRT) comparing the two models ($\chi^2 = 12.67$, p = 0.0004). Therefore, although the 3-level model introduces an additional parameter, this added complexity has improved our estimate of the pooled effect.

381

382 Publication bias assessment

Egger's regression test using the standard errors of the effect size estimates as a predictor in the meta-regression showed that the coefficient of the standard error was significant (b = -1.497, 95CI:

-2.618 to -0.3754, p = 0.0095), suggesting that the data in the funnel plot was asymmetrical (Figure 386 3A). This asymmetry may be explained by publication bias, but also by other potential causes, 387 such as different study procedures and between-study heterogeneity¹⁸⁴, which was substantial-to-388 considerable here.

The 83 Pearson's r correlation estimates were provided to the p-curve analysis. The observed p-389 390 curve included 35 statistically significant results (p < 0.05), 27 of which were highly significant (p < 0.025), and was visually right-skewed (Figure 3B). The other results were excluded because 391 they had a p > 0.05. The p-value of the right-skewness test was < 0.001 for both the half curve 392 393 (curve of p-values ≤ 0.025) and the full curve (curve of p-values < 0.05), confirming that the pcurve was right-skewed and suggesting that the effect of our meta-analysis is true, i.e., that the 394 effect we estimated is not an artifact caused by selective reporting (e.g., p-hacking) in the 395 literature¹⁸⁵. In addition, the statistical power of the studies that were included in the p-curve 396 397 analysis was 97% (90CI: 93 to 98%), suggesting that approximately 90% of the significant 398 results are expected to be replicable.

399

400 Secondary Meta-Analyses

Results of the secondary meta-analysis of 12 studies, 21 Spearman's rho correlation estimates, and 2084 participants was consistent with the main meta-analysis as it showed a statistically significant small-to-moderate negative correlation between kinesiophobia and physical activity (r = -0.20; 95CI: -0.38 to -0.01; p = 0.049) (Table 2; Supplemental Figure 2). However, we observed substantial-to-considerable between-study statistical heterogeneity (Tau² = 0.10, 95CI: 0.04 to 0.28; $I^2 = 86.3\%$) and the prediction interval ranged from r = -0.71 to 0.45, indicating that a moderate positive correlation cannot be ruled out for future studies.

408

409 Subgroup Meta-Analyses

The test of subgroup differences between health status was conducted on studies comprising 410 people with chronic (k = 35) or acute pain (k = 2), arthritis (k = 11), a cardiovascular condition (k = 11)411 = 10), a neurological condition (k = 8), surgery (k = 5), older age (k = 3), obstructive sleep apnea 412 413 (k = 2), a pulmonary condition (k = 2), fibromyalgia (k = 2), cancer (k = 1), as well as in postpartum women (k = 1) and healthy young adults (k = 1) (Table 2; Supplemental Figure 3). We 414 415 found a statistical moderating effect of health status (p = 0.0014). The relationship between 416 kinesiophobia and physical activity was statistically significant only in studies that included 417 participants with cardiac condition (r = -0.30; 95CI: -0.47 to -0.11), arthritis (r = -0.25; 95CI: -0.39 to -0.10), a neurologic condition (r = -0.53; 95CI: -0.69 to -0.32), a pulmonary condition (r = -418 0.68; 95CI: -0.82 to -0.46), or older adults (r = -0.40; 95CI: -0.60 to -0.14). We found no evidence 419 420 of an association between kinesiophobia and physical activity in studies that included participants 421 with chronic pain (r = -0.07; 95CI: -0.16 to 0.01) or acute pain (r = -0.13; 95CI: -0.45 to 0.23). Statistical heterogeneity was higher in the studies comprising people with a pulmonary condition 422 $(I^2 = 98.1\%)$, arthritis $(I^2 = 93.4\%)$, or older adults $(I^2 = 91.2\%)$ than in the studies comprising 423 people with a cardiac ($I^2 = 28.7\%$) or neurologic condition ($I^2 = 55.9\%$). 424

The test of subgroup differences between self-reported (k = 54) and device-based (k = 29) measures of physical activity showed no evidence of a moderating effect of the type of physical activity measure (p = 0.171; Table 2). Both self-reported measures (r = -0.22; 95CI: -0.29 to -0.14; $I^2 = 89.3\%$) and device-based measures (r = -0.13; 95CI: -0.24 to -0.02; $I^2 = 57.2\%$) (Supplemental Figure 4) showed a negative association between kinesiophobia and physical activity.

We also found no evidence of a moderating effect of physical activity instruments (p = 0.209) 430 (Supplemental Figure 5), physical activity outcome (p = 0.685) (Supplemental Figure 6), or 431 kinesiophobia instrument (p = 0.452) (Supplemental Figure 7). 432 433 Meta-Regressions 434 435 Age did not statistically influence the correlation estimates of the meta-analysis studies (k = 72; p = 0.349). Similarly, the proportion of women (k = 72; p = 0.555) and the mean level of pain in the 436 studies (k = 49; p = 0.481) did not influence correlation estimates. 437 438 Sensitivity Analysis 439 The meta-regression by quality score showed that a study's quality did not influence correlation 440 estimates (k = 83; p = 0.373). 441 442 DISCUSSION 443 The main objective of this study was to systematically review and meta-analyze the direct 444 relationship between kinesiophobia and physical activity. In addition, we examined the influence 445 446 of potential moderators, such as health status. To our knowledge, this is the first review of its kind on this research topic. 447 448 449 **Kinesiophobia and Physical Activity** 450 Both the main meta-analysis based on Pearson's r correlation estimates and the secondary metaanalysis based on Spearman's rho correlation estimates showed a small-to-moderate negative 451 452 correlation between kinesiophobia and physical activity. Importantly, this correlation was

453 observed bot in studies using both self-report (e.g., IPAQ) and device-based measures (i.e., 454 accelerometers or pedometers). These results are consistent with our hypothesis and the dual 455 models of physical activity³²⁻³⁵. According to these theoretical models, our findings suggest that 456 the fear of movement characteristic of kinesiophobia triggers an impulse to avoid physical activity 457 behaviors, which contributes to the maintenance or exacerbation of the initial fear. Accordingly, 458 kinesiophobia and physical inactivity would be self-perpetuating or even self-reinforcing.

459

460 Health Status

461 Our results suggest that patients with a cardiac, neurologic, arthritic, or pulmonary condition, as well as older adults, may be at greater risk for this negative relationship between kinesiophobia 462 and physical activity than those with other conditions. In individuals with a cardiac condition, 463 kinesiophobia and its impact on physical activity may be explained by a fear of inducing a new 464 cardiac event¹⁸⁶ or "causing more damage to the heart"¹⁸⁷, but also by breathlessness (i.e., 465 466 dyspnea), which reduces the ability to be physically active and damages confidence, leading to persistent anticipation of negative outcomes from physical activity¹⁸⁸. Dyspnea is also a major 467 barrier to physical activity in people with a pulmonary condition, such as chronic obstructive 468 pulmonary disease (COPD)¹⁴⁷. Patients with asthma may have additional disease-related barriers 469 to physical activity, such as the fear of provoking respiratory symptoms and exacerbations¹⁸⁹. 470 471 Regarding neurologic conditions, chest tightness reported in patients with Parkinson's disease as 472 a barrier to exercise may be a factor contributing to the association between kinesiophobia and physical activity¹⁹⁰. Another potential factor in these patients¹⁹⁰, as well as in stroke survivors¹⁹¹ 473 and healthy older adults¹⁹², is fear of falling. In patients with osteoarthritis, the belief that physical 474

activity will "damage the joints"¹⁹³ and the perceived fragility of their physical status¹⁹⁴ may be
factors contributing to the relationship between kinesiophobia and physical activity.

477 Although our results showed no evidence of an association between kinesiophobia and physical 478 activity in other health conditions such as cancer, post-surgery, post-partum, or obstructive sleep 479 apnea, these effects cannot be fully ruled out, as the lack of statistical significance could be 480 explained by a lack of statistical power in these subgroup meta-analyses including fewer estimates 481 (k = 1 to 5).

482

483 Pain versus Fear

Our results showed no evidence of an association between kinesiophobia and physical activity in people with fibromyalgia, acute pain, or chronic pain. This finding was surprising because fear of pain is a key component of kinesiophobia, appearing in 10 of the 17 items on the TSK-17 and TSK-Heart scales, and reinforces the importance of considering the multidimensional nature of kinesiophobia, which not only relates to pain but also reflects fear of injury and fear of worsening a health condition.

In addition, contrary to our expectations, we found no statistical evidence showing that pain 490 491 intensity at rest influenced the effect of kinesiophobia on physical activity, despite the substantial number of estimates included in this analysis (k = 23). This result is consistent with the weak 492 relationship that has been shown between kinesiophobia and pain¹⁹⁵, further suggesting that it is 493 494 not the actual pain that prevents physical activity, but the fear of triggering pain, injury, or 495 aggravating an underlying condition. However, this absence of evidence might be related to the 496 methods used to assess pain, which may be better assessed by pain history (e.g., pain duration in 497 months) or pain intensity during exercise.

498

499 Limitations

The results of this systematic review and meta-analysis should be interpreted with consideration 500 of several limitations. (1) We report considerable heterogeneity across the included studies, which 501 may be explained by the diversity of the methods used to assess physical activity (questionnaires 502 503 vs. accelerometers vs. pedometers), the instruments used in these methods (14 different questionnaires, 14 different accelerometers and pedometers), and the physical activity outcomes 504 (n = 6), but also by the different questionnaires used to assess kinesiophobia (n = 11). This 505 506 heterogeneity suggests that the measures of kinesiophobia and physical activity used in the 507 literature reflect different dimensions of these two constructs. For example, self-reported measures of physical activity do not accurately reflect actual levels of physical activity¹⁹⁶. (2) Because 508 kinesiophobia is a state, i.e., a dynamic psychological variable, the time difference between the 509 physical activity and kinesiophobia assessments, as well as the context of assessment, may have 510 511 influenced the results. (3) While a subgroup meta-analysis showed no evidence of an effect of the type of TSK scale, inconsistencies have been noted in the purported dimensions assessed by 512 different TSK scales or across populations¹⁹⁷, which may have influenced our results. (4) The 513 514 meta-analysis was not pre-registered because the author with this expertise (IML) joined only after the systematic review was conducted. However, since the pre-registered systematic review defines 515 the studies included in the meta-analysis and since the {meta} R package⁵⁰ provides very few 516 517 degrees of freedom, there was little room for bias in the main and secondary meta-analyses. This 518 reasoning also applies for the subgroup analyses as the health conditions, types of physical activity 519 measures, measurement instruments, and outcomes, as well as the kinesiophobia measurement 520 instruments were imposed by the studies that were included in the systematic review. (5) Only 21

of the 98 authors we contacted (21%) shared their estimates (n = 13) or raw data (n = 8) with us, which is more than reported in previous literature¹⁹⁸. Including these missing data may have had an impact on the results.

524

525 Conclusions

526 Higher levels of kinesiophobia were associated with lower levels of physical activity, especially in people with a cardiac, neurologic, arthritic, and pulmonary condition. According to theoretical 527 models, this relationship between kinesiophobia and physical activity results from automatic 528 529 processes that may be self-reinforcing and should therefore not be overlooked. However, 530 heterogeneity between studies was substantial-to-considerable for some results, and the evidence for publication bias calls for cautious conclusions about this potential relationship. In sum, our 531 results suggest that kinesiophobic individuals have a small-to-moderate risk of being more 532 physically inactive than other individuals. More evidence is required to determine the impact 533 534 kinesiophobia should have on the apeutic decisions when aiming to maintain or increase physical activity. Particularly, prospective studies are needed to better understand the factors and 535 mechanisms that influence the relationship between kinesiophobia and physical activity. 536

537

5. ARTICLE INFORMATION

538 Funding

539 Matthieu P. Boisgontier is supported by the Natural Sciences and Engineering Research Council

of Canada (NSERC; RGPIN-2021-03153), the Canada Foundation for Innovation (CFI), Mitacs,

and the Banting Research Foundation. The funders had no role in the data collection, management,

542 analysis and interpretation, writing of the report, or the decision to submit the report for

543 publication. Ata Farajzadeh is supported by an Admission Scholarship, a Doctoral International

544 Scholarship, and a Special Merit Scholarship from the University of Ottawa.

545

546 Data and Code Sharing

According to good research practices⁴⁴, the dataset, R Markdown script, and supplemental material
are freely available in Zenodo: <u>https://doi.org/10.5281/zenodo.8216112125</u>¹⁹⁹

549

550 Acknowledgements

Based on the Contributor Roles Taxonomy (CRediT)²⁰⁰ individual author contributions to this 551 work are as follows: Miriam Goubran: Conceptualization, Methodology (Systematic Review), 552 553 Investigation, Data Curation, Writing (Original Draft), Writing (Review and Editing); Ata Farajzadeh: Methodology (Systematic Review), Investigation, Data Curation, Writing (Original 554 555 Draft), Writing (Review and Editing); Ian M. Lahart: Methodology (Meta-Analysis), Formal 556 Analysis, Visualization, Data Curation, Writing (Original Draft), Writing (Review and Editing); 557 Martin Bilodeau: Conceptualization, Methodology (Systematic Review), Writing (Review and Editing), Supervision (MG); Matthieu P. Boisgontier: Conceptualization, Methodology 558 559 (Systematic Review and Meta Analysis), Investigation, Formal Analysis, Data Curation,

- 560 Visualization; Writing (Original Draft), Writing (Review and Editing), Supervision (MG and AF),
- 561 Project Administration, Funding Acquisition.

562

563 Conflict of Interest Disclosure

564 The authors declare they have no conflict of interest relating to the content of this article

REFERENCES

 Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. *Lancet.* 1953;262(6795):1053-1057.

https://doi.org/10.1016/s0140-6736(53)90665-5

 Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major noncommunicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet.* 2012;380(9838):219-229.

https://doi.org/10.1016/S0140-6736(12)61031-9

- 3. Salinas-Rodríguez A, Manrique-Espinoza B, Palazuelos-González R, Rivera-Almaraz A, Jáuregui A. Physical activity and sedentary behavior trajectories and their associations with quality of life, disability, and all-cause mortality. *Eur Rev Aging Phys Act.* 2022;19(1):13. <u>https://doi.org/10.1186/s11556-022-00291-3</u>
- 4. Wahid A, Manek N, Nichols M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. *J Am Heart Assoc.* 2016;5(9):e002495. <u>https://doi.org/10.1161/JAHA.115.002495</u>
- 5. Bleich SN, Vercammen KA, Zatz LY. Interventions to prevent global childhood overweight and obesity: a systematic review. *Lancet Diabetes Endocrinol*. 2018;6:332-346. <u>https://doi.org/10.1016/S2213-8587(17)30358-3</u>
- Schuch F, Vancampfort D, Firth J, et al. Physical activity and sedentary behavior in people with major depressive disorder: a systematic review and meta-analysis. *J Affect Disord*. 2017;210:139-150. <u>https://doi.org/10.1016/j.jad.2016.10.050</u>

7. Liu X, Zhang D, Liu Y, et al. Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies.

Hypertension. 2017;69(5):813-820.

https://doi.org/10.1161/HYPERTENSIONAHA.116.08994

- Moore SC, Lee IM, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med.* 2016;176(6):816-825. <u>https://doi.org/10.1001/jamainternmed.2016.1548</u>
- Najar J, Östling S, Gudmundsson P, et al. Cognitive and physical activity and dementia: a 44-year longitudinal population study of women. *Neurology*. 2019;92(12):E1322-E1330. https://doi.org/10.1212/WNL.0000000000007021
- World Health Organization. *Physical activity Key facts*. October 2022. Accessed May 1, 2024. https://www.who.int/news-room/fact-sheets/detail/physical-activity
- Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. *J Am Coll Cardiol*. 2019;73(12):1430-1443. <u>https://doi:10.1016/j.jacc.2018.12.072</u>
- 12. Molloy C, Long L, Mordi IR, et al. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev.* 2024;3(3):CD003331.

https://doi:10.1002/14651858.CD003331.pub6

 Daste C, Kirren Q, Akoum J, Lefèvre-Colau MM, Rannou F, Nguyen C. Physical activity for osteoarthritis: Efficiency and review of recommandations. *Joint Bone Spine*. 2021;88(6):105207. <u>http://doi:10.1016/j.jbspin.2021.105207</u>

- 14. van Allen Z, Orsholits D, Boisgontier MP. Pre-stroke physical activity matters for functional limitations: A longitudinal case-control study of 12,860 participants. *Phys Ther.* 2024. <u>http://doi.org/10.1101/2023.09.14.23295576</u>
- Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. *Neurology*. 2017;88(4):379-385.

http://doi:10.1212/WNL.00000000003534

- 16. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. *Br J Cancer*. 2018;119(7):785-792. <u>http://doi:10.1038/s41416-018-0264-x</u>
- Boisgontier MP, Iversen MD. Physical inactivity: a behavioral disorder in the physical therapist's scope of practice. *Phys Ther.* 2020;100(5):743-746.

http://doi.org/10.1093/PTJ/PZAA011

- O'Donoghue G, Perchoux C, Mensah K, et al. A systematic review of correlates of sedentary behaviour in adults aged 18-65 years: a socio-ecological approach. *BMC Public Health.* 2016;16(1):163. <u>https://doi.org/10.1186/s12889-016-2841-3</u>
- Garcia L, Mendonça G, Benedetti TRB, et al. Barriers and facilitators of domain-specific physical activity: a systematic review of reviews. *BMC Public Health*. 2022;22(1):1964. <u>https://doi.org/10.1186/s12889-022-14385-1</u>
- 20. Biddle SJH, Gorely T, Faulkner G, Mutrie N. Psychology of physical activity: a 30-year reflection on correlates, barriers, and theory. *Int J Sport Exerc Psychol.* 2023;21(1):1-14. <u>https://doi.org/10.1080/1612197X.2022.2147261</u>

- 21. Azevedo MR, Araújo CLP, Reichert FF, Siqueira FV, da Silva MC, Hallal PC. Gender differences in leisure-time physical activity. *Int J Public Health*. 2007;52(1):8-15. <u>https://doi.org/10.1007/s00038-006-5062-1</u>
- 22. Caspersen CJ, Pereira MA, Curran KM. Changes in physical activity patterns in the United States, by sex and cross-sectional age. *Med Sci Sports Exerc.* 2000;32(9):1601-1609. https://doi.org/10.1097/00005768-200009000-00013
- 23. Cheval B, Rebar AL, Miller MW, et al. Cognitive resources moderate the adverse impact of poor perceived neighborhood conditions on self-reported physical activity of older adults. *Prev Med.* 2019;126:105741. <u>https://doi.org/10.1016/j.ypmed.2019.05.029</u>
- 24. Cheval B, Orsholits D, Sieber S, Courvoisier D, Cullati S, Boisgontier MP. Relationship between decline in cognitive resources and physical activity. *Health Psychol.* 2020;39(6):519-528. <u>https://doi.org/10.1037/hea0000857</u>
- 25. Cheval B, Sieber S, Guessous I, et al. Effect of early- and adult-life socioeconomic circumstances on physical inactivity. *Med Sci Sports Exerc.* 2018;50(3):476-485. https://doi.org/10.1249/MSS.000000000001472
- Kori SH, Miller RP, Todd DD. Kinesiophobia: a new view of chronic pain behavior. *Pain Manag.* 1990;3:35-43.
- 27. Vlaeyen JWS, Kole-Snijders AMJ, Boeren RGB, van Eek H. Fear of movement/(re)injury in chronic low back pain and its relation to behavioral performance. *Pain*. 1995;62(3):363-372. <u>https://doi.org/10.1016/0304-3959(94)00279-N</u>
- Miller R, Kori S, Todd D. The Tampa Scale: a measure of kinisiophobia. *Clin J Pain*. 1991;7(1):51-52.

- 29. Bahar Özdemir Y. Investigation of low back pain in the white-collar population working from home due to the COVID-19 pandemic. *J Phys Med Rehabil Sci.* 2021;24(2):135-142. <u>https://doi.org/10.31609/jpmrs.2021-81527</u>
- Stults-Kolehmainen MA, Blacutt M, Bartholomew JB, et al. Motivation states for physical activity and sedentary behavior: desire, urge, wanting, and craving. *Front Psychol.* 2020;11:568390. <u>https://doi.org/10.3389/fpsyg.2020.568390</u>
- 31. Stevens CJ, Baldwin AS, Bryan AD, Conner M, Rhodes RE. Williams DM. Affective determinants of physical activity: a conceptual framework and narrative review. *Front Psychol.* 2020;11:568331. <u>https://doi.org/10.3389/fpsyg.2020.568331</u>
- 32. Brand R, Ekkekakis P. Affective–reflective theory of physical inactivity and exercise. Ger J Exerc Sport Res. 2018;48:48-58. <u>https://doi.org/10.1007/s12662-017-0477-9</u>
- 33. Cheval B, Boisgontier MP. Promouvoir une activité physique régulière chez les patients :
 l'importance de la perception de l'effort. *STAPS*. 2024. <u>https://doi.org/10.3917/sta.pr1.0091</u>
- 34. Cheval B, Boisgontier MP. The theory of effort minimization in physical activity. *Exerc Sport Sci Rev.* 2021;49(3):168-178. <u>https://doi.org/10.1249/JES.00000000000252</u>
- 35. Conroy DE, Berry TR. Automatic affective evaluations of physical activity. *Exerc Sport Sci Rev.* 2017;45(4):230-237. <u>http://doi.org/10.1249/JES.00000000000120</u>
- 36. Farajzadeh A, Goubran M, Beehler A, et al. Relationship between age and physical and sedentary stimuli. *Peer Community J.* 2023;3:e21. <u>https://doi.org/10.24072/pcjournal.246</u>
- 37. Hanel J, Owen PJ, Held S, et al. Effects of exercise training on fear-avoidance in pain and pain-free populations: systematic review and meta-analysis. *Sports Med.* 2020;50(1):2193-2207. <u>https://doi.org/10.1007/s40279-020-01345-1</u>

- 38. Jadhakhan F, Sobeih R, Falla D. Effects of exercise/physical activity on fear of movement in people with spine-related pain: a systematic review. *Front Psychol*. 2023;14:1213199. https://doi.org/10.3389/fpsyg.2023.1213199
- 39. Martinez-Calderon J, Flores-Cortes M, Morales-Asencio JM, Luque-Suarez A. Conservative interventions reduce fear in individuals with chronic low back pain: a systematic review. *Arch Phys Med.* 2020;101(2):329-358.

https://doi.org/10.1016/j.apmr.2019.08.470

40. Rovner GS, Sunnerhagen KS, Björkdahl A, et al. Chronic pain and sex-differences; women accept and move, while men feel blue. *PLOS One*. 2017;12(4):e0175737.

https://doi.org/10.1371/journal.pone.0175737

- 41. John JN, Ugwu EC, Okezue OC, et al. Kinesiophobia and associated factors among patients with chronic non-specific low back pain. *Disabil Rehabil*. 2023;45(16):2651-2659. https://doi.org/10.1080/09638288.2022.2103747
- 42. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ*. 2021;372:n160.
 https://doi.org/10.1136/bmj.n160
- 43. Caldwell AR, Vigotsky AD, Tenan MS, et al. Moving sport and exercise science forward: a call for the adoption of more transparent research practices. *Sports Med.* 2020;50(3):449-459. https://doi.org/10.1007/s40279-019-01227-1

44. Boisgontier MP. Research integrity requires to be aware of good and questionable research practices. *Eur Rehabil J.* 2021;2(1):1-3. https://doi.org/10.52057/erj.v2i1.24

- 45. Goubran M, Boisgontier MP, Bilodeau M. Kinesiophobia and physical activity: a systematic review. *PROSPERO* (CRD42022364063). October 17, 2022. Accessed May 1, 2024. <u>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022364063</u>
- 46. National Institutes of Health. Quality assessment tool for observational cohort and cross-sectional studies. Bethesda, MD: National Institutes of Health; 2013. Accessed May 1, 2024. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
- 47. Des Jarlais DC, Lyles C, Crepaz N; TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. *Am J Public Health*. 2004;94(3):361-366. <u>http://doi:10.2105/ajph.94.3.361</u>
- 48. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *J Pharmacol Pharmacother*. 2010;1(2):100-107. <u>http://doi:10.4103/0976-500X.72352</u>
- 49. R Core Team. R: a language and environment for statistical computing [Computer software]. Version 4.3.1. Vienna, Austria: Foundation for Statistical Computing; 2023. <u>https://www.r-project.org</u>
- 50. Schwarzer G. *meta: general package for meta-analysis* [R package]. Version 6.5-0; 2023. https://cran.r-project.org/web/packages/meta/meta.pdf
- 51. Viechtbauer W. *metafor: meta-analysis package for R* [R package]. Version 4.2-0; 2023. <u>https://cran.r-project.org/web/packages/metafor/metafor.pdf</u>
- 52. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw*. 2010;36(3):1-48. https://doi.org/10.18637/jss.v036.i03

- Harrer M, Cuijpers P, Furukawa TA, Ebert DD. *Doing Meta-Analysis with R: A Hands-On Guide*. Boca Raton, FL and London: Chapmann & Hall/CRC Press. *ISBN*. 2021;978-0-367-61007. https://doi.org/10.1201/9781003107347
- 54. Cheung M. Modeling dependent effect sizes with three-level meta-analyses: a structural equation modeling approach. *Psychol Methods*. 2014;19(2):211-229.

https://doi.org/10.1037/a0032968

55. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the randomeffects model. *J Educ Behav Stat.* 2005;30(3):261-293.

https://doi.org/10.3102/10769986030003261

- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21(11):1539-1558. <u>https://doi.org/10.1002/sim.1186</u>
- 57. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med.* 2003;22(17):2693-2710. <u>https://doi.org/10.1002/sim.1482</u>
- 58. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.; 1988.
- 59. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.

https://doi.org/10.1136/bmj.315.7109.629

- 60. Marey A. Multilevel meta analysis. RPubs, 2021. Accessed May 1, 2024. https://rpubs.com/amany33/814435
- 61. Simonsohn U, Nelson LD, Simmons JP. P-curve: A key to the file-drawer. *J Exp Psychol Gen.* 2014;143(2):534-547. <u>http://doi.org/10.1037/a0033242</u>

- Assadourian M, Bailly F, Letellier P, et al. Criteria for inclusion in programs of functional restoration for chronic low back pain: pragmatic study. *Ann Phys Rehabil Med.* 2020;63(3):189-194. <u>https://doi.org/10.1016/j.rehab.2019.06.019</u>
- 63. Baez SE, Hoch MC, Hoch JM. Psychological factors are associated with return to preinjury levels of sport and physical activity after ACL reconstruction. *Knee Surg Sports Traumatol Arthrosc.* 2020;28(2):495-501. <u>https://doi.org/10.1007/s00167-019-05696-9</u>
- 64. Luthi F, Vuistiner P, Favre C, Hilfiker R, Léger B. Avoidance, pacing, or persistence in multidisciplinary functional rehabilitation for chronic musculoskeletal pain: an observational study with cross-sectional and longitudinal analyses. *PLOS One*. 2018;13(9):e0203329. https://doi.org/10.1371/journal.pone.0203329
- 65. Alzahrani H, Mackey M, Stamatakis E, Shirley D. Wearables-based walking program in addition to usual physiotherapy care for the management of patients with low back pain at medium or high risk of chronicity: a pilot randomized controlled trial. *PLOS One*. 2021;16(8):e0256459. <u>https://doi.org/10.1371/journal.pone.0256459</u>
- 66. Koppenaal T, van Dongen JM, Kloek CJ, et al. Effectiveness and cost-effectiveness of a stratified blended physiotherapy intervention compared with face-to-face physiotherapy in patients with nonspecific low back pain: cluster randomized controlled trial. *J Med Internet Res.* 2023;25:e43034. <u>https://doi.org/10.2196/43034</u>
- 67. Palstam A, Larsson A, Bjersing J, et al. Perceived exertion at work in women with fibromyalgia: explanatory factors and comparison with healthy women. *J Rehabil Med*. 2014;46(8):773-780. <u>https://doi.org/10.2340/16501977-1843</u>
- 68. Zadro JR, Shirley D, Nilsen TI, Mork PJ, Ferreira PH. Family history influences the effectiveness of home exercise in older people with chronic low back pain: a secondary

analysis of a randomized controlled trial. *Arch Phys Med Rehabil*. 2020;101(8):1322-1331. https://doi.org/10.1016/j.apmr.2020.03.019

- 69. Marshall PW, Schabrun S, Knox MF. Physical activity and the mediating effect of fear, depression, anxiety, and catastrophizing on pain related disability in people with chronic low back pain. *PLOS One*. 2017;12(7). <u>https://doi.org/10.1371/journal.pone.0180788</u>
- 70. Marshall PW, Morrison, NM V, Mifsud A, Gibbs M, Khan N, Meade T. The moderating effect of treatment engagement on fear-avoidance beliefs in people with chronic low back pain. *Clin J Pain*. 2021;37(12):872-880. <u>https://doi.org/10.1097/AJP.00000000000991</u>
- 71. Marshal PW, Morrison NMV, Gibbs M, Schabrun SM. The effect of exercise engagement on low back disability at 12-months is mediated by pain and catastrophizing in a community sample of people with chronic low back pain. *Behav Res Ther*. 2022;159:104205. https://doi.org/10.1016/j.brat.2022.104205
- 72. Bernard P, Ninot G, Bernard PL, et al. Effects of a six-month walking intervention on depression in inactive post-menopausal women: a randomized controlled trial. *Aging Ment Health.* 2015;19(6):485-492. <u>https://doi.org/10.1080/13607863.2014.948806</u>
- 73. Priore LB, Lack S, Garcia C, Azevedo FM, de Oliveira Silva D. Two weeks of wearing a knee brace compared with minimal intervention on kinesiophobia at 2 and 6 weeks in people with patellofemoral pain: a randomized controlled trial. *Arch Phys Med Rehabil.* 2020;101(4):613-623. <u>https://doi.org/10.1016/j.apmr.2019.10.190</u>
- 74. Strandberg E, Bean C, Vassbakk-Svindland K, et al. Who makes it all the way? Participants vs. decliners, and completers vs. drop-outs, in a 6-month exercise trial during cancer treatment. Results from the Phys-Can RCT. *Support Care Cancer*. 2022;30(2):1739-1748. https://doi.org/10.1007/s00520-021-06576-0

75. Uritani D, Kasza J, Campbell PK, Metcalf B, Egerton T. The association between psychological characteristics and physical activity levels in people with knee osteoarthritis: a cross-sectional analysis. *BMC Musculoskelet Disord*. 2020;21(1):269.

https://doi.org/10.1186/s12891-020-03305-2

76. Alamam DM, Moloney N, Leaver A, Alsobayel HI, Mackey MG. Multidimensional prognostic factors for chronic low back pain-related disability: a longitudinal study in a Saudi population. *Spine J.* 2019;19(9),1548-1558.

https://doi.org/10.1016/j.spinee.2019.05.010

- 77. Massé-Alarie H, Beaulieu LD, Preuss R, Schneider C. Influence of paravertebral muscles training on brain plasticity and postural control in chronic low back pain. *Scand J Pain*. 2016;12(1):74-83. <u>https://doi.org/10.1016/j.sjpain.2016.03.005</u>
- 78. Polaski AM, Phelps AL, Smith TJ, et al. Integrated meditation and exercise therapy: a randomized controlled pilot of a combined nonpharmacological intervention focused on reducing disability and pain in patients with chronic low back pain. *Pain Med*. 2021;22(2):444-458. <u>https://doi.org/10.1093/pm/pnaa403</u>
- 79. Rabey M, Smith A, Beales D, Slater H, O'Sullivan P. Multidimensional prognostic modelling in people with chronic axial low back pain. *Clin J Pain*. 2017;33(10):877-891. <u>https://doi.org/10.1097/AJP.00000000000478</u>
- 80. Sandal LF, Bach K, Øverås CK, et al. Effectiveness of app-delivered, tailored selfmanagement support for adults with lower back pain–related disability: a SELFBACK randomized clinical trial. *JAMA Intern Med.* 2021;181(10):1288-1296. https://doi:10.1001/jamainternmed.2021.4097

81. Suttmiller AMB, Cavallario JM, Baez SE, Martinez JC, McCann RS. Perceived instability, pain, and psychological factors for prediction of function and disability in individuals with chronic ankle instability. *J Athl Train.* 2022;57(11-12):1048-1054.

https://doi.org/10.4085/1062-6050-0605.21

- 82. Demmelmaier I, Björk A, Dufour AB, Nordgren B, Opava, CH. Trajectories of fearavoidance beliefs on physical activity over two years in people with rheumatoid arthritis. *Arthritis Care Res.* 2018;70(5):695-702. <u>http://doi.org/10.1002/acr.23419</u>
- 83. Ho-A-Tham N, Struyf N, Ting-A-Kee B, de Almeida Mello J, Vanlandewijck Y, Dankaerts W. Physical activity, fear avoidance beliefs and level of disability in a multi-ethnic female population with chronic low back pain in Suriname: a population-based study. *PLOS One*. 2022;17(10):e0276974. <u>https://doi.org/10.1371/journal.pone.0276974</u>
- 84. Aydemir B, Huang CH, Foucher KC. Strength and physical activity in osteoarthritis: the mediating role of kinesiophobia. *J Orthop Res.* 2022;40(5):1135-1142. http://doi.org/10.1002/jor.25151 81
- 85. Baday-Keskin D, Ekinci B. The relationship between kinesiophobia and health-related quality of life in patients with rheumatoid arthritis: a controlled cross-sectional study. *Joint Bone Spine*. 2022;89(2):105275. <u>http://doi.org/10.1016/j.jbspin.2021.105275</u>
- 86. Dąbek J, Knapik A, Gallert-Kopyto W, Brzęk AM, Piotrkowicz J, Gąsior Z. Fear of movement (kinesiophobia) - an underestimated problem in Polish patients at various stages of coronary artery disease. *Ann Agric Environ Med.* 2020;27(1):56-60.

http://doi.org/10.26444/aaem/106143

- 87. Knapik A, Dąbek J, Brzęk A. Kinesiophobia as a problem in adherence to physical activity recommendations in elderly Polish patients with coronary artery disease. *Patient Prefer Adherence*. 2019;13:2129-2135. <u>http://doi.org/10.2147/PPA.S216196</u>
- Minetama M, Kawakami M, Teraguchi M, et al. Associations between psychological factors and daily step count in patients with lumbar spinal stenosis. *Physiother Theory Pract*. 2022;38(10):1519-1527. <u>http://doi.org/10.1080/09593985.2020.1855685</u>
- 89. Pazzinatto MF, Silva DO, Willy RW, Azevedo FM, Barton CJ. Fear of movement and (re)injury is associated with condition specific outcomes and health-related quality of life in women with patellofemoral pain. *Physiother Theory Pract.* 2022;38(9):1254-1263. http://doi.org/10.1080/09593985.2020.1830323
- 90. Wasiuk-Zowada D, Brzęk A, Krzystanek E, Knapik A. Kinesiophobia in people with multiple sclerosis and its relationship with physical activity, pain and acceptance of disease. *Medicina*. 2022;58(3):414. <u>http://doi.org/10.3390/medicina58030414</u>
- 91. Yuksel Karsli T, Bayraktar D, Ozer Kaya D, et al. Comparison of physical activity levels among different sub-types of axial spondyloarthritis patients and healthy controls. *Mod Rheumatol.* 2021;31(6):1202-1207. <u>http://doi.org/10.1080/14397595.2021.1891676</u>
- 92. Birimoglu Okuyan C, Deveci E. The effectiveness of Tai Chi Chuan on fear of movement, prevention of falls, physical activity, and cognitive status in older adults with mild cognitive impairment: a randomized controlled trial. *Perspect Psychiatr Care*. 2021;57(3):1273-1281. <u>https://doi.org/10.1111/ppc.12684</u>
- 93. de Vries HJ, Reneman MF, Groothoff JW, Geertzen JHB, Brouwer S. Workers who stay at work despite chronic nonspecific musculoskeletal pain: do they differ from workers with

sick leave? *J Occup Rehabil*. 2012;22(4):489-502. <u>https://doi.org/10.1007/s10926-012-9360-</u>6

- 94. Duarte N, Santos C, Hughes SL, Paúl C. Feasibility and impact of Fit & Strong! Program in Portuguese older adults with osteoarthritis: a pilot randomized controlled trial. *Geriatr Nurs*. 2020;41(6):804-811. <u>https://doi.org/10.1016/j.gerinurse.2020.04.005</u>
- 95. Gutke A, Lundberg M, Östgaard HC, Öberg B. Impact of postpartum lumbopelvic pain on disability, pain intensity, health-related quality of life, activity level, kinesiophobia, and depressive symptoms. *Eur Spine J.* 2011;20(3):440-448. <u>https://doi.org/10.1007/s00586-</u> 010-1487-6
- 96. Ilves O, Häkkinen A, Dekker J, et al. Effectiveness of postoperative home-exercise compared with usual care on kinesiophobia and physical activity in spondylolisthesis: a randomized controlled trial. *J Rehab Med.* 2017;49(9):751-757. https://doi.org/10.2340/16501977-2268
- 97. Jakobsson M, Brisby H, Gutke A, et al. Prediction of objectively measured physical activity and self-reported disability following lumbar fusion surgery. *World Neurosurg*.
 2019;121:e77-e88. <u>https://doi.org/10.1016/j.wneu.2018.08.229</u>
- 98. Larsson C, Ekvall Hansson E, Sundquist K, Jakobsson U. Kinesiophobia and its relation to pain characteristics and cognitive affective variables in older adults with chronic pain. BMC Geriatr. 2016;16:128. <u>https://doi.org/10.1186/s12877-016-0302-6</u>
- 99. Ledoux E, Dubois JD, Descarreaux M. Physical and psychosocial predictors of functional trunk capacity in older adults with and without low back pain. *J Manipulative Physiol Ther*. 2012;35(5):338-345. <u>https://doi.org/10.1016/j.jmpt.2012.04.007</u>

- 100. Lindbäck Y, Tropp H, Enthoven P, Abbott A, Öberg B. PREPARE: presurgery physiotherapy for patients with degenerative lumbar spine disorder: a randomized controlled trial. *Spine J.* 2018;18(8):1347-1355. <u>https://doi.org/10.1016/j.spinee.2017.12.009</u>
- 101. Lundgren S, Olausson A, Bergström G, Stenström CH. Physical activity and pain among patients with rheumatoid arthritis - a cognitive approach. *Adv Physiother*. 2005;7(2):77-83. <u>https://doi.org/10.1080/14038190510010322</u>
- 102. Nijs J, Meeus M, Heins M, Knoop H, Moorkens G, Bleijenberg G. Kinesiophobia, catastrophizing and anticipated symptoms before stair climbing in chronic fatigue syndrome: an experimental study. *Disabil Rehabil*. 2012;34(15):1299-1305.

https://doi.org/10.3109/09638288.2011.641661

103. Okan F, Özsoy AZ, Sandalcı T, Yılar Erkek Z, Zincir H. The relationship between kinesiophobia and physical activity levels, gestational weight gain, and musculoskeletal pain in pregnant women. *Women Health*.2023;63(7):551-561.

https://doi.org/10.1080/03630242.2023.2238843

- 104. Roaldsen KS, Elfving B, Stanghelle JK, Talme T, Mattsson E. Fear-avoidance beliefs and pain as predictors for low physical activity in patients with leg ulcer. *Physiother Res Int*. 2009;14(3):167-180. <u>https://doi.org/https://doi.org/10.1002/pri.433</u>
- 105. Román-Veas J, Gutiérrez-Monclus R, López-Gil JF, et al. Baseline predictors related to functional outcomes in patients older than sixty years with complex regional pain syndrome type 1 after distal radius fracture treated conservatively: a prospective observational study. *Int Orthop.* 2023;47(9):2275-2284. https://doi.org/10.1007/s00264-023-05880-0

- 106. Roussel NA, De Kooning M, Nijs J, Wouters K, Cras P, Daenen L. The role of sensorimotor incongruence in pain in professional dancers. *Motor Control*. 2015;19(4):271-288. <u>https://doi.org/10.1123/ijsnem.2013-0074</u>
- 107. Saulicz M, Saulicz E, Knapik A, et al. Impact of physical activity and fitness on the level of kinesiophobia in women of perimenopausal age. *Prz Menopauzalny*. 2016;15(2):104-111. <u>https://doi.org/10.5114/pm.2016.61193</u>
- 108. Smith TO, Parsons S, Ooms A, et al. Randomised controlled trial of a behaviour change physiotherapy intervention to increase physical activity following hip and knee replacement: the PEP-TALK trial. *BMJ Open*. 2022;12(5):e061373. <u>https://doi.org/10.1136/bmjopen-</u> 2022-061373
- 109. Tore NG, Oskay D, Haznedaroglu S. The quality of physiotherapy and rehabilitation program and the effect of telerehabilitation on patients with knee osteoarthritis. *Clin Rheumatol.* 2023;42(3):903-915. <u>https://doi.org/10.1007/s10067-022-06417-3</u>
- 110. Zhang S, Wang Z, Lin X, et al. Kinesiophobia and self-management behaviour related to physical activity in Chinese patients with coronary heart disease: the mediating role of selfefficacy. *Nurs Open*. 2023;10(1):105-114. <u>https://doi.org/10.1002/nop2.1283</u>
- 111. Alschuler KN, Hoodin F, Murphy SL, Rice J, Geisser ME. Factors contributing to physical activity in a chronic low back pain clinical sample: a comprehensive analysis using continuous ambulatory monitoring. *Pain*. 2011;152(11):2521-2527. https://doi.org/10.1016/j.pain.2011.07.017
- 112. Altuğ F, Ünal A, Kilavuz G, Kavlak E, Çitişli V, Cavlak U. Investigation of the relationship between kinesiophobia, physical activity level and quality of life in patients

with chronic low back pain. *J Back Musculoskelet Rehabil*. 2016;29(3):527-531. https://doi.org/10.3233/BMR-150653

- 113. Carvalho FA, Maher CG, Franco MR, et al. Fear of movement is not associated with objective and subjective physical activity levels in chronic nonspecific low back pain. *Arch Phys Med Rehabil.* 2017;98(1):96-104. <u>http://doi.org/10.1016/j.apmr.2016.09.115</u>
- 114. Demirbüken İ, Özgül B, Kuru Çolak T, Aydoğdu O, Sarı Z, Yurdalan SU. Kinesiophobia in relation to physical activity in chronic neck pain. *J Back Musculoskelet Rehabil.* 2016;29(1):41-47. <u>http://doi.org/10.3233/BMR-150594</u>
- 115. Elfving B, Andersson T, Grooten WJ. Low levels of physical activity in back pain patients are associated with high levels of fear-avoidance beliefs and pain catastrophizing. *Physiother Res Int.* 2007;12(1):14-24. <u>http://doi.org/10.1002/pri.355</u>
- 116. González de la Flor Á, García Pérez de Sevilla G, Domíngez Balmaseda D, Martín Vera D, Montero Martínez M, Del Blanco Muñiz JÁ. Relationship between self-efficacy and headache impact, anxiety, and physical activity levels in patients with chronic tension-type headache: an observational study. *Behav Neurol.* 2022;2022:8387249.

http://doi.org/10.1155/2022/8387249

- 117. Helmus M, Schiphorst Preuper HR, Hof AL, Geertzen JH, Reneman MF. Psychological factors unrelated to activity level in patients with chronic musculoskeletal pain. *Eur J Pain*. 2012;16(8):1158-1165. <u>http://doi.org/10.1002/j.1532-2149.2011.00109.x</u>
- 118. Huijnen IP, Verbunt JA, Peters ML, Seelen HA. Is physical functioning influenced by activity-related pain prediction and fear of movement in patients with subacute low back pain? *Eur J Pain.* 2010;14(6):661-666. <u>http://doi.org/10.1016/j.ejpain.2009.10.014</u>

- 119. Koho P, Orenius T, Kautiainen H, Haanpää M, Pohjolainen T, Hurri H. Association of fear of movement and leisure-time physical activity among patients with chronic pain. J *Rehabil Med.* 2011;43(9):794-799. <u>http://doi.org/10.2340/16501977-0850</u>
- 120. Lotzke H, Jakobsson M, Gutke A, et al. Patients with severe low back pain exhibit a low level of physical activity before lumbar fusion surgery: a cross-sectional study. *BMC Musculoskelet Disord*. 2018;19(1):365. <u>http://doi.org/10.1186/s12891-018-2274-5</u>
- 121. Navarro-Ledesma S, Pruimboom L, Lluch E, Dueñas L, Mena-Del Horno S, Gonzalez-Muñoz A. The relationship between daily physical activity, psychological factors, and vegetative symptoms in women with fibromyalgia: a cross-sectional observational study. *Int J Environ Res Public Health.* 2022;19(18):11610. <u>http://doi.org/10.3390/ijerph191811610</u>
- 122. Pedler A, Kamper SJ, Maujean A, Sterling M. Investigating the fear avoidance model in people with whiplash: the association between fear of movement and in vivo activity. *Clin J Pain.* 2018;34(2):130-137. <u>http://doi.org/10.1097/AJP.00000000000524</u>
- 123. Sertel M, Aydoğan Arslan S, Tütün Yümin E, Demirci CS, Tarsuslu Şimşek T. Investigation of the relationship between physical activity, kinesiophobia and fear of falling in older adults with chronic pain. *Somatosens Mot Res.* 2021;38(3):241-247. http://doi.org/10.1080/08990220.2021.1958774
- 124. Verbunt JA, Sieben JM, Seelen HA, et al. Decline in physical activity, disability and painrelated fear in sub-acute low back pain. *Eur J Pain*. 2005;9(4):417-425. http://doi.org/10.1016/j.ejpain.2004.09.011
- 125. Corrigan P, Cortes DH, Pontiggia L, Silbernagel KG. The degree of tendonitis is related to symptom severity and physical activity levels in patients with midportion Achilles

tendinopathy. Int J Sports Phys Ther. 2018;13(2):196-207.

http://doi.org/10.26603/ijspt20180196

126. Glaviano NR, Baellow A, Saliba S. Physical activity levels in individuals with and without patellofemoral pain. *Phys Ther Sport*. 2017;27:12-16.

https://doi.org/10.1016/j.ptsp.2017.07.002

- 127. Leonhardt C, Lehr D, Chenot JF, et al. Are fear-avoidance beliefs in low back pain patients a risk factor for low physical activity or vice versa? A cross-lagged panel analysis. *Psychosoc Med.* 2009;6:Doc01. <u>https://doi.org/10.3205/psm000057</u>
- 128. Pastor-Mira, MA, López-Roig S, Peñacoba C, Sanz-Baños Y, Lledó A, Velasco L. Predicting walking as exercise in women with fibromyalgia from the perspective of the theory of planned behavior. *Women Health*. 2020;60(4),412-425.

https://doi.org/10.1080/03630242.2019.1662869

- 129. Spaderna H, Hoffman JM, Hellwig S, Brandenburg VM. Fear of physical activity, anxiety, and depression: barriers to physical activity in outpatients with heart failure? *Eur J Health Psychol.* 2020;27(1):3-13. <u>http://doi.org/10.1027/2512-8442/a000042</u>
- 130. Baykal Şahin H, Kalaycıoğlu E, Şahin M. The effect of cardiac rehabilitation on kinesiophobia in patients with coronary artery disease. *Turk J Phys Med Rehabil*. 2021;67(2):203-210. <u>http://doi.org/10.5606/TFTRD.2021.5164</u>
- 131. Marques-Sule E, Söderlund A, Almenar L, Espí-López GV, López-Vilella R, Bäck M. Influence on kinesiophobia by disability, physical, and behavioural variables after a heart transplantation. *Eur J Cardiovasc Nurs*. 2022;21(6):537-543.

http://doi.org/10.1093/eurjcn/zvab134

132. Barchek AR, Dlugonski D, Baez SE, Hoch MC, Hoch J. The relationship between injuryrelated fear and physical activity in people with a history of anterior cruciate ligament reconstruction. *Phys Ther Sport*. 2021;50:201-205.

https://doi.org/10.1016/j.ptsp.2021.05.010

- 133. Donnarumma P, Presaghi F, Tarantino R, Fragale M, Rullo M, Delfini R. The impact of pelvic balance, physical activity, and fear-avoidance on the outcome after decompression and instrumented fusion for degenerative lumbar stenosis. *Eur Spine J*. 2017;26(2):428-433. http://doi.org/10.1007/s00586-016-4644-8
- 134. Norte GE, Solaas H, Saliba SA, Goetschius J, Slater LV, Hart JM. The relationships between kinesiophobia and clinical outcomes after ACL reconstruction differ by selfreported physical activity engagement. *Phys Ther Sport.* 2019;40:1-9. <u>http://doi.org/10.1016/j.ptsp.2019.08.002</u>
- 135. Olsson N, Karlsson J, Eriksson BI, Brorsson A, Lundberg M, Silbernagel KG. Ability to perform a single heel-rise is significantly related to patient-reported outcome after Achilles tendon rupture. *Scand J Med Sci Sports*. 2014;24(1):152-158. <u>http://doi.org/10.1111/j.1600-</u> 0838.2012.01497.x
- 136. Zelle DM, Corpeleijn E, Klaassen G, Schutte E, Navis G, Bakker SJL. Fear of movement and low self-efficacy are important barriers in physical activity after renal transplantation. *PLOS One.* 2016;11(2):e0147609. <u>http://doi.org/10.1371/journal.pone.0147609</u>
- 137. Coronado RA, Robinette PE, Henry AL, et al. Bouncing back after lumbar spine surgery: early postoperative resilience is associated with 12-month physical function, pain interference, social participation, and disability. *Spine J.* 2021;21(1):55-63.
 <u>http://doi.org/10.1016/j.spinee.2020.07.013</u>

- 138. Aykut Selçuk M, Karakoyun A. Is there a relationship between kinesiophobia and physical activity level in patients with knee osteoarthritis? *Pain Med.* 2020;21(12):3458-3469. http://doi.org/10.1093/pm/pnaa180
- 139. Doğan N, Taşci S. Pain, physical activity, and kinesiophobia levels in individuals with knee osteoarthritis: a cross-sectional study. *Turk Klin J Nurs Sci.* 2022;14(4):1144-1154. https://doi:10.5336/nurses.2022-89904
- 140. Kilinç H, Karahan S, Atilla B, Kinikli Gİ. Can fear of movement, depression and functional performance be a predictor of physical activity level in patients with knee osteoarthritis? *Arch Rheumatol.* 2019;34(3):274-280.

http://doi.org/10.5606/ArchRheumatol.2019.7160

- 141. Özlü A, Akdeniz Leblebicier M. Does remission in rheumatoid arthritis bring kinesiophobia, quality of life, fatigue, and physical activity closer to normal? *Arch Rheumatol.* 2022;37(4):603-612. <u>http://doi.org/10.46497/ArchRheumatol.2022.9552</u>
- 142. Peres D, Tordi N, Demartino AM, Cheng JL, Sagawa Jr Y, Prati C. Relationships between physical activity levels and disease activity, functional disability and kinesiophobia in chronic rheumatic diseases. *Sci Sports*. 2023;38(5-6):607-615. https://doi.org/10.1016/j.scispo.2022.07.013
- 143. Smulligan KL, Wingerson MJ, Seehusen CN, Little CC, Wilson JC, Howell DR. More physical activity is correlated with reduction in kinesiophobia for adolescents with persistent symptoms after concussion. *J Sport Rehabil*. 2022;32(2):196-202.

https://doi.org/10.1123/jsr.2022-0193

- 144. Sütçü G, Ayvat E, Kilinç M. Effects of fatigue and kinesiophobia on functional capacity, physical activity and quality of life in Parkinson's disease. *Int J Rehabil Res.* 2021;44(1):65-68. <u>http://doi.org/10.1097/MRR.0000000000449</u>
- 145. Igelström H, Emtner M, Lindberg E, Åsenlöf P. Physical activity and sedentary time in persons with obstructive sleep apnea and overweight enrolled in a randomized controlled trial for enhanced physical activity and healthy eating. *Sleep Breath*. 2013;17(4):1257-1266. <u>https://doi.org/10.1007/s11325-013-0831-6</u>
- 146. Ozer AY, Karaca S, Senocak E, Oguz S, Polat MG. Does kinesiophobia limit physical activity and quality of life in asthmatic patients? *Int J Rehabil Res.* 2022;45(3):230-236. http://doi.org/10.1097/MRR.000000000000534
- 147. Wang J, Bai C, Zhang Z, Chen O. The relationship between dyspnea-related kinesiophobia and physical activity in people with COPD: cross-sectional survey and mediated moderation analysis. *Heart Lung*. 2023;59:95-101. <u>https://doi.org/10.1016/j.hrtlng.2023.02.007</u>
- 148. Crommert ME, Flink I, Gustavsson C. Predictors of disability attributed to symptoms of increased interrecti distance in women after childbirth: an observational study. *Phys Ther*. 2021;101(6):pzab064. <u>https://doi.org/10.1093/ptj/pzab064</u>
- 149. Atıcı E, Girgin N, Çevik Saldıran T. The effects of social isolation due to COVID-19 on the fear of movement, falling, and physical activity in older people. *Australas J Ageing*. 2022;41(3):407-413. <u>http://doi.org/10.1111/ajag.1306390</u>
- 150. Miller L, Ohlman T, Naugle KM. Sensitivity to physical activity predicts daily activity among pain-free older adults. *Pain Med.* 2018;19(8):1683-1692. <u>http://doi.org/10.1093/pm/pnx251</u>

- 151. Ohlman T, Miller L, Naugle KE, Naugle KM. Physical activity levels predict exerciseinduced hypoalgesia in older adults. *Med Sci Sports Exerc*. 2018;50(10):2101-2109. <u>http://doi.org/10.1249/MSS.00000000001661</u>
- 152. Woby SR, Roach NK, Urmston M, Watson PJ. Psychometric properties of the TSK-11: a shortened version of the Tampa Scale for Kinesiophobia. *Pain.* 2005;117(1-2):137-144. <u>http://doi.org/10.1016/j.pain.2005.05.029</u>
- 153. Jørgensen MB, Damsgård E, Holtermann A, Anke A, Søgaard K, Røe C. Properties of the Tampa Scale for Kinesiophobia across workers with different pain experiences and cultural backgrounds: a Rasch analysis. *J Appl Meas*. 2015;16(2):218-227.

http://jampress.org/abst2015.htm

- 154. Bäck M, Jansson B, Cider A, Herlitz J, Lundberg M. Validation of a questionnaire to detect kinesiophobia (fear of movement) in patients with coronary artery disease. *J Rehabil Med.* 2012;44(4):363-369. <u>http://doi.org/10.2340/16501977-0942</u>
- 155. Neblett R, Hartzell MM, Mayer TG, Bradford EM, Gatchel RJ. Establishing clinically meaningful severity levels for the Tampa Scale for Kinesiophobia (TSK-13). *Eur J Pain*. 2016;20(5):701-710. <u>http://doi.org/10.1002/ejp.795</u>
- 156. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. *Pain*. 1993;52(2):157-168. <u>http://doi.org/10.1016/0304-3959(93)90127-B</u>
- 157. Knapik A, Saulicz E, Gnat R. Kinesiophobia introducing a new diagnostic tool. J Hum Kinet. 2011;28:25-31. <u>http://doi.org/10.2478/v10078-011-0019-8</u>
- 158. Shelby RA, Somers TJ, Keefe FJ, et al. Brief Fear of Movement Scale for osteoarthritis. *Arthritis Care Res.* 2012;64(6):862-871. <u>http://doi.org/10.1002/acr.21626</u>

- 159. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire:
 12-country reliability and validity. *Med Sci Sports Exerc*. 2003;35(8):1381-1395.
 http://doi.org/10.1249/01.MSS.0000078924.61453.FB
- 160. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr.* 1982;36(5):936-942. <u>http://doi.org/10.1093/ajcn/36.5.936</u>
- 161. Grimby G, Börjesson M, Jonsdottir IH, Schnohr P, Thelle DS, Saltin B. The "Saltin-Grimby Physical Activity Level Scale" and its application to health research. *Scand J Med Sci Sports*. 2015;25 Suppl 4:119-125. <u>http://doi.org/10.1111/sms.12611</u>
- 162. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. *Can J Appl Sport Sci.* 1985;10(3):141-146.
- 163. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. *J Chronic Dis.* 1978;31(12):741-755. <u>http://doi.org/10.1016/0021-9681(78)90058-9</u>
- 164. Voorrips LE, Ravelli AC, Dongelmans PC, Deurenberg P, Van Staveren WA. A physical activity questionnaire for the elderly. *Med Sci Sports Exerc.* 1991;23(8):974-979.
- 165. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. *J Clin Epidemiol*. 2003;56(12):1163-1169. <u>http://doi.org/10.1016/S0895-4356(03)00220-8</u>
- 166. Tegner Y, Lysholm J. Rating systems in the evaluation of knee ligament injuries. *Clin Orthop Relat Res.* 1985;198:43-49. <u>http://doi.org/10.1097/00003086-198509000-00007</u>

- 167. Zahiri CA, Schmalzried TP, Szuszczewicz ES, Amstutz HC. Assessing activity in joint replacement patients. *J Arthroplasty*. 1998;13(8):890-895. <u>http://doi.org/10.1016/s0883-5403(98)90195-4</u>
- 168. Mannerkorpi K, Hernelid C. Leisure time physical activity instrument and Physical Activity at Home and Work instrument. Development, face validity, construct validity and test-retest reliability for subjects with fibromyalgia. *Disabil Rehabil*. 2005;27:695-701. <u>https://doi.org/10.1080/09638280400009063</u>
- 169. Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). J Pub Health. 2006;14:66-70.

https://doi.org/10.1007/s10389-006-0024-x

- 170. Frey I, Berg A, Grathwohl D, Keul J. Freiburg Questionnaire of physical activity-development, evaluation and application. *Soz Praventivmed.* 1999;44(2):55-64. http://doi.org/10.1007/BF01667127.
- 171. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing cardiorespiratory fitness without performing exercise testing. *Am J Prev Med.* 2005;29(3):185-193. <u>https://doi.org/10.1016/j.amepre.2005.06.004</u>
- 172. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MMB. Peer reviewed: the Rapid Assessment of Physical Activity (RAPA) among older adults. *Prev Chronic Dis.* 2006;3(4):A118.
- 173. Montoye HJ, Kemper HCG, Saris WHM, Washburn RA. *Measuring physical activity and energy expenditure*. Champaign, IL:Human Kinetics. 1996.

- 174. Melzack R, Katz J. The McGill Pain Questionnaire: appraisal and current status. In: Turk DC, Melzack R, eds. *Handbook of Pain Assessment*. 2nd ed. The Guilford Press; 2001:35-52.
- 175. Ross RLP. Clinical assessment of pain. In: van Dieen JH, ed. *Assessment in Occupational Therapy and Physical Therapy*. WB Saunders; 1997:123-133.

176. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis Outcome Score (KOOS)—development of a self-administered outcome measure. J Orthop Sports Phys Ther. 1998;28(2):88-96.

http://doi.org/10.2519/jospt.1998.28.2.88

- 177. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap.* 1994;23(2):129-138.
- 178. Murray DW, Fitzpatrick R, Rogers K, et al. The use of the Oxford hip and knee scores. J Bone Joint Surg Br. 2007;89(8):1010-1014. <u>http://doi.org/10.1302/0301-620X.89B8.19424</u>
- 179. Bush JW, Kaplan RM. The quality of well-being scale (formerly the index of well-being).
 In: McDowell I, ed. *Measuring Health: A Guide to Rating Scales and Questionnaires*. 3rd
 ed. Oxford University Press; 2006:675-683.
- 180. Ware JE Jr. SF-36 health survey update. *Spine*. 2000;25(24):3130-3139. http://doi.org/10.1097/00007632-200012150-00008
- 181. Freyd M. The Graphic Rating Scale. J Educ Psychol. 1923;14:83-102. https://doi.org/10.1037/h0074329
- 182. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. *J Rheumatol.* 1991;18(5):728-733.

- 183. Melzack R, Torgerson WS. On the language of pain. *Anesthesiology*. 1971;34(1):50-59. <u>http://doi.org/10.1097/00000542-197101000-00017</u>
- 184. Page MJ, Sterne JAC, Higgins JPT, Egger M. Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: a review. *Res Synth Methods*. 2021;12(2):248-259. http://doi.org/10.1002/jrsm.1468
- 185. Simonsohn U, Simmons JP, Nelson LD. Better P-curves: making P-curve analysis more robust to errors, fraud, and ambitious P-hacking, a reply to Ulrich and Miller (2015). *J Exp Psychol Gen.* 2015;144(6):1146-1152. <u>http://doi.org/10.1037/xge0000104</u>
- 186. Coull A, Pugh G. Maintaining physical activity following myocardial infarction: a qualitative study. *BMC Cardiovasc Disord*. 2021;21(1):105. <u>http://doi.org/10.1186/s12872-021-01898-7</u>
- 187. Rogerson MC, Murphy BM, Bird S, Morris T. "I don't have the heart": a qualitative study of barriers to and facilitators of physical activity for people with coronary heart disease and depressive symptoms. *Int J Behav Nutr Phys Act*. 2012;9:140. <u>http://doi.org/10.1186/1479-5868-9-140</u>
- 188. Amirova A, Lucas R, Cowie MR, Haddad M. Perceived barriers and enablers influencing physical activity in heart failure: a qualitative one-to-one interview study. *PLOS One*. 2022;17(8):e0271743. <u>http://doi.org/10.1371/journal.pone.0271743</u>
- 189. Freeman AT, Hill D, Newell C, et al. Patient perceived barriers to exercise and their clinical associations in difficult asthma. *Asthma Res Pract*. 2020;6:5. http://doi.org/10.1186/s40733-020-00058-6
- 190. Ellis T, Boudreau JK, DeAngelis TR, et al. Barriers to exercise in people with Parkinson disease. *Phys Ther*. 2013;93(5):628-636. <u>http://doi.org/10.2522/ptj.20120279</u>

- 191. Simpson LA, Eng JJ, Tawashy AE. Exercise perceptions among people with stroke: Barriers and facilitators to participation. *Int J Ther Rehabil.* 2011;18(9):520-530. http://doi.org/10.12968/ijtr.2011.18.9.520
- 192. Ramsey KA, Zhou W, Rojer AGM, Reijnierse EM, Maier AB. Associations of objectively measured physical activity and sedentary behaviour with fall-related outcomes in older adults: A systematic review. *Ann Phys Rehabil Med.* 2022;65(2):101571.

http://doi.org/10.1016/j.rehab.2021.101571

- 193. Gay C, Eschalier B, Levyckyj C, Bonnin A, Coudeyre E. Motivators for and barriers to physical activity in people with knee osteoarthritis: A qualitative study. *Joint Bone Spine*. 2018;85(4):481-486. <u>http://doi.org/10.1016/j.jbspin.2017.07.007</u>
- 194. Lööf H, Johansson UB. "A body in transformation"-An empirical phenomenological study about fear-avoidance beliefs towards physical activity among persons experiencing moderate-to-severe rheumatic pain. *J Clin Nurs*. 2019;28(1-2):321-329. http://doi.org/10.1111/jocn.14606
- 195. Rethman KK, Mansfield C, Moeller J, et al. Kinesiophobia is associated with poor function and modifiable through interventions in people with patellofemoral pain: a systematic review with individual participant data correlation meta-analysis. *Phys Ther.* 2023;103(9):pzad074. <u>http://doi.org/10.1093/ptj/pzad074</u>
- 196. Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. *Int J Behav Nutr Phys Act.* 2008;5:56. <u>http://doi.org/10.1186/1479-5868-5-56</u>

197. Lundberg M, Styf J, Jansson B. On what patients does the Tampa Scale for Kinesiophobia fit? *Physiother Theory Pract*. 2009;25(7):495-506.

http://doi.org/10.3109/09593980802662160

198. Gabelica M, Bojčić R, Puljak L. Many researchers were not compliant with their published data sharing statement: a mixed-methods study. *J Clin Epidemiol*. 2022;150:33-

41. <u>http://doi.org/10.1016/j.jclinepi.2022.05.019</u>

- 199. Lahart IM, Boisgontier MP. Kinesiophobia and physical activity: data and Rmd script for meta-analysis. [Data set, Rmd scripts, supplementary material]. Version 1.1; 2024. <u>https://doi.org/10.5281/zenodo.8216112</u>
- 200. Allen L, O'Connell A, Kiermer V. How can we ensure visibility and diversity in research contributions? How the contributor role taxonomy (CRediT) is helping the shift from authorship to contributorship. *Learn Publ.* 2019;32(1):71-74. https://doi.org/http://doi.org/10.1002/leap.1210

TABLES AND FIGURES

Table 1.	Sample	characteristics	of	studies	included	in	the	systematic	review.

Study (Year)	N (# women)	Mean age (SD or range)	Health status	Mean kinesiophobia (SD or range; measure)	Mean physical activity (SD or range; tool)	Level of pain (tool)	Study Design	Context of Assessment	Normalized Quality Score	Corr.	p- value
Alamam (2019)	100 (62)	40 (13.6)	Chronic low back pain	n.a. (FABQ)	n.a. (IPAQ)	4.8 (VAS)	Cohort	Clinical	7.0	r = -0.17	0.116
Alzahrani (2021)	26 (11)	43.6 (14.3)	Chronic low back pain	40.19 (9.20; TKS- 17)	MPA: 76.07 min/day (34.45, wrist accelero.) VPA: 0.29 min/day (1.22; wrist accelero.) 13302 steps/day (5141; wrist accelero.)	4(3.VAS)	RCT	Clinical	8.8	r = 0.22 r = -0.05 r = -0.21	0.28 [‡] 0.003 [‡] 0.30 [‡]
Alschuler (2011)	20 (9)	46.1 (9.35)	Chronic low back pain	30.55 (TSK-17)	228 counts/min (wrist accelero.)	4.87 (NRS)	Cross- Sectional	Clinical	6.0	r= -0.48 [‡]	0.03
Altuğ (2016)	112 (73)	45.0 (14.6)	Chronic low back pain	44.30 (TSK-17)	5495 MET-min/week (IPAQ)	3.45 (VAS)	Cross- Sectional	Clinical	8.0	r = -0.096	0.313
Assadourian (2020)	147 (88)	49 (12)	Chronic low back pain	n.a. (TSK-17)	n.a. (diary; $<$ vs. \ge 1h/week)	6.7 (NRS)	Cross- Sectional	n.a.	8.0	$r = -0.022^{\dagger}$	0.813†
Atici (2022)	254 (171)	n.a. (>65)	Older adults	54.55 (KCS)	182.8 (PASE)	n.a.	Cross- Sectional	Online	9.0	$\rho = -0.345$	< 0.001
Ayedemir (2022)	37 (25)	58.8 (8.6)	Knee osteoarthritis	40.3 (TSK-17)	4.8 (UCLA)	52.0 (KOOS-P)	Cross- Sectional	Clinical	7.0	r = -0.773	< 0.05
Aykut Selcuk (2020)	67 (67) 29 (0)	60.6 (8.0) 61.6 (8.1)	Knee osteoarthritis Knee osteoarthritis	44.8 (TSK-17) 42.0 (TSK-17)	n.a. (IPAQ; low vs. moderate vs. high) n.a. (IPAQ; low vs. moderate vs. high)	4.6 (VAS) 2.9 (VAS)	Cross- Sectional	Clinical	7.0	r = -0.247 r = -0.309	0.019 0.116
Baday-Keskin (2022)	88 (67) 93 (67)	52 (n.a.) 45 (n.a.)	Rheumatoid arthritis Healthy adults	45 (TSK-17) 39 (TSK-17)	594 MET-min/week (IPAQ) 971 MET-min/week (IPAQ)	4.8 (VAS) n.a.	Cross- Sectional	Clinical	7.0	r = -0.12 n.a.	>0.05
Baez (2020)	40 (24)	24.3 (4.1)	Surgery (ACLR)	18.2 (TSK-11)	8 657 steps/day (hip pedo.) 7.7 (TAS)	81.5 (KOOS-P)	Cross- Sectional	Clinical	8.0	$r = 0.181^{\dagger}$ n.a.	0.265 [†] n.a.
Bahar Özdemir (2021)	101 (59)	33.9 (6.0)	Healthy	36.4 (5.8; TSK-17)	756 MET-min/week (1090; IPAQ)	3.1 (3.3; NRS)	Cross- Sectional	Online	8.0	$r = -0.007^{\dagger}$	0.944†
Barchek (2021)	19 (13)	22.9 (3.2)	Anterior cruciate ligament reconstruction	6 (8; FABQ)	11 237.7 steps/day (5667.7; wrist accelero.)	n.a.	Cross- Sectional	Clinical	7.0	$\begin{array}{l} \rho_{steps/day} = \\ 0.12 \\ \rho_{counts/min} = - \\ 0.13 \end{array}$	0.63 0.59
Baykal Şahin (2021)	98 (35)	58.1 (10.4)	Coronary artery disease	41.4 (6.2; TSK-17)	839 MET-min/week (1212; IPAQ)	60.1 (27.2; SF-36)	Cross- Sectional	Clinical	8.0	r = -0.315	0.002
Bernard (2015)	121 (121)	. ,	Post-menopausal women	36 (TSK-17)	n.a. (PAQE)	n.a.	RCT	Clinical	8.8	$r = -0.05^{\dagger}$	0.55^{\dagger}
Carvalho (2017)	119 (82)	39.1 (11.2)	Chronic low back pain	41 (TSK-17)	6844 steps/day (hip accelero.) 296 counts/min (hip accelero.) 22 min MVPA/day (hip accelero.) 333 min LPA/day (hip accelero.) 6.7 (BHPAQ)	6.7 (NRS)	Cross- Sectional	Clinical	9.0	$\rho = -0.15 r = -0.02 \rho = -0.13 r = 0.09 r = -0.18$	>0.05 >0.05 >0.05 >0.05 >0.05 <0.05
Coronado (2021)	248 (126)	62.2 (11.9)	Surgery (laminectomy)	28.4 (TSK-13)	427 counts/min (hip accelerometer)	3.1 (NRS)	Cohort	n.a.	8.0	r = -0.05	>0.05
Corrigan (2018)	53 (18)	54.8 (34-65)	Achilles tendinopathy	35.4 (TSK-17)	n.a. (SGPALS)	n.a.	Cross- Sectional	Clinical	8.0	r = -0.005 [‡]	0.969
Crommert (2021)	139 (139)	37 (4.9)	Post-partum disability	n.a. (TSK-17)	n.a. (hip accelero.)	n.a.	Cross- Sectional	Online	7.0	r = -0.13	>0.05
Dąbek (2020)	130 (n.a) 119 (n.a)	n.a.	Coronary disease Hypertension	44.3 (TSK-Heart) 44.4 (TSK-Heart)	1545 MET-min/week (IPAQ) 1509 MET-min/week (IPAQ)	n.a.	Cross- Sectional	Clinical	8.0	r = -0.523 r = -0.410	<0.001 <0.001

	27 (n.a) 72 (n.a) 86 (n.a) 18 (n.a) 15 (n.a)		Heart valve defect Myocardial infarction Rhythm disorder Stroke Other CVD	44.4 (TSK-Heart) 46.7 (TSK-Heart) 43.3 (TSK-Heart) 49.7 (TSK-Heart) 44.2 (TSK-Heart)	1308 MET-min/week (IPAQ) 1369 MET-min/week (IPAQ) 1660 MET-min/week (IPAQ) 1135 MET-min/week (IPAQ) 2207 MET-min/week (IPAQ)					r = -0.201 r = -0.428 r = -0.563 r = -0.868 r = -0.663	>0.05 <0.001 <0.001 <0.001 0.01
Demmelmaier (2018)	2569 (1875)	60 (11)	Rheumatoid arthritis	n.a. (FABQ)	n.a. (IPAQ)	3.2 (VAS)	Cross- Sectional	Online	9.0	r = -0.005 $r = -0.07^{*}$	< 0.001
Demirbüken (2016)	99 (65)	43.5 (12.8)	Chronic neck pain	41.82 (TSK-17)	3749 MET-min/week (IPAQ)	6.47 (VAS)	Cross- Sectional	Clinical	8.0	r = -0.153	0.13 [‡]
Doğan (2022)	290 (178)	59.86 (15.64)	Knee Osteoarthritis	45.3 (8.6; TSK-17)	n.a. (IPAQ)	5.23 (1.52, VAS)	Cross- Sectional	Clinical	8.0	r = -0.061	0.299
Donnarumma (2017)	51 (12)	61.9 (13.9)	Surgery (laminectomy)	n.a. (TSK-17)	n.a. (IPAQ)	3.5 (GRS)	Cohort	Clinical	7.0	r= - 0.35 [‡]	0.01
Elfving (2007)	64 (39)	47 (19-64)	Chronic low back pain	n.a. (TSK-13)	n.a. (SGPALS)	n.a.	Cross-		9.0	$r = -0.31^{+}$	0.010
5()	()		· · · · · · · · · · · · · · · · · · ·				Sectional	Online			
Glaviano (2017)	20 (15)	22.2 (2.6)	Patellofemoral pain	13.6 (4.4; FABQ)	8629.7 steps/day (1665.3; wrist accelero.)	4.4 (1.9; VAS)	Cross- Sectional	Clinical	8.0	r = -0.481	0.02
González de La Flor (2022)	42 (32)	36.7 (13.2)	Chronic headache	9 (TSK-11)	n.a. (IPAQ)	7.14 (NRS)	Cross- Sectional	n.a.	8.0	$\rho = 0.204$	0.20 [‡]
Helmus (2012)	53 (37)	39.9 (11.3)	Chronic MSK pain	35.4 (TSK-17)	138 counts/min (hip accelero.)	5.8 (VAS)	Cross- Sectional	Clinical	8.0	r = -0.05	0.75
Ho-A-Tham (2022)	210 (210)	48.7 (16.9)	Chronic low back pain	n.a. (FABQ)	2,240 MET-min/week (GPAQ)	n.a.(NRS)	Cross- Sectional	Home Visit	8.0	r = -0.04*	0.49
Huijnen (2010)	111 (52)	44.1 (10.3)	Subacute low back pain	36.0 (TSK-17)	n.a. (trunk accelero.)	n.a. (NRS)	Cohort	Clinical	7.0	$\beta = 0.12$	>0.05
Igelström (2013)	63 (15)	55 (12)	Obstructive sleep apnea syndrome	12.4 (3.1, TSK-7)	7734 steps (3528; armband accelero.) 77 min (54)(MVPA; armband accelero.)	n.a.	Cross- Sectional	Clinical	8.0	r= - 0.251 r= - 0.115	0.049 0.37
Kilinç (2019)	200 (120)	53.2 (6.0)	Knee osteoarthritis	31.8. (TSK-17)	1947 MET-min/week (IPAQ)	24.1 (OKS)	Cross- Sectional	Clinical	8.0	r = -0.693	< 0.001
Knapik (2019)	135 (59)	71.9 (4.8)	Coronary artery disease	43 (TSK-Heart)	2.60 (ad-hoc questionnaire)	n.a.	Cross- Sectional	Clinical	8.0	$\rho = -0.8$	2.6x10 ^{-35‡}
Koppenaal (2022)	204(102)	47.68 (49.05)	Chronic low back pain	26.5 (16.1; FABQ)	77.58 minutes/day (38.85; accelero,)	5.3 (2; NRS)	RCT	Clinical	9.2	r _{MPA} =-0.06 r _{VPA} =-0.03	0.39 0.69
Koho (2011)	93 (60)			n.a. (TSK-17)	n.a. (LTPAQ)	6.4 (VAS)	Cohort	Clinical	7.0	r = 0.10	>0.05
Leonhardt (2009)	449 (224) 338 (17)	45.4 (12.3) 50.4 (13.2)	Acute back pain Chronic back pain	17 (FABQ) 18.4 (FABQ)	34.7 (FQPA) 44.1 (FQPA)	4.9 (1.7; NRS)	Cohort	Clinical	7.0	ρ= -0.93 ρ=-0.95	<0.05 >0.05
Lotzke (2018)	118 (63)	46 (8)	Chronic low back pain	38.1 (TSK-17)	198 min MVPA/week (accelero.) 7493.5 steps/day (accelero.)	6.1 (VAS)	Cross- Sectional	Clinical	9.0	n.a. $r = -0.19^{+}$	n.a. 0.034
Luthi (2018)	433 (n.a.)	n.a.	Chronic MSK pain	44.6 (TSK-17)	4.45 (BHPAQ)	4.45 (BPI-S)	Cross- Sectional	Clinical	8.0	$r=0.067^{\dagger}$	0.759^{\dagger}
Marques-Sule (2022)	117 (51)	56 (12.1)	Heart transplantation	32.5 (TSK-11)	219 MET-min/week (IPAQ)	n.a.	Cross- Sectional	Clinical	9.0	r = -0.32	0.001
Marshall (2017)	218 (130)	36.3 (6.6)	Chronic low back pain	13.8 (5.6, FABQ))	n.a. (open-ended questions < vs. ≥ 30 min/week)	3.6 (2.3; VAS)	Cross- Sectional	Clinical	8.0	r = -0.24	0.0003 [‡]
Marshall (2021)	508 (259)	38.2 (11.8)	Chronic low back pain	13.2 (5.7, FABQ)	n.a. (open-ended questions, $< vs.$ $\ge 30 \text{ min/week}$)	4.5 (2.5, VAS)	Cross- Sectional	Clinical	8.0	r = -0.28	1.3x10 ^{-10‡}
Marshall (2022)	393 (193)	39.2 (12.2)	Chronic low back pain	13.3 (5.2, FABQ)	n.a. (AHS-derived questions, < vs. ≥ 30 min/week)	4.3 (2.3; VAS)	Cohort	Laboratory and Online	7.0	r = -0.01	0.84*
Massé-Alarie (2016)	22 (8)	n.a	Chronic low back pain	n.a. (TSK-17)	n.a MET-min/week (GPAQ)	n.a (VAS)	RCT	Clinical	7.8	r = 0.09	0.69 [‡]
Miller (2018)	52 (32)	67.4 (5.1)	Older Adults	18.9 (TSK-17)	6743 steps/day (hip accelero.)	1.4 (QWBS-P)	Cross- Sectional	Clinical	7.0	r = -0.54	< 0.001
Minetama (2022)	71 (36)	71.6 (5.6)	Lumbar spinal stenosis	24.8 (TSK-11)	3601 steps/day (pedo.)	6.2 (NRS)	Cross- Sectional	Clinical	7.0	r = -0.229	0.055
Navarro-Ledesma (2022)	41 (41)	52.6 (8.0)	Fibromyalgia	27.5 (6.9; TSK-11)	29.1 (18.2; GLTEQ)	n.a.	Cross- Sectional	n.a.	7.0	r = -0.059	>0.05

Norte (2019)	77 (35)	21.6 (7.8)	Surgery (ACLR)	32.9 (6.0; TSK-17)	72.7 (34.9; GLTEQ)	91.4 (9.2; KOOS-P)	Cross- Sectional	Laboratory	7.0	r = -0.312	< 0.05
Ohlman (2018)	52 (33)	67.4 (5.1)	Older adults	18.8 (4.5; TSK-11)	n.a. (hip accelero.)	n.a.	Cohort	Laboratory	8.0	$\rho = -0.29$	< 0.05
Olsson (2014)	81 (12)	40.0 (9.6)	Achilles tendon rupture	35.9 (7.5; TSK-17)	2.9 (1.0; SGPALS)	n.a.	Cross- Sectional	Clinical and Laboratory	7.0	ρ = -0.275	0.013
Ozer (2022)	62 (30)	36.8 (6.1)	Asthma	39.6 (5.8; TSK-17)	2249 MET-min/week (1333; IPAQ)	n.a.	Cross- Sectional	n.a.	8.0	r = -0.889	0.001
Özlü (2022)	45 (45)	54.22 (8.2)	Rheumatoid arthritis	38.5 (15.7; TSK-17)	1980.7 MET-min/week (1104.8; IPAQ)	2.4 (1.7; VAS)	Controlled Trial	Clinical	7.3	r = 0.152	0.32
Palstam (2014)	73 (73)	50.4 (9.3)	Fibromyalgia	9.7 (6.08; FABQ)	4.47(3.64; LTPAI)	58.07 (20.29; FIQpain)	Cross- Sectional	Clinical	7.0	$r_{MPA} = 0.03$ $r_{VPA} = -0.14$	0.80 [‡] 0.23 [‡]
Pastor-Mira (2020)	274 (274)	51.8 (9.1)	Fibromyalgia	27.5 (7.1; TSK-11)	3922.40 steps/week (n.a.; pedo.	6.51 (1.62; NRS)	Cohort	Clinical	8.0	r=0.01	>0.05
Pazzinatto (2022)	92 (92)	n.a. (18-35)	Patellofemoral pain	35.3 (6.8; TSK-17)	7.8 (1.5; BHPAQ)	5.1 (2.1; VAS)	Cross- Sectional	Clinical	8.0	$\rho = -0.14$	0.18 [±]
Pedler (2018)	103 (74)	39.7 (13.9)	Whiplash injury	26 (TSK-11)	9.9% of active time (8.2; trunk accelero.)	4.0 (2.4; VAS)	Cross- Sectional	n.a.	7.0	r = 0.140	>0.05
Peres (2023)	50 (38) 50 (31)	62.8 (10.9) 46.8 (12.3)	Rheumatoid arthritis Spondyloarthritis	42.7 (7.8; TSK-17) 40.8 (7.6; TSK-17)	3706.9 MET-min/week (2958.3; SQUASH) 5614.9 MET-min/week (3681.7; SQUASH)		Cross- Sectional	n.a.	8.0	r = -0.251 r = 0.170	0.055 0.188
Polaski (2021)	38 (26)	37.6 (13.4)	Chronic low back pain	19.5 (12.6; FABQ)	2821 MET-min/week (IPAQ) 11 441 steps/day (accelero.)	3.1 (VAS)	RCT	Clinical	8.4	n.a. r = -0.033	n.a. 0.42
Priore (2020)	50 (37)	22.4 (3.9)	Patellofemoral pain	36.7 (TSK-17)	3088 MET-min/week (IPAQ)	n.a. (VAS)	RCT	Laboratory	9.2	$r = -0.251^{\dagger}$	0.072^{\dagger}
Rabey (2017)	266 (157)	51 (n.a.)	Chronic low back pain	14.3 (FABQ)	114 (0, 302.5) MET-min/week (IPAQ)	5.8 (NRS)	Cohort	Clinical	8.0	r = 0.077	0.25 [*]
Roaldsen (2009)	98 (62)	76 (60-86)	Leg ulcer	12 (FABQ)	2.6 (SGPALS)	1.3 (VRS)	Cross- Sectional	Online	8.0	$r = -0.39^{\dagger}$	7.1x10 ^{-5‡}
Sandal (2021)	461 (255)	45.7 (14.7)	Chronic low back pain	10.3 (5.4; FABQ)	n.a. (SGPALS)	4.9 (1.9; NRS)	RCT	Online	8.8	r = -0.024	0.66*
Saulicz (2016)	105 (105)	n.a.	Older adults	45.2 (15.6; KCS)	n.a. (BHPAQ)	n.a.	Cross- Sectional	Online	7.0	$r = -0.577^{\dagger}$	< 0.001 [†]
Sertel (2021)	163 (76)	71.4 (6.0)	Chronic pain	44.4 (7.7; TSK-17)	171.3 (76.2; PASE)	n.a. (VAS)	Cross- Sectional	Home Visit	7.0	r = -0.021	>0.05
Smulligan (2023)	23 (11)	14.9 (1.8)	Concussion (no persistant symptoms)	37 (TSK-17)	10545 steps/day (3405; wrist accelero.) 4.4 sessions/week (1.9; wrist	n.a.	Cohort	Clinical	8.0	$r_{steps} = -0.18$ $r_{frequency} = -$ 0.34	0.41 0.12 0.67
	18 (9)	14.5 (2)	Concussion (persistant symptoms)	41 (TSK-17)	accelero.) 46.8 min/session (26.2; wrist accelero.) 7047 steps/day (2499; wrist	n.a.				$\begin{array}{l} \rho_{duration} = 0.10 \\ r_{steps} = -0.60 \\ r_{frequency} = -0.63 \end{array}$	
					accelero.) 2.3 sessions/week (2.1; wrist accelero.) 38 min/session (12; wrist accelero.)					$\rho_{duration} = -$ 0.12	
Spaderna (2020)	61 (13)	67.5 (10.7)	Heart failure	1.5 (FActS)	2332 kcal/day (hip accelero.)	n.a.	Cross- Sectional	Laboratory	9.0	r = -0.28	< 0.05
Strandberg (2022)	451 ^{††} (n.a.)	n.a.	Cancer	n.a. (TSK-14)	n. 1.3 h MVPA/week (arm accelero.)	n.a.	RCT	Laboratory	8.8	$r = -0.084^{\dagger}$	0.074^{+}
Sütçü (2021)	20 (10)	69.8 (9.4)	Parkinson's disease	39.8 (7.4; TSK-17)	3078 steps/day (arm accelero.) 2055 kcal/day (475; arm accelero.)	n.a.	Cross- Sectional	n.a.	6.0	$r = -0.32^{\ddagger}$ $r = -0.54^{\ddagger}$	0.157 0.013
Suttmiller (2022)	126 (107)	32.69 (4.38)	Chronic pain	21.36 (5.53; TSK- 11)	n.a. (JPAS)	n.a. (ad-hoc questionnaire, Yes and No)	Cross- Sectional	Online	8.0	r = 0.219	0.014
Uritani (2020)	167 (105)	62.2 (7.5)	Knee osteoarthritis	12.5 (BFMSO)	7998 steps/day (thigh accelero.)	5.7 (NRS)	Cross- Sectional	n.a.	7.0	r = -0.163 [†]	0.035†

Verbunt (2005)	123 (57)	44.1 (10.3)	Subacute low back pain	36.0 (TSK-17)	n.a. (hip accelero.)	4.2 (VAS)	Cross- Sectional	n.a.	7.0	$\rho = 0.06$	>0.05
Wang (2023)	223 (37)	72.35 (8.96)	Pulmonary (COPD)	20.72 (3.79; BBQ)	n.a. (IPAQ)	n.a.	Cross- Sectional	n.a.	7.0	r = -0.35	< 0.001
Wasiuk-Zowada (2022)	80 (60)	45.5 (8.6)	Multiple sclerosis	36.6 (TSK-17)	5.1 (BHPAQ)	3.5 (VAS)	Cross- Sectional	Clinical	7.0	r = -0.363	0.001
Yuksel Karsli (2021)	34 (12)	41 (n.a.)	Radiographic SpA	42 (TSK-17)	2203 min LPA/day (hip accelero.) 210 min MPA/day (hip accelero.)	n.a.	Cross- Sectional	Clinical	8.0	$\rho = -0.16$ $\rho = -0.158$ $\rho = -0.394$	0.929 0.373 0.021
	33 (10)	33 (n.a.)	Non-radiographic SpA	36 (TSK-17)	0 min VPA/day (hip accelero.) 2576 min LPA/day (hip accelero.) 265 min MPA/day (hip accelero.) 2 min VPA/day (hip accelero.)					$\rho = -0.001$ $\rho = 0.013$ $\rho = -0.240$	0.997 0.947 0.209
Zadro (2019)	60 (31)	68.3 (5.7)	Chronic low back pain	34.2 (5.9; TSK-17)	n.a.	5 (1.7; NRS)	RCT	Laboratory	3.2	r _{MPA} = -0.18 r _{VPA} =-0.12	0.16 [‡] 0.36 [‡]
Zelle (2016)	487 (209)	51.6 (12.5)	Renal transplantation	n.a. (TSK-11)	165 METs (MLTPAQ and TOAQ)	n.a.	Cross- Sectional	n.a.	7.0	r = -0.22	< 0.001

Notes. Accelero. = Accelerometer, ACLR = anterior cruciate ligament reconstruction, BBQ = Breathlessness Beliefs Questionnaire (17-85), BFOMSO = Brief Fear of Movement Scale for Osteoarthritis (6 - 24), BHPAO = Baecke Habitual Physical Activity Questionnaire (3 - 15), BPI-S= Brief Pain Inventory-Severity (1 - 10), COPD = Chronic Obstructive Pulmonary Disease, CVD = cardiovascular disease, FABO = Fear-Avoidance Belief Questionnaire (0 - 24), FActS = Fear of Activity in Situations (0 - 30), GLTEQ = Godin Leisure Time Exercise Questionnaire (0 -119), GPAQ = Global Physical Activity Questionnaire, GRS = Graphic Rating Scale (0 - 10), IPAQ = short form of the International Physical Activity Questionnaire, JPAS = Jurka Physical Activity Scale, KCS = Kinesiophobia Causes Scale (0 - 100), KOOS-P = Knee Injury andOsteoarthritis Outcome Score – Pain (0 - 100), LPA = light physical activity, LTPAI = Leisure Time Physical Activity Index, n.a. = not available, MLTPAQ = Minnesota Leisure Time Physical Activity Questionnaire, MPA = moderate physical activity, MSK = Musculoskeletal, MVPA = moderate-to-vigorous physical activity, NRS = Numeric Rating Scale (maximum score = 0 - 10), OKS = Oxford Knee Score – Pain (0-28), PA = Physical Activity, PAOE = Physical Activity Questionnaire for the Elderly (0-3), PASE = Physical Activity Scale for the Elderly, Pedo. = Pedometer, r = Pearson's correlation coefficient, RAPAO = Rapid Assessment of Physical Activity questionnaire (0-3), $\rho = Spearman's$ correlation coefficient, SF-36 = 36-Item Short Form Survey (0 - 100), OWBS-P = Quality of Well-Being Scale-Pain (0-5), SGPALS = Saltin-Grimby Physical Activity Level Scale (1 - 4), SpA = axial spondyloarthritis, SQUASH = Short Questionnaire to Assess Health Enhancing Questionnaires, TAS = Tegner Activity Scale (0 - 10), TOAQ = Tecumseh Occupational Activity Questionnaire, TSK = Tampa Scale of Kinesiophobia [TSK-17: 17 - 68, TSK-Heart = 17 - 68, TSK-14 = 14 - 56, TSK-13 = 13 - 52, TSK-11 = 11 - 44), UCLA = University of California Los Angeles activity score (1 - 10), VAS = Visual Analog Scale (0 - 10), VPA = vigorous physical activity, VRS = Verbal Rating Scale for pain assessment (0 - 5), [†]Obtained by emailfrom authors, ^{††}Number of participants used to calculate the correlation, according to the email sent by the authors, [‡]When Pearson's correlation coefficient (r) was not reported in an article, but the exact p-value and sample size (n) were available and it was possible to know the sign of the correlation based on the information provided in the article, the r value was computed using an ad-hoc R code (Supplemental Code 1A). [‡]When exact p-values were not reported in an article, but the sample size (n) and Pearson's correlation coefficient were available, the exact p-value was computed using an ad-hoc R code (Supplemental Codel 1B).

	n	k	0	cor.	95% CI	$I^{2}(\%)$	р
Main: Pearson's r estimates							<.000
Kinesiophobia and physical activity	63	83	12278	19	[26;13]	85	
Secondary: Spearman's rho estimates							.0486
Kinesiophobia and device-based physical activity	12	21	2084	20	[38; .001]	86	
Subgroup: Health status							<.000
Chronic pain	29	35	5091	07	[16; .01]	62	
Arthritis	9	11	3592	25	[39;10]	93	
Cardiovascular condition	5	10	823	30	[47;11]	29	
Neurological condition	4	8	220	53	[69;32]	56	
Surgery	5	5	903	16	[36; .05]	69	
Older adults	3	3	278	40	[60;14]	91	
Acute pain	2	2	103	13	[29; .04]	34	
Pulmonary condition	2	2	285	68	[82;46]	98	
Obstructive sleep apnea	1	2	146	18	[56; .26]	0	
Fibromyalgia	1	2	146	06	[46; .37]	2	
Cancer	1	1	451	19	[26;13]	2	
Post-partum women	1	1	139	13	[29;04]		
Young adults	1	1	139	15 01	[29;04]		
	1	1	101	01	[20, .19]		.1714
Subgroup: Physical activity measure	4.4	5 /	0007	22	[20: 14]	80	.1/14
Self-reported	44	54	9882 2206	22	[29;14]	89 57	
Device-based	20	29	2396	13	[24;02]	57	2007
Subgroup: Physical activity instrument	10	27	2462	17	F 20 051		.2092
Accelerometer	18	27	2462	17	[29;05]	55	
IPAQ	18	25	5034	28	[39;16]	93	
BHPAQ	4	4	737	34	[50;15]	94	
SGPALS	4	4	675	19	[43; .08]	80	
Ad-hoc questionnaire	4	4	1240	15	[39; .11]	85	
Pedometer	3	3	385	02	[33; .29]	59	
GPAQ	2	2	232	.01	[38; .40]	0	
MLTPAQ	2	2	580	07	[42; .29]	87	
GLTEQ	2	2	118	20	[54; .20]	43	
LTPAI	1	2	146	06	[52; .44]	2	
SQUASH	1	2	100	04	[52; .46]	77	
RAPAQ	1	2	120	15	[59; .30]	0	
JPAS	1	1	126	.22	[.05; .38]		
PASE	1	1	163	02	[17; .13]		
UCLA	1	1	37	77	[88;60]		
Diary	1	1	123	02	[20; .16]		
Subgroup: Physical activity outcome			-	-			.609
MET-min/week	25	35	6439	20	[30;09]	91	
Score	15	16	2090	24	[36;11]	85	
Steps/day	12	13	945	18	[33;03]	56	
Active time	10	12	2144	11	[25; .03]	77	
Counts/min	5	5	579	14	[33; .05]	8	
Kcal/day	2	2	81	38	[67; .02]	24	
Subgroup: Kinesiophobia instrument	-	2	01	.50	[.07,102]	- 1	.4520
TSK-17	33	44	3679	23	[32;14]	86	.152
FABQ	13	15	5434	13	[27; .02]	74	
TSK-11	8	8	1259	04	[23; .15]	82	
TSK-Heart	8 1	8 7	467	04 51	[78;08]	61	
TSK-Heart	3	3	372	16	[44; .16]	44	
	5 1	5 1		10 08	[44; .10] [17; .01]	44	
TSK-14			451				
TSK-12	1	1	60 222	18	[41; .08]		
BBQ	1	1	223	35	[46;23]		
BFOMSO	1	1	167	16	[31;01]		
FActS	1	1	61	28	[50;03]		
KCS	1	1	105	57	[69;42]		

Table 2. Results of the main, secondary, and subgroup meta-analyses

Notes. 95% CI = 95% confidence interval, BBQ = Breathlessness Beliefs Questionnaire, BFOMSO = Brief Fear of Movement Scale for Osteoarthritis, BHPAQ = Baecke Habitual

Physical Activity Questionnaire, Cor. = Correlation estimate, FABQ = Fear-Avoidance Belief Questionnaire, FActS = Fear of Activity in Situations, GLTEQ = Godin Leisure Time Exercise Questionnaire, GPAQ = Global Physical Activity Questionnaire, IPAQ = short form of the International Physical Activity Questionnaire, JPAS = Jurka Physical Activity Scale, k = numberof estimates, KCS = Kinesiophobia Causes Scale, LTPAI = Leisure Time Physical Activity Index, MLTPAQ = Minnesota Leisure Time Physical Activity Questionnaire, n = number of studies, o =number of observations (participants), p = p-value for between-group difference, PAQE =Physical Activity Questionnaire for the Elderly, PASE = Physical Activity Scale for the Elderly, RAPAQ = Rapid Assessment of Physical Activity questionnaire, SGPALS = Saltin-Grimby Physical Activity Level Scale, SQUASH = Short Questionnaire to Assess Health Enhancing Questionnaires, TSK = Tampa Scale of Kinesiophobia, UCLA = University of California Los Angeles activity score.

Figure 1. PRISMA 2020 flow diagram





Figure 2. Main meta-analysis: Correlation between kinesiophobia and physical activity

Notes: 95% CI = 95% confidence interval, IV = Inverse variance method, Random = Random effects method.

Study	Cluster	Total	Weight	Correlation IV, Random, 95% Cl	Correlation IV, Random, 95% CI
Alamam, 2019	sample_1	100	1.6%	-0.17 [-0.35; 0.03]	-
Alschuler, 2011	sample_2	20	1.0%	-0.48 [-0.76; -0.05]	
Altug, 2016	sample_3	112	1.6%	-0.10 [-0.28; 0.09]	
Alzahrani, 2021	sample_4	26	0.5%	0.22 [-0.18; 0.56]	
Alzahrani, 2021	sample_4	26	0.5%	-0.05 [-0.43; 0.34]	
Alzahrani, 2021	sample_4	26	0.5%	-0.21 [-0.55; 0.19]	
Assadourian, 2020 Aydemir, 2022	sample_5 sample_6	123 37	1.6% 1.3%	-0.02 [-0.20; 0.16] -0.77 [-0.88; -0.60]	-
Aykut Selcuk, 2020	sample_0	67	1.1%	-0.25 [-0.46; -0.01]	-
Aykut Selcuk, 2020	sample_7	29	0.5%	-0.31 [-0.61; 0.06]	
Baday-Keskin, 2022	sample_8	88	1.6%	-0.12 [-0.32; 0.09]	
Baez, 2020	sample 9	40	1.3%	0.18 [-0.14; 0.47]	
Bahar Ozdemir, 2021	sample_10	101	1.6%	-0.01 [-0.20; 0.19]	
Baykal Sahin, 2021	sample_11	98	1.6%	-0.32 [-0.48; -0.12]	- -
Bernard, 2015	sample_12	121	1.6%	-0.05 [-0.23; 0.13]	
Carvalho, 2017	sample_13	119	0.6%	-0.18 [-0.35; -0.00]	
Carvalho, 2017	sample_13	119	0.6%	0.09 [-0.09; 0.27]	
Carvalho, 2017	sample_13	119	0.6%	-0.02 [-0.20; 0.16]	
Coronado, 2021	sample_14	248	1.7%	-0.05 [-0.17; 0.08]	
Corrigan, 2018	sample_15	53	1.4%	-0.00 [-0.27; 0.27]	
Cromert, 2021	sample_16	139	1.7%	-0.13 [-0.29; 0.04]	
Dabek, 2020	sample_17	72	0.3%	-0.43 [-0.60; -0.22]	
Dabek, 2020	sample_17	18	0.1%	-0.87 [-0.95; -0.67]	
Dabek, 2020	sample_17	130	0.5%	-0.52 [-0.64; -0.39]	
Dabek, 2020	sample_17	119	0.5%	-0.41 [-0.55; -0.25]	-
Dabek, 2020	sample_17	27	0.1%	-0.20 [-0.54; 0.19]	
Dabek, 2020	sample_17	86	0.4%	-0.56 [-0.69; -0.40]	
Dabek, 2020	sample_17	15	0.1%	-0.66 [-0.88; -0.23]	
Demirbuken, 2016	sample_18 sample 19	99 2569	1.6% 1.8%	-0.15 [-0.34; 0.05]	
Demmelmaier, 2018 Dogan, 2022	sample_19 sample_20	2569	1.8%	-0.07 [-0.11; -0.03] -0.06 [-0.17; 0.05]	
Dogan, 2022 Donnarumma, 2017	sample_20 sample_21	290	1.6%	-0.06 [-0.17; 0.05] -0.35 [-0.57; -0.08]	
Elfving, 2007	sample_21	64	1.5%	-0.31 [-0.52; -0.07]	
Glaviano, 2017	sample_22	20	1.0%	-0.48 [-0.76; -0.05]	
Helmus, 2012	sample 24	53	1.4%	-0.05 [-0.32; 0.22]	
Ho-A-Tham, 2022	sample 25	210	1.7%	-0.04 [-0.17; 0.10]	
gelstrom, 2013	sample 26	73	0.9%	-0.25 [-0.45; -0.02]	
gelstrom, 2013	sample_26	73	0.9%	-0.11 [-0.33; 0.12]	
Kilinc, 2019	sample 27	200	1.7%	-0.69 [-0.76; -0.61]	-
Koho, 2011	sample 28	93	1.6%	0.10 [-0.11; 0.30]	
Koppenaal, 2023	sample_29	204	0.9%	-0.06 [-0.20; 0.08]	
Koppenaal, 2023	sample_29	204	0.9%	-0.03 [-0.17; 0.11]	
_otzke, 2018	sample_30	118	1.6%	-0.19 [-0.36; -0.01]	
uthi, 2022	sample_31	433	1.8%	0.06 [-0.03; 0.15]	
Marques-Sule, 2022	sample_32	117	1.6%	-0.32 [-0.47; -0.15]	
Marshall, 2017	sample_33	218	1.7%	-0.24 [-0.36; -0.11]	
Marshall, 2021	sample_34	508	1.8%	-0.28 [-0.36; -0.20]	—
Marshall, 2022	sample_35	393	1.8%	-0.01 [-0.11; 0.09]	
Masse-Alarie, 2016	sample_36	22	1.0%	0.09 [-0.34; 0.49]	_
Viller, 2018	sample_37	52	1.4%	-0.54 [-0.71; -0.31]	
Minetama, 2022	sample_38	71	1.5%	-0.23 [-0.44; 0.00]	
	sample_39 sample_40	41 77	1.3% 1.5%	-0.06 [-0.36; 0.25]	
Norte, 2019 Dzer, 2022	sample_40 sample_41	62	1.5%	-0.31 [-0.50; -0.09] -0.89 [-0.93; -0.82]	
Ozlu, 2022	sample_41 sample_42	45	1.4%	0.15 [-0.15; 0.42]	-
Palstam, 2014	sample_42 sample_43	73	0.9%	0.03 [-0.20; 0.26]	
Palstam, 2014	sample_43	73	0.9%	-0.14 [-0.36; 0.09]	- i
Pastor-Mira, 2020	sample 44	274	1.8%	0.01 [-0.11: 0.13]	-
Pedler, 2018	sample_45	103	1.6%	0.14 [-0.06; 0.32]	T-
Peres, 2023	sample_46	50	0.8%	-0.25 [-0.49; 0.03]	
Peres, 2023	sample_46	50	0.8%	0.17 [-0.11; 0.43]	
Polaski, 2021	sample_47	38	1.3%	-0.03 [-0.35; 0.29]	
Priore, 2020	sample_48	50	1.4%	-0.25 [-0.49; 0.03]	
Rabey, 2017	sample_49	266	1.8%	0.07 [-0.05; 0.19]	
Roaldsen, 2009	sample_50	98	1.6%	-0.39 [-0.55; -0.21]	-
Sandal, 2021	sample_51	460	1.8%	-0.02 [-0.12; 0.07]	
Saulicz, 2016	sample_52	105	1.6%	-0.57 [-0.69; -0.42]	-
Sertel, 2021	sample_53	163	1.7%	-0.02 [-0.17; 0.13]	
Smulligan, 2023	sample_54	23	0.5%	-0.18 [-0.55; 0.25]	
Smulligan, 2023	sample_54	23	0.5%	-0.34 [-0.66; 0.08]	
Smulligan, 2023	sample_54	18	0.3%	-0.60 [-0.83; -0.18]	
Smulligan, 2023	sample_54	18	0.3%	-0.63 [-0.85; -0.23]	
Spaderna, 2020	sample_55	61	1.5% 1.8%	-0.28 [-0.50; -0.03]	
Strandberg, 2022	sample_56 sample 57	451		-0.08 [-0.17; 0.01]	
Sutcu, 2021 Sutcu, 2021	sample_57 sample 57	20 20	0.7% 0.7%	-0.32 [-0.67; 0.14]	
Suttmiller, 2022	sample_57 sample_58	126	1.6%	-0.54 [-0.79; -0.13] 0.22 [0.05; 0.38]	
Jritani, 2020		167	1.0%		· · · · · · · · · · · · · · · · · · ·
Nang , 2023	sample_59 sample_60	223	1.7%	-0.16 [-0.31; -0.01] -0.35 [-0.46; -0.23]	-
Vang , 2023 Vasiuk-Zowada, 2022	sample_60 sample_61	80	1.7%	-0.36 [-0.46; -0.23]	
Zadro, 2019	sample_61 sample_62	60	0.9%	-0.38 [-0.54; -0.18]	-
Zadro, 2019	sample_62	60	0.9%	-0.12 [-0.36; 0.14]	
Zelle, 2016	sample_63	487	1.8%	-0.12 [-0.30; -0.14]	_
	sample_00	407	1.0 /0	J.LL [-0.00, -0.13]	
otal (95% CI)		12278	100.0%	-0.19 -0.26 -0.130	•
otal (95% CI) Prediction interval		12278	100.0%	-0.19 [-0.26; -0.13] [-0.61; 0.30]	•

Heterogeneity: Tau² = 0.0634; Chi² = 564.77, df = 82 (P < 0.01); I² = 85%

Figure 3. Publication bias assessment. Contour-enhanced funnel plot of the main meta-analysis (A). The vertical dashed line represents the average effect size. The two other dashed lines represent the idealized funnel-shape that studies are expected to follow. P-curve analysis (B). The blue line indicates the distribution of the analyzed p-values. The red dotted line illustrates a uniform distribution of the p-values, indicating the absence of a true effect.



SUPPLEMENTAL MATERIAL

Physical Activity and Kinesiophobia: A Systematic Review and Meta-Analysis

Miriam Goubran¹, Ata Farajzadeh¹, Ian M. Lahart², Martin Bilodeau¹, & Matthieu P. Boisgontier^{1,3,*}

¹School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Canada; ²Faculty of Education, Health and Wellbeing, Institute of Human Sciences, University of Wolverhampton, Wolverhampton, UK; ³Perley Health Centre of Excellence in Frailty-Informed Care, Ottawa, Canada. *Corresponding author: <u>matthieu.boisgontier@uottawa.ca</u>

Supplemental Code 1. R scripts.

Supplemental Figure 1. Heterogeneity variance.

Supplemental Figure 2. Secondary meta-analysis based on Pearson's rho estimates.

Supplemental Figure 3. Subgroup meta-analysis: Differences by health status.

Supplemental Figure 4. Subgroup meta-analysis: Differences by physical activity measure (self-reported vs. device-based).

Supplemental Figure 5. Subgroup meta-analysis: Differences by physical activity measurement instrument.

Supplemental Figure 6. Subgroup meta-analysis: Differences by physical activity outcome

Supplemental Figure 7. Subgroup meta-analysis: Differences by kinesiophobia measurement instrument.

Supplemental Code 1. R scripts.

A. R script for the calculation of Pearson's r estimate based on the degrees of freedom (sample size - 2) and exact p-value, when the direction of the relationship is known.

Sample size n <- 50 # Pearson correlation coefficient r <- -0.57 # Compute the t-statistic t_statistic <- r * sqrt((n - 2) / (1 - r^2)) # Degrees of freedom df <- n - 2 # Compute the p-value p_value <- 2 * pt(abs(t_statistic), df = df, lower.tail = FALSE) # Print the p-value print(p_value)

B. R script for the calculation of exact p-values based on sample size (n) and Pearson's correlation coefficient (r).

Sample size n <- 45

Pearson correlation coefficient r <- -0.25

Compute the t-statistic
t_statistic <- r * sqrt((n - 2) / (1 - r^2))</pre>

Degrees of freedom df <- n - 2

Compute the p-value
p_value <- 2 * pt(abs(t_statistic), df = df, lower.tail = FALSE)</pre>

Print the p-value
print(p_value)

Supplemental Figure 1. Heterogeneity variance.



Supplemental Figure 2. Secondary meta-analysis based on Pearson's rho estimates.

Study	Cluster	Total	Weight	Correlation IV, Random, 95% Cl	Correlation IV, Random, 95% CI
Atici	sample_1	254	9.0%	-0.34 [-0.45; -0.23]	
Barchek, 2021	sample_2	19	3.6%	0.12 [-0.35; 0.54]	
Barchek, 2021	sample_2	19	3.6%	-0.13 [-0.55; 0.34]	
Carvalho, 2017	sample_3	119	4.5%	-0.15 [-0.32; 0.03]	— — ——————————————————————————————————
Carvalho, 2017	sample_3	119	4.5%	-0.13 [-0.30; 0.05]	
Gonzalez de La Flor, 2022	sample_4	42	7.5%	0.20 [-0.11; 0.48]	i -
Knapik, 2019	sample_5	135	8.7%	-0.80 [-0.85; -0.73]	-
Leonhardt, 2009	sample_6	449	5.3%	-0.09 [-0.18; -0.00]	
Leonhardt, 2009	sample_6	338	4.0%	-0.10 [-0.20; 0.01]	÷=
Ohlman, 2018	sample_7	52	7.8%	-0.29 [-0.52; -0.02]	
Olsson, 2014	sample_8	81	8.3%	-0.27 [-0.46; -0.05]	
Pazzinato, 2022	sample_9	92	8.4%	-0.14 [-0.34; 0.07]	
Smulligan, 2023	sample_10	23	4.2%	0.10 [-0.33; 0.49]	
Smulligan, 2023	sample_10	18	3.1%	-0.12 [-0.56; 0.37]	
Verbunt, 2005	sample_11	123	8.7%	0.06 [-0.12; 0.23]	
Yuksel Karsli, 2019	sample_12	34	1.5%	-0.39 [-0.64; -0.06]	
Yuksel Karsli, 2019	sample_12	34	1.5%	-0.16 [-0.47; 0.19]	
Yuksel Karsli, 2019	sample_12	34	1.5%	-0.16 [-0.47; 0.19]	
Yuksel Karsli, 2019	sample_12	33	1.5%	-0.01 [-0.35; 0.33]	
Yuksel Karsli, 2019	sample_12	33	1.5%	0.01 [-0.33; 0.35]	
Yuksel Karsli, 2019	sample_12	33	1.5%	-0.24 [-0.54; 0.11]	
Total (95% CI)		2084	100.0%	-0.20 [-0.38; -0.00]	-
Prediction interval				[-0.71; 0.45]	
Heterogeneity: Tau ² = 0.0982	2; Chr = 146.0	J2, df =	20 (P < 0		
					-1 -0.5 0 0.5

Supplemental Figure 3. Subgroup meta-analysis: Differences according to health status


Health_status = Chro Alamam, 2019 Alschuler, 2011 Altug, 2016 Alzahrani, 2021 Alzahrani, 2021	nic pain sample_1			IV, Randon		
Alamam, 2019 Alschuler, 2011 Altug, 2016 Alzahrani, 2021						
Altug, 2016 Alzahrani, 2021		100	1.6%	-0.17 [-0.3	5; 0.03]	
Alzahrani, 2021	sample_2	20 112	1.0%	-0.48 [-0.7		
Alexhane: 2024	sample_3 sample_4	26	0.5%	-0.10 [-0.2	8: 0.561	
	sample_4	26	0.5%	-0.05 [-0.4	3 0.341	
Alzahrani, 2021	sample_4	26	0.5%	-0.21 [-0.5	5: 0.19	
Assadourian, 2020	sample_5	123	1.6%	-0.02 [-0.2	0: 0.16]	
Carvalho, 2017	sample_13	119	0.6%	-0.18 [-0.3	5: -0.001	
Carvalho, 2017	sample 13	119	0.6%	0.09 [-0.0	9; 0.27]	
Carvalho, 2017	sample 13	119	0.6%	-0.02 [-0.2	0; 0.16]	
Demirbuken, 2016	sample_18	99	1.6%	-0.15 [-0.3	4; 0.05]	
Elfving, 2007	sample_22	64	1.5%	-0.31 [-0.5		
Slaviano, 2017	sample_23	20	1.0%	-0.48 [-0.7	6; -0.05]	
felmus, 2012	sample_24	53	1.4%	-0.05 [-0.3	2; 0.22]	
Io-A-Tham, 2022	sample_25	210	1.7%	-0.04 [-0.1	7; 0.10]	
(oho, 2011	sample_28	93	1.6%	0.10 [-0.1	1; 0.30]	
Koppenaal, 2023	sample_29	204	0.9%	-0.06 [-0.2	0; 0.08]	
Koppenaal, 2023	sample_29	204	0.9%	-0.03 [-0.1	7: 0.11]	
otzke, 2018	sample_30	118	1.6%	-0.19 [-0.3	6; -0.01]	
uthi, 2022	sample 31	433	1.8%	0.06 [-0.03	3; 0.15]	
Aarshall, 2017	sample_33	218	1.7%	-0.24 [-0.3	6; -0.11]	
Aarshall, 2021	sample 34	508	1.8%	-0.28 [-0.3	6; -0.20]	-
Aarshall, 2022	sample_35	393	1.8%	-0.01 [-0.1	1; 0.09]	
Aasse-Alarie, 2016	sample_36	22	1.0%	0.09 [-0.3	4; 0.49]	
Ainetama, 2022	sample_38	71	1.5%	-0.23 [-0.4	4; 0.00]	
avarro-Ledesma, 202	22 sample_39	41	1.3%	-0.06 [-0.3	6; 0.25]	
Pastor-Mira, 2020	sample_44	274	1.8%	0.01 [-0.1		
Pedler, 2018	sample_45	103	1.6%	0.14 [-0.0	6; 0.32]	
Polaski, 2021	sample_47	38	1.3%	-0.03 [-0.3	5; 0.29]	
Rabey, 2017	sample_49	266	1.8%	0.07 [-0.0	5; 0.19]	-
Sandal, 2021	sample_51	460	1.8%	-0.02 [-0.1	2; 0.07]	
Sertel, 2021	sample_53	163	1.7%	-0.02 [-0.1	7; 0.13]	
Suttmiller, 2022	sample_58	126	1.6%	0.22 [0.0	5; 0.38]	
Zadro, 2019	sample_62	60	0.9%	-0.18 [-0.4	1; 0.08]	
Zadro, 2019	sample_62	60	0.9%	-0.18 [-0.4 -0.12 [-0.3	6; 0.14]	
fotal (95% CI)		5091	45.8%	-0.07 [-0.1	6; 0.01]	•
leterogeneity: Tau ² = 0.04	47; Chi ² = 90.07, o	# = 34 (P	< 0.01); 7	* = 62%		
lealth_status = Arthr	ritis					
Aydemir, 2022	sample_6	37	1.3%	-0.77 [-0.8	8; -0.60]	-
Aykut Selcuk, 2020	sample_7	67	1.1%	-0.25 [-0.4	6; -0.01]	
ykut Selcuk, 2020	sample_7	29	0.5%	-0.31 [-0.6	1: 0.06]	-
aday-Keskin, 2022	sample_8	88	1.6%	-0.12 [-0.3		
Demmelmaier, 2018	sample_19	2569	1.8%	-0.07 [-0.1		
Dogan, 2022	sample_20	290	1.8%	-0.06 [-0.1	7: 0.05]	· · · · · · · · · · · · · · · · · · ·
Glinc, 2019	sample_27	200	1.7%	-0.69 [-0.7	0;-0.61]	
Dzlu, 2022	sample_42	45	1.4%	0.15 [-0.1	0; 0.42]	
Peres, 2023	sample_46	50 50	0.8%	-0.25 [-0.4	a; 0.03]	
Peres, 2023 Jritani, 2020	sample_46	50 167	0.8%	0.17 [-0.1	1.0.01	
fotal (95% CI)	sample_59	3592	14.5%	-0.25 [-0.3	9: -0.101	-
feterogeneity: Tau ² = 0.04	47; Chi ² = 151.57,			12 = 93%		
Health_status = Surg	erv					
Baez, 2020	sample_9	40	1.3%	0.18 [-0.14	4: 0.471	
Coronado, 2021	sample_14	248	1.7%	-0.05 [-0.1	7: 0.081	
Donnarumma, 2017	sample 21	51	1.4%	-0.35 [-0.5	7: -0.08]	
Norte, 2019	sample 40	77	1.5%	-0.31 [-0.5	0;-0.09]	
Zelle, 2016	sample_63	487	1.8%	-0.22 [-0.3	0; -0.13]	-
fotal (95% CI)		903	7.8%	-0.16 [-0.3		-
ieterogeneity: Tau ² = 0.04	47; Chi ² = 13.07, o	ff = 4 (P =	= 0.01); I ²	= 69%		
Health_status = Youn	g adults					
Bahar Özdemir, 2021	sample_10	101	1.6%	-0.01 [-0.2	0; 0.19]	
lealth status = Card	in the second second	dition				
Health_status = Card Baykal Sahin, 2021	sample_11	98	1.6%	-0.32 [-0.4	8: -0.121	
Dabek, 2020	sample_17	72	0.3%	-0.43 [-0.6	0 -0.221	
Dabek, 2020	sample_17	130	0.5%	-0.52 [-0.6		
Dabek, 2020	sample_17	119	0.5%	-0.41 [-0.5	5; -0.25]	
	sample_17	27	0.1%	0.0010.0	4-0191	
Dabek, 2020				-0.20 [-0.5		
Dabek, 2020 Dabek, 2020	sample_17	86	0.4%	-0.56 [-0.6	9; -0.40]	
Dabek, 2020 Dabek, 2020 Dabek, 2020	sample_17 sample_17	15	0.4% 0.1%	-0.56 [-0.6	9; -0.40] 8; -0.23]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022	sample_17 sample_17 sample_32	15 117	0.4% 0.1% 1.6%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4	9; -0.40] 8; -0.23] 7; -0.15]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022 Roaldsen, 2009	sample_17 sample_17 sample_32 sample_50	15 117 98	0.4% 0.1% 1.6% 1.6%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022 Roaldsen, 2009 Spadema, 2020	sample_17 sample_17 sample_32	15 117 98 61	0.4% 0.1% 1.6% 1.6% 1.5%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022 Roaldsen, 2009 Spadema, 2020 Fotal (95% CI)	sample_17 sample_17 sample_32 sample_50 sample_55	15 117 98 61 823	0.4% 0.1% 1.6% 1.6% 1.5% 8.1%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jarques-Sule, 2022 Roaldsen, 2009 Spadema, 2020 fotal (95% CI) Ieterogeneity: Tau ² = 0.04	sample_17 sample_17 sample_32 sample_50 sample_55 47: Chi ² = 12.63, c	15 117 98 61 823	0.4% 0.1% 1.6% 1.6% 1.5% 8.1%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03]	+
Jabek, 2020 Dabek, 2020 Jabek, 2020 Marques-Sule, 2022 Roaldsen, 2009 Spaderna, 2020 fotal (95% CI) feterogeneity: Tau ² = 0.04 Health status = Olde	sample_17 sample_17 sample_32 sample_50 sample_55 47: Chi ² = 12.63, o r adults	15 117 98 61 823 # = 9 (P	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% = 0.18): 1 ²	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29%	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022 Roaldsen, 2009 Spaderna, 2020 Fotal (95% CI) teterogeneity: Tau ² = 0.04 Health_status = Older Bernard, 2015	sample_17 sample_17 sample_32 sample_50 sample_55 47: Chi ² = 12.63, or r adults sample_12	15 117 98 61 823 #=9 (P	0.4% 0.1% 1.6% 1.6% 8.1% = 0.18]: 1 ²	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29%	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11]	
Dabek, 2020 Dabek, 2020 Dabek, 2020 Marques-Sule, 2022 Roaldsen, 2029 Fotal (95% CI) feterogeneity: Tau ² = 0.04 Health_status = Olde Bernard, 2015 Miler, 2018	sample_17 sample_17 sample_32 sample_50 sample_55 47: Chi ² = 12.63, o r adults sample_12 sample_37	15 117 98 61 823 #=9(P 121 52	0.4% 0.1% 1.6% 1.6% 8.1% = 0.18]: I ² 1.6% 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jackens-Sule, 2022 Spadema, 2020 Fotal (95% CI) Heterogenehr, Tau ² = 0.04 Health_status = Olde Bernard, 2015 Miller, 2016 Saulicz, 2016	sample_17 sample_17 sample_32 sample_50 sample_55 47: Chi ² = 12.63, or r adults sample_12	15 117 98 61 823 # = 9 (P 121 52 105	0.4% 0.1% 1.6% 1.5% 8.1% = 0.18): I ² 1.6% 1.4% 1.6%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7 -0.57 [-0.6	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2022 Jabek, 2022 Jabek, 2029 Jabek, 2029 Jabek, 2018 Jaulicz, 2018 Jaulicz, 2018 Jaulicz, 2018	sample_17 sample_17 sample_32 sample_50 sample_55 47; Ch ² = 12.63, 6 r adults sample_12 sample_12 sample_52	15 117 98 61 823 # = 9 (P - 121 52 105 278	0.4% 0.1% 1.6% 1.5% 8.1% = 0.18): t ² 1.6% 1.4% 1.6%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.39 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7 -0.57 [-0.6	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42]	*
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Aarques-Sule, 2022 Koaldsen, 2020 Jotal (95% Cl ² = 0.04 Health, status = Oldes Semard, 2016 Jotal (95% Cl) Heterogenety: Tau ² = 0.04	sample_17 sample_17 sample_32 sample_50 sample_50 sample_55 47: Ch ² = 12.63, or r adults sample_12 sample_12 sample_52 47: Ch ² = 22.61, or	15 117 98 61 823 # = 9 (P - 121 52 105 278	0.4% 0.1% 1.6% 1.5% 8.1% = 0.18): t ² 1.6% 1.4% 1.6%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.39 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7 -0.57 [-0.6	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42]	÷ ÷
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Marques-Sule, 2022 Roaldsen, 2009 Fotal (95% CI) Heterogenety: Tau ² = 0.04 Health_status = Olde Bernard, 2015 Miler, 2015 Jaulicz, 2016 Fotal (95% CI) Heterogenety: Tau ² = 0.04 Health_status = Acut	sample_17 sample_72 sample_32 sample_50 sample_55 47; Ch ² = 12.63, of r adults sample_12 sample_12 sample_52 47; Ch ² = 22.61, of e pain	15 117 98 61 823 # = 9 (P : 121 52 105 278 # = 2 (P :	0.4% 0.1% 1.6% 1.6% 8.1% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7%	-0.56 [-0.6 -0.66 [-0.8 -0.39 [-0.5 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.57 [-0.6 -0.57 [-0.6 -0.40 [-0.6 = 91%	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 5: -0.21] 7: -0.11] 3: -0.13] 1: -0.31] 9: -0.42] 0: -0.14]	÷. •
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jargues, 2020 Jargues, 2020 Joan Jargues, 2020 Joan Jack, 2020	sample_17 sample_17 sample_32 sample_50 sample_50 sample_52 47: Chi ² = 12.63, c r adults sample_12 sample_12 sample_52 47: Chi ² = 22.61, c e pain sample_15	15 117 98 61 823 # = 9 (P : 121 52 105 278 # = 2 (P :	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% = 0.18): t ² 1.6% 1.4% 4.7% < 0.01): t ² 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7 -0.57 [-0.6 -0.40 [-0.6 = 91%	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27]	÷ ŧ ŧ
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jahek, 2020 Jahrques-Sule, 2022 Sandrus, 2020 Jeterogenety, Tau ² = 0.14 Health_status = Olde Heard, 2015 Jahler,	sample_17 sample_72 sample_32 sample_50 sample_55 47; Ch ² = 12.63, of r adults sample_12 sample_12 sample_52 47; Ch ² = 22.61, of e pain	15 117 98 61 823 #f = 9 (P 121 52 105 278 #f = 2 (P 53 50	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 1.4% 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.32 [-0.4 -0.32 [-0.4 -0.32 [-0.4 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.7 -0.55 [-0.2 -0.54 [-0.7 -0.57 [-0.6 -0.40 [-0.5 = 91%	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03]	
vabek, 2020 vabek,	sample_17 sample_7 sample_32 sample_55 47; Ch ² = 12.63, d r adults sample_12 sample_37 sample_32 47; Ch ² = 22.61, d e pain sample_15 sample_15 sample_48	15 117 98 61 823 # = 9 (P 121 52 105 278 # = 2 (P 53 50 103	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 1.4% 1.4% 1.4% 1.4% 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.57 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.4	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03]	
babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 babel,	sample_17 sample_77 sample_32 sample_50 sample_55 47: Chi ² = 12.63, of r adults sample_12 sample_52 47: Chi ² = 22.61, of e pain sample_15 sample_48 47: Chi ² = 1.52, of	15 117 98 61 823 # = 9 (P) 121 52 105 278 # = 2 (P) 53 50 103 = 1 (P =	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 1.4% 1.4% 1.4% 1.4% 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.57 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.4	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03]	
abake, 2020 abake, 2020 abake, 2020 tangues-Sule, 2022 totaliden, 2020 otal (95% CI) elemand, 2015 filter, 2018 auticz, 2016 otal (95% CI) eterogenetiy-Taw ² = 0.44 conting, 2016 otal (95% CI) eterogenetiy-Taw ² = 0.44 terogenetiy-taw ² = 0.44	sample_17 sample_77 sample_30 sample_50 sample_50 sample_55 47; Chi ² = 12.63, c r adults sample_12 sample_37 sample_52 47; Chi ² = 22.61, c e pain sample_15 sample_15 sample_48 47; Chi ² = 1.52, df	15 117 98 823 #f = 9 (P 121 52 105 278 #f = 2 (P 53 50 103 = 1 (P =	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 1.4% 2.8% 0.22): l ² =	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.32 [-0.4 -0.38 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.55 [-0.2 -0.55 [-0.2 -0.55 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.4 34%	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03] 5; 0.23]	
habek, 2020 babek, 2020 babek, 2020 shabek, 2020 spadem, 2022 spadem, 2020 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teath, status = Acte teath, status = Acte Torigan, 2015 teterogravity, 7ax ² = 0.04 teath, status = Post romert, 2021	sample_17 sample_132 sample_32 sample_55 47: Ch ² = 12.63, 47 r adults sample_52 47: Ch ² = 12.63, 47 r adults sample_12 sample_12 47: Ch ² = 22.61, 4 e pain sample_15 sample_15 ample_15 ample_16	15 117 98 117 98 117 98 117 98 105 278 105 278 105 278 117 105 278 117 105 278 117 105 278 117 105 105 278 117 105 105 278 117 105 105 105 105 105 105 105 105	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 1.4% 1.4% 1.4% 1.4% 1.4%	-0.56 [-0.6 -0.66 [-0.8 -0.32 [-0.4 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.57 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.4	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03] 5; 0.23]	
habek, 2020 babek, 2020 babek, 2020 shabek, 2020 spadem, 2022 spadem, 2020 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teterogravity, 7ax ² = 0.04 teath, status = Acte teath, status = Acte Torigan, 2015 teterogravity, 7ax ² = 0.04 teath, status = Post romert, 2021	sample_17 sample_132 sample_32 sample_55 47: Ch ² = 12.63, 47 r adults sample_52 47: Ch ² = 12.63, 47 r adults sample_12 sample_12 47: Ch ² = 22.61, 4 e pain sample_15 sample_15 ample_15 ample_16	15 117 98 117 98 117 98 117 98 105 278 105 278 105 278 117 105 278 117 105 278 117 105 278 117 105 105 278 117 105 105 278 117 105 105 105 105 105 105 105 105	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 4.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4	-0.56 [-0.6 -0.32 [-0.4 -0.32 [-0.4 -0.32 [-0.4 -0.38 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.57 [-0.6 -0.57 [-0.6 -0.57 [-0.6 -0.57 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.2	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 0: -0.03] 7: -0.11] 3: 0.13] 1: -0.31] 9: -0.42] 0: -0.14] 7: 0.27] 9: 0.03] 5: 0.23] 9: 0.04]	
babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 coal (b3% CI) teterogramity: Tax ² = 0.04 teterogramity: Tax ² = 0.04 tet	sample_17 sample_17 sample_32 sample_55 47. Ch ² = 12.63. ch sample_55 47. Ch ² = 12.63. ch sample_37 sample_37 sample_52 47. Ch ² = 22.61. ch sample_15 sample_16 47. Ch ² = 22.61. ch sample_16 ample_16 ample_16 sample_16 ch sample_16 sample_16 sample_16 sample_16 ch sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 ch sample_16 s	15 117 98 61 823 15 27 121 52 278 278 278 53 50 103 139 139 139 15 105 105 105 105 105 105 107 107 107 107 107 107 107 107	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.4% 4.7% 4.7% 4.7% 0.01): I ² 1.4% 1.4% 2.8% 0.22): I ² 1.7% 0.1%	-0.56 [-0.6 -0.66 [-0.8 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.2 = 29% -0.05 [-0.2 -0.55 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 0: -0.03] 7: -0.11] 3: 0.13] 1: -0.31] 9: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 9: 0.03] 5: 0.23] 9: 0.04] 5: -0.67]	
habek, 2020 habek, 2020 habek, 2020 habek, 2020 kanques-Sule, 2022 coald (g9% C) etermand, 2023 dota (g9% C) etermand, 2015 diller, 2016 diller, 2016 diller, 2016 diller, 2016 diller, 2016 dealth_status = Acut oringan, 2018 hoter, 2016 dealth_status = Acut oringan, 2018 hoter, 2021 dealth_status = Acut oringan, 2018 hoter, 2021 dealth_status = Neur pathe, 2020 hotel, 2023	sample_17 sample_17 sample_32 sample_32 sample_55 47: CN ² = 12.63, cf r aduts sample_55 47: CN ² = 22.61, cf r aduts sample_12 47: CN ² = 22.61, cf r aduts sample_15 sample_16 sample_17 sample_17 sample_17 sample_17	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 823\\ tf=9 (P \\ 121\\ 105\\ 278\\ tf=2 (P \\ 105\\ 105\\ 278\\ 105\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103$	0.4% 0.1% 1.6% 1.6% 1.5% 8.1% 1.6% 1.4% 1.6% 4.7% 4.7% 4.7% 2.8% 0.22): l ² 1.7% 0.1% 0.5%	-0.56 [-0.6 -0.66 [-0.8 -0.66 [-0.8 -0.32 [-0.4 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.2 = 29% -0.05 [-0.2 -0.55 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 0: -0.03] 7: -0.11] 3: 0.13] 1: -0.31] 9: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 9: 0.03] 5: 0.23] 9: 0.04] 5: -0.67]	
babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 cold (b3% CI) teterogeneity: Tas ² = 0.04 teterogeneity: Tas ² = 0.04 teterogeneity: Tas ² = 0.04 balecz, 2015 biler, 2015 bil	sample_17 sample_17 sample_32 sample_55 47; Ch ² = 12.63, ch ² = 12.63, ch ² = 12.63, ch ² = 12.63, ch ² = 12.63, ch ² = 12.61, ch ² =	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 823\\ 3f=9\ (P)\\ 1211\\ 52\\ 105\\ 278\\ af=2\ (P-1)\\ 105\\ 278\\ af=2\ (P-1)\\ 139\\ 103\\ 103\\ 23\\ 23\\ 23\\ \end{array}$	0.4% 0.1% 1.6% 1.6% 1.5% 1.5% 1.5% 1.5% 1.4% 1.4% 1.6% 4.7% 4.7% 2.8% 0.22 ; t^2 1.7% 0.1% 0.5%	-0.56 [-0.6 -0.66 [-0.8 -0.66 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.55 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.13 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9 -0.34 [-0.6	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 0: -0.03] 7: -0.11] 9: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 9: 0.03] 5: 0.27] 9: 0.03] 5: 0.27] 9: 0.04] 5: -0.67] 5: -0.67] 5: -0.25] 6: 0.08]	
babek, 2020 babek, 2020 babek, 2020 babek, 2020 babek, 2020 2022 2	sample_17 sample_17 sample_32 sample_32 sample_56 47. Ch ² = 12.83. (raduits sample_47 47. Ch ² = 22.81. (e pain sample_37 sample_37 sample_48 47. Ch ² = 12.8. (ch ² =	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 823\\ 4f=9\ (P \\ \\ 121\\ 105\\ 278\\ 4f=2\ (P \\ \\ 105\\ 278\\ 105\\ 278\\ 105\\ 278\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103$	0.4% 0.1% 1.6% 1.6% 1.6% 1.6% 1.6% 1.4% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 4.7% 4	-0.56 [-0.6 -0.66 [-0.8 -0.66 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.55 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.13 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9 -0.34 [-0.6	9: -0.40] 8: -0.23] 7: -0.15] 5: -0.21] 0: -0.03] 7: -0.11] 9: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 0: -0.42] 9: 0.03] 5: 0.27] 9: 0.03] 5: 0.27] 9: 0.04] 5: -0.67] 5: -0.67] 5: -0.25] 6: 0.08]	
habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 hat was seen and a seen and har was seen and har was seen and har was seen and habel, 2020 habel, 2020	sample_17 sample_17 sample_132 sample_132 sample_50 sample_50 47: Ch ² = 12.83, (sample_12 sample_55 47: Ch ² = 12.83, (sample_52 47: Ch ² = 22.81, (sample_52 47: Ch ² = 12, d 47: Ch ² = 152, d sample_48 47: Ch ² = 152, d Sample_17 sample_18 sample_17 sample_18 sample_17 sample_18 sample_54	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 823\\ 47=9\ (P\\ 121\\ 52\\ 105\\ 278\\ 47=2\ (P\\ 103\\ 103\\ 103\\ 103\\ 139\\ 139\\ 139\\ 139\\ 139\\ 139\\ 18\\ 18\\ 18\\ 18\\ 18\end{array}$	0.4% 0.1% 1.6% 1.6% 8.1% 0.15% 1.6% 8.1% 0.18; f 1.6% 1.4% 1.4% 1.4% 0.01; f 1.4% 0.01; f 1.4% 0.01; f 1.6% 0.01; f 0.01; f 0.03; f 0.	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.55 [-0.2 -0.55 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9 -0.34 [-0.6 -0.53 [-0.3 [-0.3 -0.34 [-0.6 -0.65 [-0.8]	9; -0.40] 8; -0.23] 7; -0.15] 5; -0.21] 0; -0.03] 7; -0.11] 3; 0.13] 1; -0.31] 9; -0.42] 0; -0.14] 7; 0.27] 9; 0.03] 5; 0.23] 9; 0.04] 5; -0.67] 5; 0.25] 6; 0.08] 3; -0.18] 5; -0.28]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jeans,	sample_17 sample_17 sample_32 sample_50 sample_50 sample_56 47. Ch ² = 12.63. (r adults sample_12 sample_12 sample_14 epain sample_15 sample_16 sample_16 sample_16 sample_16 sample_16 sample_54 sample_54 sample_54 sample_54 sample_54 sample_54	15 117 98 823 #= 9 (P 1211 52 105 52 78 8 278 # = 2 (P 53 53 53 103 103 103 103 103 103 103 10	$\begin{array}{c} 0.4\%\\ 0.1\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 8.1\%\\ 2.8\%\\ 0.101; t^2\\ 1.4\%\\ 1.6\%\\ 0.101; t^2\\ 1.4\%\\ 0.022; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.7\%$	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.7 -0.51 [-0.2 -0.54 [-0.7 -0.57 [-0.6 -0.44 [-0.6 -0.40 [-0.8 -0.40 [-0.8 -0.43 [-0.4 -0.13 [-0.4 -0.13 [-0.4 -0.13 [-0.2 -0.34 [-0.5 -0.34 [-0.5 -0.34 [-0.5 -0.34 [-0.5 -0.34 [-0.5] -0.33 [-0.6	9: 0.401 7: -0.15 5: -0.21 7: -0.15 5: -0.21 7: -0.15 7: -0.15 7: -0.11 9: -0.42 0: -0.14 9: -0.42 0: -0.14 9: -0.42 9:	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Marques-Sule, 2022 Koldden, 2009 Jatek, 2020 Joal (BS-CI) Heterogeneity-Tau ² = 0.04 Heterogeneity-Tau ²	sample_17 sample_17 sample_32 sample_52 47; Ch ² = 12.83, (sample_56 47; Ch ² = 12.83, (sample_52 47; Ch ² = 12.83, (sample_52 47; Ch ² = 22.81, (sample_52 47; Ch ² = 12.8, (sample_52 47; Ch ² = 152, d 47; Ch ² = 152, d 48; ample_54 sample_54 sample_57 sample_57	15 117 98 61 823 4f = 9 (P) 1211 52 1055 278 278 278 278 103 103 103 103 103 109 109 109 109 109 109 109 109	$\begin{array}{c} 0.4\%\\ 0.1\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ \textbf{8.1\%}\\ \textbf{8.1\%}\\ \textbf{9.15\%}\\ \textbf{8.1\%}\\ \textbf{1.6\%}\\ \textbf{1.15\%}\\ \textbf{8.1\%}\\ \textbf{1.6\%}\\ \textbf{1.15\%}\\ \textbf{1.15\%}\\ \textbf{1.15\%}\\ \textbf{1.15\%}\\ \textbf{0.11\%}\\ \textbf{1.15\%}\\ \textbf{0.11\%}\\ \textbf{1.15\%}\\ \textbf{0.121}\\ \textbf{1.17\%}\\ \textbf{0.15\%}\\ \textbf{0.221}\\ \textbf{1.7\%}\\ \textbf{0.15\%}\\ \textbf{0.3\%}\\ \textbf{0.3\%}\\ \textbf{0.3\%}\\ \textbf{0.7\%}\\ \textbf{0.7\%}\\ \textbf{0.7\%} \end{array}$	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.7 -0.30 [-0.4 = 29% -0.05 [-0.2 -0.54 [-0.7 -0.57 [-0.6 -0.40 [-0.6 = 91% -0.00 [-0.2 -0.25 [-0.4 -0.13 [-0.2 -0.87 [-0.9 -0.13 [-0.2 -0.34 [-0.6 -0.63 [-0.8 -0.36 [-0.8 -0.63 [-0.8 -0.56 [-0.7]	9; -0.40] 7; -0.15] 5; -0.21] 7; -0.15] 6; -0.21] 7; -0.15] 7; -0.15] 7; -0.15] 7; -0.11] 7; -0.11] 7; -0.11] 7; -0.11] 7; -0.11] 7; -0.27] 7; -0.27] 7; -0.21] 9; -0.42] 9; -0.42] 9; -0.44] 9; -0.45] 9; -0.45]	
babek, 2020 babek, 2020 babek, 2020 babek, 2020 sized, 2022 sized, 2022 sized, 2022 sized, 2022 teterogenety, Tau ² = 0.04 teterogenety, Tau ² = 0.04 teterogenety, Tau ² = 0.04 teath, status = Acut teath, status = Acut teath, status = Post compar, 2021 teath, status = Post commert, 2021 teath, status = Neut babek, 2020 imuligan, 2023 imuligan, 2023 imulig	sample_17 sample_17 sample_32 sample_52 47; Ch ² = 12.83, (sample_56 47; Ch ² = 12.83, (sample_52 47; Ch ² = 12.83, (sample_52 47; Ch ² = 22.81, (sample_52 47; Ch ² = 12.8, (sample_52 47; Ch ² = 152, d 47; Ch ² = 152, d 48; ample_54 sample_54 sample_57 sample_57	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 823\\ at=9 \ (P \\ 121\\ 52\\ 278\\ at=2 \ (P \\ 121\\ 52\\ 278\\ at=2 \ (P \\ 133\\ 218\\ 103\\ 218\\ 103\\ 20\\ 20\\ 20\\ 80\\ 80\\ \end{array}$	0.4% 0.1% 1.6% 1.6% 8.1% 9.01% 1.6% 8.1% 1.6% 1.4% 1.4% 1.4% 1.6% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.57 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.41 [-0.4 34% -0.13 [-0.4 -0.18 [-0.5 -0.38 [-0.4 -0.48 [-0.7 -0.38 [-0.3 -0.32 [-0.6 -0.38 [-0.7 -0.38 [-0.7]]	9; -0.40] 7; -0.15] 5; -0.21] 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 4; -0.31 9; -0.42] 9; 0.041 4; 0.231 9; 0.041 4; 0.231 5; -0.231 9; 0.041 4; 0.231 5; -0.231 7; 0.141 9; 0.041 4; 0.231 5; 0.231 9; 0.041 4; 0.231 5; 0.231	
habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 habek, 2020 heterogenety, Tax ² = 0.44 health_status = Acute health_status = Acute heterogenety, Tax ² = 0.44 health_status = Acute heterogenety, Tax ² = 0.04 heterogenety, Tax ²	sample_17 sample_17 sample_32 sample_52 47: ON ² = 12.63. (asample_56 47: ON ² = 12.63. (asample_72 sample_72 47: ON ² = 22.61. (asample_17 sample_52 47: ON ² = 22.61. (asample_16 sample_16 sample_16 sample_16 sample_16 sample_54 sample_54 sample_54 sample_54 sample_54 sample_57 sample_54	15 117 98 823 #=9(P) 1211 52 278 #=2(P) 105 103 103 139 139 103 18 18 18 18 18 200 2	$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 9.16\%\\ 1.6\%\\ 8.1\%\\ 9.10\%\\ 1.4\%\\ 4.7\%\\ 4.7\%\\ 4.7\%\\ 0.1\%\\ 1.4\%\\ 0.022; t^2\\ 1.4\%\\ 0.022; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.5\%$	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.38 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.55 [-0.6 -0.40 [-0.6] [-0.40 [9; -0.40] 7; -0.15] 5; -0.21] 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 4; -0.31 9; -0.42] 9; 0.041 4; 0.231 9; 0.041 4; 0.231 5; -0.231 9; 0.041 4; 0.231 5; -0.231 7; 0.141 9; 0.041 4; 0.231 5; 0.231 9; 0.041 4; 0.231 5; 0.231	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2016 Jotal (95% C1) Heterogeneity, Tac ² = 0.04 Jabek, 2020 Imuligan, 2021 Jackh, 2020 Imuligan, 2023 Imuligan, 2023 Jackh, 2020 Imuligan, 2023 Imuligan, 2024 Catal (95% C1) <td>sample_17 sample_17 sample_32 sample_52 47: ON² = 12.63. (asample_56 47: ON² = 12.63. (asample_72 sample_52 47: ON² = 22.61. (asample_15 sample_15 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_54 sample_55</td> <td>15 177 98 823 823 823 105 278 105 278 50 103 103 103 103 103 103 103 10</td> <td>$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 9.16\%\\ 1.6\%\\ 8.1\%\\ 9.10\%\\ 1.4\%\\ 4.7\%\\ 4.7\%\\ 4.7\%\\ 0.1\%\\ 1.4\%\\ 0.022; t^2\\ 1.4\%\\ 0.022; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.5\%$</td> <td>-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.38 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.55 [-0.6 -0.40 [-0.6] [-0.40 [</td> <td>9; -0.40] 7; -0.15] 5; -0.21] 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 4; -0.31 9; -0.42] 9; 0.041 4; 0.231 9; 0.041 4; 0.231 5; -0.231 9; 0.041 4; 0.231 5; -0.231 7; 0.141 9; 0.041 4; 0.231 5; 0.231 9; 0.041 4; 0.231 5; 0.231</td> <td></td>	sample_17 sample_17 sample_32 sample_52 47: ON ² = 12.63. (asample_56 47: ON ² = 12.63. (asample_72 sample_52 47: ON ² = 22.61. (asample_15 sample_15 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_54 sample_55	15 177 98 823 823 823 105 278 105 278 50 103 103 103 103 103 103 103 10	$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 9.16\%\\ 1.6\%\\ 8.1\%\\ 9.10\%\\ 1.4\%\\ 4.7\%\\ 4.7\%\\ 4.7\%\\ 0.1\%\\ 1.4\%\\ 0.022; t^2\\ 1.4\%\\ 0.022; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.3\%\\ 0.7\%\\ 1.5\%\\ 0.5\%$	-0.56 [-0.6 -0.66 [-0.8 -0.36 [-0.8 -0.38 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.30 [-0.4 -0.55 [-0.6 -0.40 [-0.6] [-0.40 [9; -0.40] 7; -0.15] 5; -0.21] 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 3; 0.131 4; -0.31 9; -0.42] 9; 0.041 4; 0.231 9; 0.041 4; 0.231 5; -0.231 9; 0.041 4; 0.231 5; -0.231 7; 0.141 9; 0.041 4; 0.231 5; 0.231 9; 0.041 4; 0.231 5; 0.231	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Salake, 2020 Salake, 2020 Salake, 2020 Salake, 2020 Salake, 2020 Salake, 2020 Salake, 2015 Salake,	sample_17 sample_17 sample_32 sample_52 sample_56 rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 22.81, cf pain sample_52 rad/CN ² = 12.81, cf rad/CN ² = 12.81, cf r	15 177 188 823 823 121 121 125 278 350 103 103 103 103 103 103 103 10	$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 2.5\%\\ 8.1\%\\ 1.6\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 0.72; t^2\\ 1.4\%\\ 0.22; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.7\%\\ 0.5\%\\ 0.7\%\\ 1.5\%\\ 4.6\%\\ 0.7\%\\ 4.6\%\\ 0.03; t^2\\ 1.5\%$	-0.56 [-0.6 -0.66 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.4 -0.30 [-0.4 -0.35 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.2 -0.57 [-0.6 -0.40 [-0.2 -0.45 [-0.2] [-0.2 -0.45 [-0.2] [-0.2 -0.45 [-0.2] [-0.2] [-0.2 -0.45 [-0.2]	9; -0.40] 9; -0.40] 7; -0.15 0; -0.03] 1; -0.03] 1; -0.03] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 2; -0.42] 2; -0.43] 2;	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jeannes,	sample_17 sample_17 sample_32 sample_32 sample_54 47. CN ² = 12.83. (r adults sample_15 sample_15 sample_15 sample_15 r adults sample_16 s ample_16 s ample_16 s a	15 117 98 61 121 52 105 278 33 15 278 33 103 103 103 103 103 103 103	$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 8.1\%\\ 2.5\%\\ 8.1\%\\ 1.6\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 1.4\%\\ 0.72; t^2\\ 1.4\%\\ 0.22; t^2\\ 1.7\%\\ 0.1\%\\ 0.5\%\\ 0.7\%\\ 0.5\%\\ 0.7\%\\ 1.5\%\\ 4.6\%\\ 0.7\%\\ 4.6\%\\ 0.03; t^2\\ 1.5\%$	-0.56 [-0.6 -0.66 [-0.8 -0.39 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.5 -0.28 [-0.4 -0.30 [-0.4 -0.35 [-0.6 -0.40 [-0.6 -0.40 [-0.6 -0.40 [-0.2 -0.57 [-0.6 -0.40 [-0.2 -0.45 [-0.2] [-0.2 -0.45 [-0.2] [-0.2 -0.45 [-0.2] [-0.2] [-0.2 -0.45 [-0.2]	9; -0.40] 9; -0.40] 7; -0.15 0; -0.03] 1; -0.03] 1; -0.03] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 2; -0.42] 2; -0.43] 2;	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jarques-Sule, 2022 Jarques-Sule, 2022 Jarques-Sule, 2022 Jarques-Jabek, 2020 Jata (195% CI) Heterogeneity-Tas ² = 0.04 Heterogeneity-Tas	sample_17 sample_17 sample_32 sample_52 sample_56 rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 12.83, cf rad/CN ² = 22.81, cf pain sample_52 rad/CN ² = 12.81, cf rad/CN ² = 12.81, cf r	$\begin{array}{c} 15\\ 117\\ 98\\ 61\\ 121\\ 523\\ 278\\ af=9\ (P \\ 121\\ 155\\ 278\\ af=2\ (P \\ 139\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103$	0.4% 0.1% 1.6% 1.6% 8.1% 1.6% 8.1% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 2.8% 2.8% 2.8% 2.8% 2.8% 0.222 P = 1.7% 0.1% 0.5% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.5%	0.56 [0.0 0.56 [0.0 0.32 [0.1 0.33 [0.5 0.33 [0.5 0.35 [0.1 0.35 [0.1 \ 0.35 [0.1 \ 0.35 [0.1 \ 0.35 [0.1 \ 0.35 [0.1 \ 0.35 [9; -0.40] 9; -0.40] 7; -0.15] 4; -0.23] 7; -0.11] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 9; -0.42] 9; -0.43] 9; -0.43] 1; -0.45] 1; -0.45]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2021 Jack, 2022 Jack, 2022 Jack, 2022 Jack, 2022 Jack, 2023 Jack, 2015 Jack,	sample_17 sample_17 sample_32 sample_32 sample_55 47; CN ² = 12.83, cf sample_55 47; CN ² = 12.83, cf sample_52 47; CN ² = 12.83, cf sample_15 sample_16 sample_15 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_	15 117 98 61 121 152 105 278 823 823 823 823 152 53 50 103 103 103 103 103 103 109 109 109 109 109 109 109 109	0.4% 0.1% 1.6% 1.6% 8.1% 0.1% 1.6% 8.1% 8.1% 4.7% 4.7% 4.7% 0.22; r ² 1.7% 0.1% 0.3% 0.22; r ² 1.6% 0.3%	0.56 [0.6 0.66 [0.8 0.32 [0.4 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.4 0.33 [0.4 0.35 [0.7 0.35 [0.7 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.	9; -0.40] 9; -0.40] 7; -0.15] 4; -0.23] 7; -0.11] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 9; -0.42] 9; -0.43] 9; -0.43] 1; -0.45] 1; -0.45]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2021 Jabek, 2021 Jabek, 2021 Jabek, 2021 Jabek, 2015 Jabek, 2015 Jabek, 2015 Jabek, 2015 Jabek, 2015 Jabek, 2020 Jabek,	sample_17 sample_17 sample_32 sample_32 sample_55 47; CN ² = 12.83, cf sample_55 47; CN ² = 12.83, cf sample_52 47; CN ² = 12.83, cf sample_15 sample_16 sample_15 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_	15 117 98 61 121 152 105 278 823 823 823 823 152 53 50 103 103 103 103 103 103 109 109 109 109 109 109 109 109	0.4% 0.1% 1.6% 1.6% 8.1% 0.1% 1.6% 8.1% 8.1% 4.7% 4.7% 4.7% 0.22; r ² 1.7% 0.1% 0.3% 0.22; r ² 1.6% 0.3%	0.56 [0.6 0.66 [0.8 0.32 [0.4 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.4 0.33 [0.4 0.35 [0.7 0.35 [0.7 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.4 0.40 [0.	9; -0.40] 9; -0.40] 7; -0.15] 4; -0.23] 7; -0.11] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 1; -0.31] 9; -0.42] 9; -0.43] 9; -0.43] 1; -0.45] 1; -0.45]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Joadsen, 2009 Joadsen, 2009 Intercognesity, Tac ² = 0.44 teathystics , 2016 Total (95% CI) teterogravity, Tac ² = 0.64 teathystics , 2016 Total (95% CI) teterogravity, Tac ² = 0.04 teterogravity , Tac ² = 0.	sample_17 sample_17 sample_12 sample_52 47: CN ² = 12.63. or sample_55 47: CN ² = 12.63. or sample_52 47: CN ² = 22.61. or sample_15 sample_15 sample_16 47: CN ² = 15.2. or sample_16 sample_54 sample_55 sam	$\begin{array}{c} 15\\ 16\\ 10\\ 98\\ 823\\ 4=9\\ (P\\ 121\\ 52\\ 105\\ 278\\ 4=2\\ (P\\ 10\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\$	$\begin{array}{c} 0.4\%\\ 0.4\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.5\%\\ 2.16\%\\ 1.4\%\\ 1.4\%\\ 2.011\ 1.4\%\\ 1.4\%\\ 0.021\ 1^2\\ 1.4\%\\ 0.021\ 1^2\\ 1.4\%\\ 0.021\ 1^2\\ 1.4\%\\ 0.021\ 1^2\\ 1.4\%\\ 0.021\ 1^2\\ 1.7\%\\ 0.1\%\\ 0.0\%\\ 1.7\%\\ 0.030\ 1^2\\ 1.7\%$	0.056 [0.0 0.066 [0.0 0.032 [0.4] 0.033 [0.5] 0.033 [0.5] 0.033 [0.5] 0.035 [0.2] 0.055 [0	9; -0.40] 9; -0.40] 3; -0.13] 3; -0.13] 3; -0.11] 3; -0.11] 3; -0.11] 3; -0.42] 4; -0.42]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jack, 2021 Jack, 2020 Jack, 2020 Jack, 2020 Jean, 2020	sample_17 sample_17 sample_32 sample_32 sample_56 $(-7)^{-1}$ (C) $(-7)^{-1}$	$\begin{array}{c} 155\\ 117\\ 98\\ 61\\ 121\\ 522\\ 105\\ 278\\ af=9 (P\\ 53\\ 50\\ 103\\ af=1 (P=\\ 139\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103$	0.4% 0.1% 0.1% 1.6% 8.1% 8.1% 1.6% 8.1% 1.4% 1.4% 0.1% 0.021; f ² 1.4% 0.52; f ² 1.7% 0.3% 0.5% 0.3%	0.56 [0.6 0.66 [0.8 0.32 [0.4 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.35 [0.7 0.55 [0.7] [0.7 0.55 [0.7] [0.7 0.55 [0.7] [0.7 0.55 [0.7]	9: 0.401 9: 0.401 9: 0.401 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 9: 0.421 9: 0.421 9: 0.421 9: 0.4141 9: 0.421 9: 0.441 9: 0.441	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jeadems, 3000 Heterogeneity, Tas ² = 0.4 Hearth, 341us = Acte Total (95% CI) Heterogeneity, Tas ² = 0.04 Heath, 341us = Acte Jordal (95% CI) Heterogeneity, Tas ² = 0.04 Heath, 341us = Acte Jordal (95% CI) Heath, 341us = Post Jordel, 2023 Jinuligan, 2023 Jinuli	sample_17 sample_17 sample_12 sample_52 47: CN ² = 12.63. or sample_55 47: CN ² = 12.63. or sample_52 47: CN ² = 22.61. or sample_15 sample_15 sample_16 47: CN ² = 15.2. or sample_16 sample_54 sample_55 sam	$\begin{array}{c} 155\\ 117\\ 98\\ 823\\ 823\\ 4=9 (P \\ 121\\ 52\\ 278\\ 33\\ 105\\ 278\\ 105\\ 278\\ 105\\ 278\\ 105\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103\\ 103$	0.4% 0.1% 0.1% 1.6% 8.1% 8.1% 1.6% 8.1% 1.4% 1.4% 0.1% 0.021; f ² 1.4% 0.52; f ² 1.7% 0.3% 0.5% 0.3%	0.56 [0.6 0.66 [0.8 0.32 [0.4 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.35 [0.7 0.55 [0.7] [0.7 0.55 [0.7] [0.7 0.55 [0.7] [0.7 0.55 [0.7]	9: 0.401 9: 0.401 9: 0.401 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 9: 0.421 9: 0.421 9: 0.421 9: 0.4141 9: 0.421 9: 0.441 9: 0.441	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jean (Jabek, 2022 Jean (Jabek, 2020 Jean (Jabek, 2020 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016) Jean (Jabek, 2017) Jean (Jabek, 2017) Je	sample_17 sample_17 sample_32 sample_32 sample_52 sample_52 relation of the sample_52 relation of the sample_32 relation of the sample_32 relation of the sample_15 sample_15 sample_15 relation of the sample_15 relation of the sample_15 relation of the sample_15 relation of the sample_16 relation of the sample_17 relation of the sample_16 relation of the sample_17 relation of the sample_17 relation of the sample_16 relation of the	15 117 188 198 823 823 823 823 823 823 105 105 105 105 105 105 105 105	0.4% 0.1% 1.6% 1.6% 1.6% 1.6% 1.4% 1.1% 4.7% 4.7% 4.7% 0.02E ² F ² 1.4% 0.22E ² F ² 0.7% 0.3% ² F ² 0.3% ² 1.7% 0.3% ² F ² 1.7% 0.3% ² F ² 0.3% ²	0.056 0.0 0.056 0.0 0.032 0.0 0.032 0.0 0.032 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.034 0.0 0.054 0.0 0.055 0	9: 0.401 9: 0.401 9: 0.401 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 9: 0.421 9: 0.421 9: 0.421 9: 0.4141 9: 0.421 9: 0.441 9: 0.441	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jean (Jabek, 2022 Jean (Jabek, 2022 Jean (Jabek, 2020 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016) Jean (Jabek, 2017) Jean (Jabek, 2017) Je	sample_17 sample_17 sample_12 sample_12 sample_25 arangle_52 aradults sample_52 aradults sample_12 sample_12 sample_12 sample_12 aradults sample_12 aradults sample_12 aradults sample_12 aradults sample_12 aradults sample_14 sample_14 sample_15 aradults sample_15 aradults sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_16 sample_17 sample_16 sample_17 sample_16 aradults sample_16 sample_17 sample_16 samp	15 117 188 198 823 823 823 823 823 823 105 105 105 105 105 105 105 105	0.4% 0.1% 1.6% 1.6% 1.6% 1.6% 1.4% 1.1% 4.7% 4.7% 4.7% 0.02E ² F ² 1.4% 0.22E ² F ² 0.7% 0.3% ² F ² 0.3% ² 1.7% 0.3% ² F ² 1.7% 0.3% ² F ² 0.3% ²	0.056 0.0 0.056 0.0 0.032 0.0 0.032 0.0 0.032 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.034 0.0 0.054 0.0 0.055 0	9: 0.401 9: 0.401 9: 0.401 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 3: 0.131 9: 0.421 9: 0.421 9: 0.421 9: 0.4141 9: 0.421 9: 0.441 9: 0.441	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2015 Jack, 2015	sample_17 sample_17 sample_32 sample_32 sample_54 47. CN ² = 12.83. (r adults sample_15 sample_15 sample_15 sample_15 sample_16 s ample_16 s ample_56 s ample_56 s ample_56 s ample_57 s ample_57 s ample_57 s ample_57 s ample_57 s ample_57 s ample_57 s ample_57 s ample_57 s ample_56 s ample_57 s br>s ample_57 s s s s s s s s s s	$\begin{array}{c} 1 & 5 \\ 1 & 17 \\ 8 & 23 \\ 1 & 9 & 10 \\ 1 & 278 \\ 1 & 105 \\ 278 \\ 1 & 278 \\ 1 & 105 \\ 278 \\ 1 & 105 \\ 278 \\ 1 & 105 \\ 1 $	0.4% 0.1% 1.8% 1.8% 1.8% 1.8% 1.8% 1.4% 2.81% 2.0% 1.4% 2.8% 2.8% 0.0% 1.4% 2.8% 0.0% 1.4% 2.8% 0.0% 1.4% 2.8% 0.0% 1.4% 0.1% 5.0% 0.0% 1.4% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0	0.56 [0.0 0.66 [0.0 0.32 [0.4] 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.33 [0.5 0.35 [0.7] 0.55 [9: -0.40] 9: -0.40] 7: -0.15 0: -0.021] 9: -0.421 9: -0.422 9: -0.422 9: -0.422 9: -0.423 9: -0.433 9: -0.445 9: -0.455 9: -0.455 9: -0.455 9: -0.455 9: -0.455	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2015 Jack, 2015	sample_17 sample_17 sample_132 sample_52 47: CN ² = 12.63. (asample_55 47: CN ² = 12.63. (asample_52 47: CN ² = 22.61. (asample_52 47: CN ² = 15.2. dl asample_15 sample_16 asample_16 asample_16 asample_16 asample_16 asample_16 asample_17 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_54 asample_64 asample_64 asample_64 asample_64	$\begin{array}{c} 1 & 1 \\ 1 & 1 \\ 1 & 7 \\$	0.4% 0.1% 0.1% 1.8% 1.6% 1.4% 1.4% 1.4% 2.8% 4.7% 0.22): f' = 1.7% 0.5% 0.22): f' = 1.5% 0.3%; 0.3%; 4.6% 0.3%; 1.5% 0.3%;	0.056 [0.0 0.056 [0.0 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.05] [0.2 0.05] [0.2\\	9: -0.40] 9: -0.40] 7: -0.15 0: -0.021] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 9: -0.42] 9: -0.44] 9: -0.44]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jean (Jabek, 2020 Jean (Jabek, 2015 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2017) Jean (J	sample_17 sample_17 sample_32 sample_32 sample_55 47: CN ² = 12.63. (asample_55 47: CN ² = 12.63. (asample_52 47: CN ² = 22.61. (asample_52 47: CN ² = 22.61. (asample_52 47: CN ² = 22.61. (asample_54 sample_15 sample_16 asample_16 sample_16 asample_17 sample_54 sample_555 sample_555 sample_555 sample_5555 sample_555555555555555555555555555555555555	$\begin{array}{c} 1 & 5 \\ 1 & 1 \\ 1 & 2 \\ 1 & 1 \\ 1 & 7 \\ 1 & 1 \\ 1 & 7 \\ 1 & 1 \\ 1 & 1 \\ 1 & 2 \\ 1 & 1 \\ 1 & 2 \\ 1 & 1 \\ 1 & 2 \\ 1 & 2 \\ 1 & 1 \\ 1 & 2 \\ 1 & 2 \\ 1 & 1 \\ 1 & 1 \\ 1 & 2 \\ 1 & 2 \\ 1 & 1 \\ 1 & 1 \\ 1 & 1 \\ 1 & 2 \\ 1 & 2 \\ 1 & 1 \\$	0.4% 0.1% 0.1% 1.8% 1.6% 1.6% 1.4% 1.4% 4.7% 0.001; i ² 1.4% 0.22; i ² 1.7% 0.22; i ² 1.7% 0.0% 0.23; i ² 1.5% 0.23; i ² 1.5% 0.24; i ² 1.5% 0.25; i ² 1.5% 0.26% 0	0.056 [0.0 0.066 [0.0 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.05] [0.10]	9: -0.40] 9: -0.40] 7: -0.15 0: -0.021] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 9: -0.42] 9: -0.44] 9: -0.44]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2021 Jack, 2015 Jack, 2015	sample_17 sample_17 sample_32 sample_32 sample_55 47: CN ² = 12.63. (asample_55 47: CN ² = 12.63. (asample_52 47: CN ² = 22.61. (asample_52 47: CN ² = 22.61. (asample_52 47: CN ² = 22.61. (asample_54 sample_15 sample_16 asample_16 sample_16 asample_17 sample_54 sample_555 sample_555 sample_555 sample_5555 sample_555555555555555555555555555555555555	$\begin{array}{c} 115\\ 117\\ 823\\ 419\\ 117\\ 127\\ 125\\ 105\\ 278\\ 105\\ 105\\ 278\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105$	0.4% 0.1% 0.1% 1.8% 1.6% 1.6% 1.4% 1.4% 4.7% 0.001; i ² 1.4% 0.22; i ² 1.7% 0.22; i ² 1.7% 0.0% 0.23; i ² 1.5% 0.23; i ² 1.5% 0.24; i ² 1.5% 0.25; i ² 1.5% 0.26% 0	0.056 [0.0 0.066 [0.0 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.05] [0.10]	9: -0.40] 9: -0.40] 7: -0.15 0: -0.021] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 9: -0.42] 9: -0.44] 9: -0.44]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jeadems, 2020 Teleforgensib, Tar ² = 0.4 Heard, 2015 Jeadems, 2016 Teleforgensib, Tar ² = 0.6 Heard, 2015 Jeadems, 2016 Teleforgensib, Tar ² = 0.6 Heard, 2015 Jeadems, 2016 Teleforgensib, Tar ² = 0.6 Heard, 2017 Heard, 2018 Jeadems, 2018 Jeadem	sample_17 sample_17 sample_32 sample_32 sample_55 47: $Ok^2 = 12.63$, or sample_55 47: $Ok^2 = 12.63$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 152$, or sample_15 sample_16 sample_16 sample_16 sample_16 sample_54 sample_54 sample_54 sample_56 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_27 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_27 sample_26 sample_27 sample_26	$\begin{array}{c} 115\\ 117\\ 823\\ 419\\ 117\\ 127\\ 125\\ 105\\ 278\\ 105\\ 105\\ 278\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105$	0.4% 0.1% 0.1% 1.8% 1.6% 1.6% 1.4% 1.4% 4.7% 0.001; i ² 1.4% 0.22; i ² 1.7% 0.22; i ² 1.7% 0.0% 0.23; i ² 1.5% 0.23; i ² 1.7% 0.29; i ² 1.7%	0.056 [0.0 0.066 [0.0 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.05] [0.10]	9: -0.40] 9: -0.40] 7: -0.15 0: -0.021] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 3: -0.13] 9: -0.42] 9: -0.44] 9: -0.44]	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jeadems, 2020 Jeadems, 2020 Jeadems, 2020 Jeadems, 2020 Jeadems, 2016 Jeanad, 2015 Jeanad, 2015 Jeanad, 2016 Jeanad, 2015 Jeanad, 2016 Jeanad, 2015 Jeanad, 2016 Jeanad, 2016 Jeanad, 2016 Jeanad, 2016 Jeanad, 2017 Jeanad, 2018 Jean, 2	sample_17 sample_17 sample_32 sample_32 sample_55 47: $Ok^2 = 12.63$, or sample_55 47: $Ok^2 = 12.63$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 22.61$, or sample_52 47: $Ok^2 = 152$, or sample_15 sample_16 sample_16 sample_16 sample_16 sample_54 sample_54 sample_54 sample_56 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_27 sample_26 sample_26 sample_26 sample_26 sample_26 sample_26 sample_27 sample_26 sample_27 sample_26	$\begin{array}{c} 115\\ 117\\ 823\\ 419\\ 117\\ 127\\ 125\\ 105\\ 278\\ 105\\ 105\\ 278\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105\\ 105$	0.4% 0.1% 1.6% 1.6% 1.1% 1	0.056 [0.0 0.066 [0.0 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.03] [0.1 0.05] [0.10]	6:-0.40 6:-0.23 7:-0.15 6:-0.23 7:-0.15 7:-0.17 7:-0.17 9:-0.42 6:-0.67 7:-0.21 9:-0.42 6:-0.67 7:-0.21 9:-0.42 9:-	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Jean (Jabek, 2022 Jean (Jabek, 2022 Jean (Jabek, 2023 Jean (Jabek, 2020 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016 Jean (Jabek, 2016) Jean	sample_17 sample_17 sample_12 sample_12 sample_52 47: CN ² = 12.63, or sample_52 47: CN ² = 12.63, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 152, or sample_15 sample_16 sample_16 sample_16 loogical condi sample_16 sample_17 sample_54 sample_56 sample_28 sample_29 sample_29 sample_29 sample_21 sample_21 sample_24 sample_24 sample_41 sample_41 sample_43	$\begin{array}{c} 1 & 1 \\ 1 & 1 \\ 9 \\ 8 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	0.4% 0.4% 0.1% 1.8% 1.18% 0.18; f 1.18% 0.19; f 1.18% 0.19; f 1.4% 0.19; f 0.19; f 0.19; f 0.22; f 0.1% 0.22; f 0.1% 0.22; f 0.1% 0.5% 0.22; f 0.1% 0.5% 0.23; f 0.1% 0.5% 0.23; f 0.1% 0.25; f 0.1% 0.25; f 0.25; f 0	0.056 [0.0 0.056 [0.0 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.03] [0.5 0.05] [0.5\\	6:-0.401 7:-0.121 7:-0.121 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 3:.0.133 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 7:.0.271 9:.0.411 9:.0.4	
Jabek, 2020 Jabek, 2020 Jabek, 2020 Jabek, 2020 Status, 2021 Status, 2022 Status, 2022 Status, 2022 Status, 2023 Status, 2026 Status, 2027 Status, 2020 Status, 2021 Status,	sample_17 sample_17 sample_12 sample_12 sample_52 47: CN ² = 12.63, or sample_52 47: CN ² = 12.63, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 22.61, or sample_52 47: CN ² = 152, or sample_15 sample_16 sample_16 sample_16 loogical condi sample_16 sample_17 sample_54 sample_56 sample_28 sample_29 sample_29 sample_29 sample_21 sample_21 sample_24 sample_24 sample_41 sample_41 sample_43	$\begin{array}{c} 1 & 1 \\ 1 & 1 \\ 9 \\ 8 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	0.4% 0.4% 0.1% 1.8% 1.18% 0.18; f 1.18% 0.19; f 1.18% 0.19; f 1.4% 0.19; f 0.19; f 0.19; f 0.22; f 0.1% 0.22; f 0.1% 0.22; f 0.1% 0.5% 0.22; f 0.1% 0.5% 0.23; f 0.1% 0.5% 0.23; f 0.1% 0.25; f 0.1% 0.25; f 0.25; f 0	0.056 0.0 0.056 0.0 0.032 0.0 0.032 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.033 0.0 0.034 0.0 0.054 0.0 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.	e;-0.40] e;-0.23] ;7;-0.15;-0.21] ;0;-0.02] ;0;-0.03] ;0;-0.14] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.41] ;0;-0.42] ;0;-0.41] ;0;-0.42] ;0;-0,-0]	

Supplemental Figure 4. Subgroup meta-analysis: Differences according to physical activity measure (self-reported vs. device-based).

	Cluster	Total	Weight	Correlation IV, Random, 95% Cl	Correlation IV, Random, 95% C
A_objectivity = Self-re					
lamam, 2019	sample_1	100	1.6%	-0.17 [-0.35; 0.03]	
ltug, 2016 ssadourian, 2020	sample_3 sample_5	112 123	1.6% 1.6%	-0.10 [-0.28; 0.09] -0.02 [-0.20; 0.16]	
ydemir, 2022	sample_6	37	1.3%	-0.77 [-0.88; -0.60]	- T
ykut Selcuk, 2020	sample_7	67	1.1%	-0.25 [-0.46; -0.01]	
ykut Selcuk, 2020	sample_7	29	0.5%	-0.31 [-0.61; 0.06]	
aday-Keskin, 2022	sample_8	88	1.6%	-0.12 [-0.32; 0.09]	
ahar Ozdemir, 2021 aykal Sahin, 2021	sample_10	101 98	1.6% 1.6%	-0.01 [-0.20; 0.19]	
ernard, 2015	sample_11 sample_12	121	1.6%	-0.32 [-0.48; -0.12] -0.05 [-0.23; 0.13]	
arvalho, 2017	sample_13	119	0.6%	-0.18 [-0.35; -0.00]	
orrigan, 2018	sample_15	53	1.4%	-0.00 [-0.27; 0.27]	÷ 📫
abek, 2020	sample_17	72	0.3%	-0.43 [-0.60; -0.22]	
abek, 2020	sample_17	18	0.1%	-0.87 [-0.95; -0.67]	-
abek, 2020	sample_17	130	0.5%	-0.52 [-0.64; -0.39]	
abek, 2020 abek, 2020	sample_17 sample 17	119 27	0.5%	-0.41 [-0.55; -0.25] -0.20 [-0.54; 0.19]	
abek, 2020	sample_17	86	0.4%	-0.56 [-0.69; -0.40]	_
abek, 2020	sample 17	15	0.1%	-0.66 [-0.88; -0.23]	
emirbuken, 2016	sample_18	99	1.6%	-0.15 [-0.34; 0.05]	
emmelmaier, 2018	sample_19	2569	1.8%	-0.07 [-0.11; -0.03]	
ogan, 2022	sample_20	290	1.8%	-0.06 [-0.17; 0.05]	
onnarumma, 2017	sample_21	51	1.4%	-0.35 [-0.57; -0.08]	-
Ifving, 2007	sample_22	64	1.5%	-0.31 [-0.52; -0.07]	
o-A-Tham, 2022	sample_25	210	1.7%	-0.04 [-0.17; 0.10]	-
ilinc, 2019 oho, 2011	sample_27 sample_28	200 93	1.7% 1.6%	-0.69 [-0.76; -0.61] 0.10 [-0.11; 0.30]	· · · · · · · · · · · · · · · · · · ·
uthi, 2022	sample_28 sample_31	433	1.6%	0.06 [-0.03; 0.15]	
arques-Sule, 2022	sample_32	117	1.6%	-0.32 [-0.47; -0.15]	
arshall, 2017	sample_33	218	1.7%	-0.24 [-0.36; -0.11]	
arshall, 2021	sample_34	508	1.8%	-0.28 [-0.36; -0.20]	-
arshall, 2022	sample_35	393	1.8%	-0.01 [-0.11; 0.09]	-
asse-Alarie, 2016	sample_36	22	1.0%	0.09 [-0.34; 0.49]	
avarro-Ledesma, 2022		41	1.3%	-0.06 [-0.36; 0.25]	_
orte, 2019	sample_40	77 62	1.5% 1.5%	-0.31 [-0.50; -0.09]	
zer, 2022 zlu, 2022	sample_41 sample_42	45	1.4%	-0.89 [-0.93; -0.82] 0.15 [-0.15; 0.42]	-
alstam, 2014	sample_42	73	0.9%	0.03 [-0.20; 0.26]	
alstam, 2014	sample_43	73	0.9%	-0.14 [-0.36; 0.09]	
eres, 2023	sample_46	50	0.8%	-0.25 [-0.49; 0.03]	
eres, 2023	sample_46	50	0.8%	0.17 [-0.11; 0.43]	
riore, 2020	sample_48	50	1.4%	-0.25 [-0.49; 0.03]	
abey, 2017	sample_49	266	1.8%	0.07 [-0.05; 0.19]	
oaldsen, 2009	sample_50	98	1.6%	-0.39 [-0.55; -0.21]	
andal, 2021 aulicz, 2016	sample_51	460 105	1.8% 1.6%	-0.02 [-0.12; 0.07]	
ertel, 2021	sample_52 sample_53	163	1.7%	-0.57 [-0.69; -0.42] -0.02 [-0.17; 0.13]	-
trandberg, 2022	sample_56	451	1.8%	-0.08 [-0.17; 0.01]	
uttmiller, 2022	sample_58	126	1.6%	0.22 [0.05; 0.38]	
/ang , 2023	sample_60	223	1.7%	-0.35 [-0.46; -0.23]	-
/asiuk-Zowada, 2022	sample_61	80	1.5%	-0.36 [-0.54; -0.16]	
adro, 2019	sample_62	60	0.9%	-0.18 [-0.41; 0.08]	
adro, 2019	sample_62	60	0.9%	-0.12 [-0.36; 0.14]	
elle, 2016 otal (95% CI)	sample_63	487 9882	1.8% 70.2%	-0.22 [-0.30; -0.13] -0.22 [-0.29; -0.14]	
eterogeneity: Tau ² = 0.0638	Chi ² = 493 17			1 ² = 89%	
	- 400.17	ai - 03			
A_objectivity = Device	e-based mea	sure			
	sample_2	20	1.0%	-0.48 [-0.76; -0.05]	
schuler, 2011 zahrani, 2021	sample_4	26	0.5%	0.22 [-0.18; 0.56]	
schuler, 2011 zahrani, 2021 zahrani, 2021	sample_4 sample_4	26 26	0.5% 0.5%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021	sample_4 sample_4 sample_4	26 26 26	0.5% 0.5% 0.5%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020	sample_4 sample_4 sample_4 sample_9	26 26 26 40	0.5% 0.5% 0.5% 1.3%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020 arvalho, 2017	sample_4 sample_4 sample_9 sample_13	26 26 26 40 119	0.5% 0.5% 1.3% 0.6%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017	sample_4 sample_4 sample_9 sample_13 sample_13	26 26 20 119 119	0.5% 0.5% 1.3% 0.6% 0.6%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017 oronado, 2021	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14	26 26 26 40 119	0.5% 0.5% 1.3% 0.6%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16] -0.05 [-0.17; 0.08]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017 oronado, 2021	sample_4 sample_4 sample_9 sample_13 sample_13	26 26 40 119 119 248	0.5% 0.5% 1.3% 0.6% 0.6% 1.7%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017 oronado, 2021 romert, 2021 laviano, 2017 elmus, 2012	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_16 sample_23 sample_24	26 26 40 119 119 248 139 20 53	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.0% 1.4%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16] -0.05 [-0.17; 0.08] -0.13 [-0.29; 0.04] -0.48 [-0.76; -0.05] -0.05 [-0.32; 0.22]	
schuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017 oronado, 2017 oronado, 2017 Iaviano, 2017 elmus, 2012 elstrom, 2013	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_16 sample_23 sample_24 sample_26	26 26 40 119 248 139 20 53 73	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.0% 1.4% 0.9%	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] 0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16] -0.05 [-0.17; 0.08] -0.13 [-0.29; 0.04] -0.48 [-0.76; -0.05] -0.05 [-0.32; 0.22] -0.25 [-0.45; -0.02]	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 arvalho, 2017 arvalho, 2017 oronado, 2021 romatr, 2021 alviano, 2017 elmus, 2017 elstrom, 2013 elstrom, 2013	sample_4 sample_4 sample_9 sample_13 sample_13 sample_13 sample_14 sample_16 sample_24 sample_26 sample_26	26 26 40 119 248 139 20 53 73 73	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.0% 1.4% 0.9% 0.9%	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.02 \ [-0.20; \ 0.16] \\ -0.05 \ [-0.20; \ 0.16] \\ -0.05 \ [-0.20; \ 0.04] \\ -0.13 \ [-0.29; \ 0.04] \\ -0.48 \ [-0.76; \ -0.05] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.25 \ [-0.43; \ 0.02] \\ -0.11 \ [-0.33; \ 0.12] \end{array}$	
schuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 arvalho, 2017 arvalho, 2017 oronado, 2021 romert, 2021 Iaviano, 2017 elemus, 2012 elestrom, 2013 oppenaal, 2023	sample_4 sample_4 sample_9 sample_13 sample_13 sample_13 sample_14 sample_23 sample_24 sample_26 sample_29	26 26 26 40 119 248 139 20 53 73 73 204	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.0% 1.4% 0.9% 0.9% 0.9%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[0.43; \ 0.34 \right] \\ -0.21 \left[-0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ 0.09 \left[-0.09; \ 0.27 \right] \\ -0.02 \left[-0.20; \ 0.16 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.31 \left[-0.29; \ 0.04 \right] \\ -0.48 \left[-0.76; \ -0.05 \right] \\ -0.55 \left[-0.22; \ 0.22 \right] \\ -0.25 \left[-0.45; \ 0.22 \right] \\ -0.25 \left[-0.45; \ 0.02 \right] \\ -0.36 \left[-0.20; \ 0.18 \right] \\ -0.66 \left[-0.20; \ 0.08 \right] \end{array}$	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 arvalho, 2017 oronado, 2017 oronado, 2021 oromado, 2021 arvalno, 2017 elmus, 2017 elstrom, 2013 elstrom, 2013 elstrom, 2013 oppenaal, 2023	sample_4 sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_23 sample_24 sample_26 sample_29 sample_29	26 26 40 119 248 139 20 53 73 73 204 204	0.5% 0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[0.43; \ 0.34 \right] \\ -0.21 \left[0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ 0.9 \left[-0.09; \ 0.27 \right] \\ -0.02 \left[-0.20; \ 0.16 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.13 \left[-0.29; \ 0.04 \right] \\ -0.48 \left[-0.76; \ -0.05 \right] \\ -0.48 \left[-0.76; \ -0.05 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.21 \left[-0.23; \ 0.12 \right] \\ -0.06 \left[-0.20; \ 0.02 \right] \\ -0.03 \left[-0.17; \ 0.11 \right] \end{array}$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Arvalho, 2017 arvalho, 2017 oronado, 2021 romart, 2021 Iaviano, 2017 elmus, 2012 eleistrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_14 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29	26 26 26 40 119 248 139 20 53 73 73 204 204 118	0.5% 0.5% 1.3% 0.6% 0.6% 1.7% 1.0% 1.4% 0.9% 0.9% 0.9% 0.9%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[0.043; \ 0.34 \right] \\ -0.05 \left[0.043; \ 0.34 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ 0.09 \left[-0.09 \right] \\ 0.09 \left[-0.09 \right] \\ 0.09 \left[-0.09 \right] \\ 0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.13 \left[-0.29; \ 0.04 \right] \\ -0.48 \left[-0.76; \ -0.02 \right] \\ 0.05 \left[-0.33; \ 0.22 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.11 \left[-0.33; \ 0.12 \right] \\ -0.11 \left[-0.33; \ 0.12 \right] \\ -0.36 \left[-0.20; \ 0.08 \right] \\ -0.36 \left[-0.36; \ -0.01 \right] \\ -0.19 \left[-0.36; \ -0.01 \right] \end{array}$	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 zarvalho, 2017 arvalho, 2017 oronado, 2021 aviano, 2017 elstrom, 2013 elstrom, 2013 elstrom, 2013 elstrom, 2013 oppenaal, 2023 oppenaal, 2023 tzke, 2018	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_16 sample_24 sample_26 sample_29 sample_29 sample_29 sample_37	26 26 26 40 119 248 139 20 53 73 73 204 204 118 52	0.5% 0.5% 1.3% 0.6% 0.6% 1.7% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9% 0.9% 1.6% 1.4%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[0.43; \ 0.34 \right] \\ -0.21 \left[0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ -0.09 \left[-0.09; \ 0.27 \right] \\ -0.02 \left[-0.20; \ 0.16 \right] \\ -0.05 \left[-0.22; \ 0.04 \right] \\ -0.13 \left[-0.29; \ 0.04 \right] \\ -0.48 \left[-0.76; \ -0.05 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.16 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.27; \ 0.01 \right] \\ -0.19 \left[-0.36; \ -0.01 \right] \\ -0.54 \left[-0.71; \ -0.31 \right] \end{array}$	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 arvalho, 2017 arvalho, 2017 oronado, 2021 romatr, 2021 laviano, 2017 elstrom, 2013 elstrom, 2013 oppenaal, 2023 oppenaal, 2023 bzke, 2018 liller, 2018 linetama, 2022	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_24 sample_24 sample_26 sample_26 sample_29 sample_29 sample_29 sample_37	26 26 40 119 248 139 20 53 73 73 204 204 118 52 71	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9% 0.9% 1.4% 1.4%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.21 \left[-0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ -0.09 \left[-0.09 \right] \\ -0.09 \left[-0.09 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.33; \ 0.12 \right] \\ -0.05 \left[-0.34; \ 0.01 \right] \\ -0.34 \left[-0.44; \ 0.00 \right] \\ -0.32 \left[-0.44; \ 0.00 \right] \\ -0.32 \left[-0.44; \ 0.00 \right] \\ -0.32 \left[-0.44; \ 0.00 \right] \\ -0.35 \left[-0.35; \ 0.01 \right] \\ -0.32 \left[-0.44; \ 0.00 \right] \\ -0.35 \left[-0.35; \ 0.01 \right] \\ -0.35 \left[-0.35; \ 0.01 \right] \\ -0.35 \left[-0.35; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.35; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.34; \ 0.01 \right] \\ -0.35 \left[-0.35;	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 arvalho, 2017 arvalho, 2017 oronado, 2021 romert, 2021 laviano, 2017 eletrom, 2013 eletrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 soppenaal, 2023 soppenaal, 2023 soppenaal, 2023 soppenaal, 2023 soppenaal, 2023 soppenaal, 2023 soppenaal, 2023	sample_4 sample_4 sample_4 sample_13 sample_13 sample_14 sample_16 sample_23 sample_24 sample_26 sample_29 sample_29 sample_30 sample_30 sample_38 sample_38 sample_44	26 26 26 40 119 248 139 20 53 73 73 204 204 118 52	0.5% 0.5% 1.3% 0.6% 0.6% 1.7% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9% 0.9% 1.6% 1.4%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.21 \left[-0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ -0.09 \left[-0.09; \ 0.27 \right] \\ -0.02 \left[-0.02; \ 0.16 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.22; \ 0.22 \right] \\ -0.05 \left[-0.22; \ 0.22 \right] \\ -0.05 \left[-0.22; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.35; \ 0.22 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.05 \left[-0.20; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.11 \right] \\ -0.23 \left[-0.44; \ 0.00 \right] \\ -0.01 \left[-0.11; \ 0.13 \right] \\ \end{array}$	
schuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 aez, 2020 arvalho, 2017 arvalho, 2017 oronado, 2021 romert, 2021 laviano, 2017 elems, 2012 elelstrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 astor-Mira, 2020 astor-Mira, 2020 astor-Mira, 2020 astor-Mira, 2020 astor-Mira, 2021	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_24 sample_24 sample_26 sample_26 sample_29 sample_29 sample_29 sample_37	26 26 26 40 119 248 139 20 53 73 73 204 204 118 52 71 274	0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.0% 1.4% 0.9% 0.9% 0.9% 1.6% 1.5% 1.5%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[0.43; \ 0.34 \right] \\ -0.21 \left[0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ 0.9 \left[-0.09; \ 0.27 \right] \\ -0.02 \left[-0.20; \ 0.16 \right] \\ -0.05 \left[-0.22; \ 0.04 \right] \\ -0.13 \left[-0.29; \ 0.04 \right] \\ -0.48 \left[-0.76; \ -0.05 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.25 \left[-0.45; \ -0.02 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.03 \left[-0.17; \ 0.11 \right] \\ -0.19 \left[-0.36; \ -0.011 \right] \\ -0.54 \left[-0.77; \ -0.31 \right] \\ -0.54 \left[-0.77; \ -0.31 \right] \\ -0.23 \left[-0.44; \ 0.00 \right] \\ 0.01 \left[-0.11; \ 0.013 \right] \\ 0.14 \left[-0.06; \ 0.32 \right] \end{array}$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2021 oronado, 2021 Iaviano, 2017 elmus, 2012 eleistrom, 2013 eleistrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 stzke, 2018 liiter, 2018 intetama, 2022 astor-Mira, 2020 edler, 2018 Jastor-Mira, 2020	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_23 sample_24 sample_26 sample_29 sample_29 sample_29 sample_30 sample_30 sample_44 sample_45 sample_47 sample_47	26 26 26 40 119 248 139 20 53 73 73 204 204 118 52 71 274 103 88 23	0.5% 0.5% 0.6% 0.6% 1.7% 1.0% 1.4% 0.9% 0.9% 0.9% 0.9% 1.6% 1.4% 1.5% 1.8% 1.6% 1.3%	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.02 \ [-0.20; \ 0.16] \\ -0.05 \ [-0.29; \ 0.04] \\ -0.05 \ [-0.29; \ 0.04] \\ -0.48 \ [-0.76; \ -0.05] \\ -0.05 \ [-0.22; \ 0.22] \\ -0.05 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.05 \ [-0.20; \ 0.22] \\ -0.11 \ [-0.33; \ 0.22] \\ -0.06 \ [-0.20; \ 0.08] \\ -0.06 \ [-0$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2017 oronado, 2021 romart, 2021 Iaviano, 2017 eletstrom, 2013 eletstrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 otzke, 2018 Iliter, 2018 Iliter, 2021 Biller, 2018 olaski, 2021 olaski, 2021 mulligan, 2023	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_16 sample_23 sample_24 sample_29 sample_29 sample_29 sample_29 sample_34 sample_44 sample_44 sample_45 sample_54 sample_54	26 26 40 119 248 139 20 53 73 73 204 204 118 52 71 274 103 38 23	0.5% 0.5% 0.5% 1.3% 0.6% 1.7% 1.0% 1.7% 1.9% 0.9% 0.9% 0.9% 0.9% 1.4% 1.5% 1.8% 1.6% 1.3% 0.5%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.21 \left[.0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ -0.21 \left[.0.25; \ 0.19 \right] \\ -0.09 \left[-0.09 \right] \\ -0.09 \left[-0.09 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.33; \ 0.12 \right] \\ -0.03 \left[-0.36; \ 0.01 \right] \\ -0.34 \left[-0.66; \ 0.08 \right] \\ -0.34 \left[-0.66$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 arvalho, 2017 oronado, 2021 Iaviano, 2017 elefixom, 2013 elefixom, 2013 milligen, 2023 mulligan, 2023	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_29 sample_30 sample_45 sample_45 sample_54 sample_54	26 26 40 119 248 139 20 53 73 204 118 52 71 103 38 23 23 23 8 8	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.6\%\\ 0.6\%\\ 1.7\%\\ 1.7\%\\ 1.7\%\\ 1.7\%\\ 1.4\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.5\%\\ 1.8\%\\ 1.6\%\\ 1.3\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ \end{array}$	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.21 \ [-0.55; \ 0.17] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.05 \ [-0.22; \ 0.16] \\ -0.05 \ [-0.22; \ 0.22] \\ -0.05 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.25] \\ -0.48 \ [-0.55; \ 0.25] \\ -0.48 \ [-0.55; \ 0.25] \\ -0.48 \ [-0.65; \ 0.25] \\ -0.48 \ [-0.66] \ [-0.83; \ -0.18] \\ \end{array}$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2021 oronado, 2021 oronado, 2021 Iaviano, 2017 eleistrom, 2013 ielstrom, 2013 ielstrom, 2013 oppenaal, 2023 oppenaal, 2023 otzke, 2018 linetama, 2022 astor-Mira, 2020 astor-Mira, 2020 astor-Mira, 2020 astor-Mira, 2023 mulligan, 2023 mulligan, 2023	sample_4 sample_4 sample_9 sample_13 sample_13 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_29 sample_30 sample_43 sample_44 sample_44 sample_54 sample_54 sample_54	26 26 40 119 248 139 248 139 204 118 53 73 73 204 118 52 204 103 38 23 23 103 38 23 8 23 8 23 8 23 8 23 8 23 8 26 10 26 26 26 26 26 26 26 26 26 26 26 26 26	0.5% 0.5% 0.5% 0.6% 0.6% 1.7% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9% 0.9% 1.6% 1.8% 1.5% 1.8% 1.5% 0.5% 0.5% 0.3%	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.02 \ [-0.20; \ 0.16] \\ -0.05 \ [-0.22; \ 0.04] \\ -0.05 \ [-0.22; \ 0.04] \\ -0.45 \ [-0.45; \ 0.02] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.05 \ [-0.20; \ 0.08] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.39 \ [-0.35; \ 0.25] \\ -0.34 \ [-0.66; \ 0.08] \\ -0.60 \ [-0.83; \ 0.23] \end{array}$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2021 oronado, 2021 romert, 2021 elistvom, 2013 elistvom, 2013 elistrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 astor-Mira, 2020 edler, 2018 Ilider, 2018 Inetama, 2022 astor-Mira, 2020 edler, 2018 Iolaski, 2021 mulligan, 2023 mulligan, 2023 mulligan, 2023 mulligan, 2023	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_26 sample_26 sample_28 sample_29 sample_29 sample_29 sample_44 sample_45 sample_54 sample_54 sample_54	26 26 26 40 119 119 20 53 73 73 204 204 204 204 204 204 204 204 204 204	0.5% 0.5% 0.5% 1.3% 0.6% 1.7% 1.7% 1.4% 0.9% 0.9% 0.9% 0.9% 1.4% 1.5% 1.4% 1.5% 1.3% 0.5% 0.3% 0.3%	$\begin{array}{c} 0.22 \left[0.18; \ 0.56 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.05 \left[-0.43; \ 0.34 \right] \\ -0.21 \left[.0.55; \ 0.19 \right] \\ 0.18 \left[-0.14; \ 0.47 \right] \\ -0.09 \left[-0.09 \right] \\ -0.09 \left[-0.09 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.17; \ 0.08 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.05 \left[-0.32; \ 0.22 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.06 \left[-0.20; \ 0.08 \right] \\ -0.03 \left[-0.36; \ 0.01 \right] \\ -0.23 \left[-0.44; \ 0.00 \right] \\ -0.34 \left[-0.66; \ 0.08 \right] \\ -0.34 \left[-0.66; \ 0.08 \right] \\ -0.36 \left[-0.38; \ 0.21 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55; \ 0.25 \right] \\ -0.34 \left[-0.56; \ 0.08 \right] \\ -0.34 \left[-0.56; \ 0.08 \right] \\ -0.36 \left[-0.55; \ 0.25 \right] \\ -0.38 \left[-0.55$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2021 oronado, 2021 oronado, 2021 alvaiano, 2017 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2013 eleistrom, 2023 astor-Mira, 2020 edier, 2018 olaski, 2021 mulligan, 2023 mulligan, 2023 mulligan, 2023	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_30 sample_44 sample_45 sample_54 sample_55 sample_55	26 26 26 40 119 248 373 73 73 73 73 73 204 204 204 118 52 274 103 38 23 23 18 18 18 23 23 24 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.5\%\\ 1.3\%\\ 0.6\%\\ 1.7\%\\ 1.7\%\\ 1.7\%\\ 1.4\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.6\%\\ 1.8\%\\ 1.6\%\\ 1.8\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 0.3\%\\ 0.3\%\\ 0.7\%$	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.02 \ [-0.20; \ 0.16] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.25 \ [-0.45; \ -0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.16 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.20; \ 0.28] \\ -0.06 \ [-0.65; \ 0.28] \\ -0.35 \ [-0.45; \ 0.29] \\ -0.36 \ [-0.55; \ 0.25] \\ -0.36 \ [-0.85; \ 0.28] \\ -0.66 \ [-0.85; \ 0.28] \\ -0.66 \ [-0.85; \ 0.28] \\ -0.66 \ [-0.85; \ 0.28] \\ -0.66 \ [-0.85; \ 0.28] \\ -0.28 \ [-0.56; \ 0.03] \\ -0.28 \ [-0.56; \ 0.03] \\ -0.32 \ [-0.56; \ 0.03] \\ -0.32 \ [-0.56; \ 0.14] \end{array}$	
Ischuler, 2011 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 Izahrani, 2021 arvalho, 2017 oronado, 2017 oronado, 2021 romert, 2021 Iaviano, 2017 eletstrom, 2013 eletstrom, 2013 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 oppenaal, 2023 astor-Mira, 2020 edler, 2018 olaski, 2021 mulligan, 2023 mulligan, 2023 mulligan, 2023 padema, 2020 utcu, 2021	sample_4 sample_4 sample_9 sample_13 sample_13 sample_14 sample_16 sample_23 sample_24 sample_26 sample_29 sample_29 sample_29 sample_29 sample_44 sample_44 sample_45 sample_54 sample_54 sample_54 sample_57 sample_57	26 26 26 40 119 248 30 20 20 20 20 20 20 20 20 4 20 4 20 4	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.5\%\\ 1.3\%\\ 0.6\%\\ 1.7\%\\ 1.0\%\\ 1.7\%\\ 1.0\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.5\%\\ 1.8\%\\ 1.5\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 0.5\%\\ 0.3\%\\ 0.7\%\\ 0.0\%\\ 0.7\%\\ 0.0\%$	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ -0.05 \ [-0.13; \ 0.05] \\ -0.09 \ [-0.09; \ 0.09] \\ -0.09 \ [-0.09; \ 0.07] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.05 \ [-0.33; \ 0.12] \\ -0.05 \ [-0.33; \ 0.12] \\ -0.06 \ [-0.20; \ 0.08] \\ -0.03 \ [-0.36; \ 0.01] \\ -0.36 \ [-0.20; \ 0.08] \\ -0.03 \ [-0.36; \ 0.01] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.11] \\ -0.36 \ [-0.12] \\ -0.36 \ [-0.35; \ 0.22] \\ -0.36 \ [-0.35; \ 0.22] \\ -0.36 \ [-0.35; \ 0.22] \\ -0.36 \ [-0.36; \ 0.08] \\ -0.36 \ [-0.85; \ 0.22] \\ -0.36 \ [-0.36; \ 0.03] \\ -0.36 \ [-0.36; \ 0.36] \\ -0.36 \ [-0.36; $	
schuler, 2011 zahrani, 2021 zahrani, 2021 zahrani, 2021 zahrani, 2021 zahrani, 2021 arvalho, 2017 zronado, 2021 ormert, 2021 aviano, 2017 almus, 2017 almus, 2017 almus, 2017 almus, 2018 elstrom, 2013 oppenaal, 2023 oppenaal, 2023 tzke, 2018 lier, 2018 enetama, 2022 tzke, 2018 unetama, 2020 dider, 2018 olaski, 2021 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023 nulligan, 2023	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_30 sample_44 sample_45 sample_54 sample_55 sample_55	266 266 266 268 248 248 248 204 204 204 204 204 204 118 202 204 103 38 203 204 103 203 203 204 103 203 203 203 204 205 205 205 205 205 205 205 205 205 205	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.6\%\\ 1.3\%\\ 0.6\%\\ 1.7\%\\ 1.7\%\\ 1.0\%\\ 1.4\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.8\%\\ 1.6\%\\ 1.8\%\\ 1.6\%\\ 0.5\%\\ 0.3\%\\ 0.5\%\\ 0.7\%\\ 0.7\%\\ 0.7\%\\ 1.7\%\\ 0.7\%$	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.22; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.36 \ [-0.20; \ 0.08] \\ -0.36 \ [-0.20; \ 0.08] \\ -0.36 \ [-0.35; \ 0.02] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.36 \ [-0.35; \ 0.29] \\ -0.32 \ [-0.67; \ 0.14] \\ -0.54 \ [-0.$	
schuler, 2011 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 rivalho, 2017 ronado, 2021 mut, 2017 mora, 2021 vistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2023 tistrom, 2023 tistrom, 2023 tulligan, 2023 uulligan, 2023 aderma, 2020 tou, 2021	sample_4 sample_4 sample_9 sample_13 sample_13 sample_16 sample_23 sample_24 sample_26 sample_29 sample_29 sample_29 sample_30 sample_30 sample_44 sample_54 sample_55 sample_57 sample_59	266 266 266 40 119 119 248 248 237 73 73 73 73 73 73 73 70 4 204 204 204 204 204 204 204 204 204	0.5% 0.5% 0.5% 1.3% 0.6% 1.7% 1.0% 1.7% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 1.6% 1.5% 0.5% 0.5% 0.3% 1.5% 0.3% 1.5% 0.3% 0.7% 1.5% 0.2% 0.5% 0.2% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9	$\begin{array}{c} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.09 \ [-0.09 \ 0.27] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.15 \ [-0.17; \ 0.08] \\ -0.15 \ [-0.17; \ 0.08] \\ -0.13 \ [-0.22; \ 0.04] \\ -0.48 \ [-0.76; \ -0.05] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.25 \ [-0.45; \ -0.05] \\ -0.05 \ [-0.33; \ 0.12] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.17; \ 0.11] \\ -0.03 \ [-0.15; \ 0.25] \\ -0.03 \ [-0.35; \ 0.25] \\ -0.34 \ [-0.66; \ 0.08] \\ -0.60 \ [-0.83; \ 0.18] \\ -0.56 \ [-0.83; \ 0.13] \\ -0.54 \ [-0.77; \ 0.13] \\ -0.54 \ [-0.77; \ 0.13] \\ -0.15 \ [-0.34; \ -0.02] \end{array}$	
chuler, 2011 ahrani, 2021 iahrani, 2021 iahrani, 2021 iahrani, 2021 iahrani, 2021 iahrani, 2021 vralho, 2017 ronado, 2021 ronado, 2017 Imus, 2017 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2013 Istrom, 2023 tor-Mira, 2020 Ider, 2018 Iaski, 2021 Iuliigan, 2023 Iuliigan, 2024 Iuliigan, 2020 Iuliigan, 2025 Iuliigan, 2026 Iuliigan, 2027 Iuliigan, 2027 Iuliigan, 2028 Iuliigan, 2029 Iuliigan, 2029 Iuliigan, 2029 Iuliigan, 2029 Iuliigan, 2029 Iuliigan, 2020 Iuliigan, 2020 Iuliigan, 2020 Iuliigan, 2020 Iuliigan, 2020 Iuliigan, 2020 Iuliigan, 2020 Iuliiigan, 2020 Iuliiigan, 2020 Iuliiigan, 2020 Iuliiigan	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_29 sample_29 sample_45 sample_45 sample_54 sample_57 sample_59 ch ² = 65.36,	266 266 400 1199 2488 1399 204 204 204 204 204 204 204 204 204 204	0.5% 0.5% 0.5% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9	$\begin{array}{l} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.25; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.29] \\ -0.35 \ [-0.3$	
schuler, 2011 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 tahrani, 2021 trvalho, 2017 ronado, 2021 mert, 2021 visitor, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 tistrom, 2013 ppenaal, 2023 tzke, 2018 ler, 2018 ler, 2018 ler, 2018 taki, 2021 tuligan, 2023 tuligan, 2020 tu, 2021 tani, 2020 tat (95% CI)	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_29 sample_29 sample_45 sample_45 sample_54 sample_57 sample_59 ch ² = 65.36,	266 266 400 1199 2488 1399 204 204 204 204 204 204 204 204 204 204	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 1.3\%\\ 0.6\%\\ 1.7\%\\ 1.0\%\\ 1.7\%\\ 1.0\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.9\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.5\%\\ 0.3\%\\ 1.5\%\\ 0.7\%\\ 1.7\%\\ 29.8\%\end{array}$	0.22 [-0.18; 0.56] -0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19] 0.18 [-0.14; 0.47] -0.09 [-0.09; 0.27] -0.02 [-0.20; 0.16] -0.13 [-0.29; 0.04] -0.48 [-0.76; -0.02] -0.25 [-0.45; -0.02] -0.25 [-0.45; -0.02] -0.25 [-0.45; -0.02] -0.25 [-0.45; -0.02] -0.25 [-0.45; -0.02] -0.33 [-0.26; -0.11] -0.48 [-0.76; -0.13] -0.44 [-0.06; 0.32] -0.33 [-0.35; 0.229] -0.34 [-0.66; 0.08] -0.34 [-0.79; -0.13] -0.54 [-0.79; -0.13] -0.15 [-0.24; -0.02] ² = 57% -0.19 [-0.26; -0.13]	
chuler, 2011 ahrani, 2021 ahrani, 2021 ahrani, 2021 ahrani, 2021 arani, 2021 ahrani, 2021 vralho, 2017 ronado, 2021 ronado, 2017 imus, 2017 istrom, 2017 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2013 istrom, 2023 istro-Mira, 2020 istro-Mira, 2020 istro-Mira, 2023 iulligan, 2020 iulligan, 2020	sample_4 sample_4 sample_4 sample_9 sample_13 sample_14 sample_16 sample_26 sample_26 sample_29 sample_29 sample_29 sample_29 sample_29 sample_29 sample_45 sample_45 sample_54 sample_57 sample_59 ch ² = 65.36,	266 266 400 1199 2488 1399 204 204 204 204 204 204 204 204 204 204	0.5% 0.5% 0.5% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9	$\begin{array}{l} 0.22 \ [-0.18; \ 0.56] \\ -0.05 \ [-0.43; \ 0.34] \\ -0.21 \ [-0.55; \ 0.19] \\ 0.18 \ [-0.14; \ 0.47] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.09 \ [-0.09; \ 0.27] \\ -0.05 \ [-0.17; \ 0.08] \\ -0.05 \ [-0.32; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.25; \ 0.22] \\ -0.25 \ [-0.45; \ 0.02] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.22] \\ -0.35 \ [-0.35; \ 0.29] \\ -0.35 \ [-0.3$	

 $\begin{array}{l} \mbox{Heterogeneity: Tau^2 = 0.0634; Chi^2 = 564.77, \ df = 82 \ (P < 0.01); \ l^2 = 85\% \\ \mbox{Residual heterogeneity: Tau^2 = 0.0656; Chi^2 = 558.53, \ df = 81 \ (P < 0.01); \ l^2 = 85\% \\ \mbox{Test for subgroup differences: } F = 1.90, \ df = 1, \ 81 \ (P = 0.17) \end{array}$

Supplemental Figure 5. Subgroup meta-analysis: Differences by physical activity measurement instrument.



 $\begin{array}{l} \mbox{Haterogeneity: Tau^2 = 0.0634: Chi^2 = 564.77, \ df = 82 \ (P < 0.01); \ l^2 = 85\% \\ \mbox{Residual heterogeneity: Tau^2 = 0.0605; Chl^2 = 490.86, \ df = 67 \ (P < 0.01); \ l^2 = 86\% \\ \ \mbox{Test for subgroup differences: } F = 1.33, \ df = 15, \ 67 \ (P = 0.21) \end{array}$

Supplemental Figure 6. Subgroup meta-analysis: Differences by physical activity outcome

PA_outcome = MET-mi Alamam, 2019	Cluster	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI
Alamam, 2019	n/week				
	sample_1	100	1.6%	-0.17 [-0.35; 0.03]	
Altug, 2016	sample_3	112	1.6%	-0.10 [-0.28; 0.09]	
Alzahrani, 2021	sample_4	26	0.5%	0.22 [-0.18; 0.56]	
Alzahrani, 2021	sample_4	26	0.5%	-0.05 [-0.43; 0.34]	
Aykut Selcuk, 2020	sample_7	67	1.1%	-0.25 [-0.46; -0.01]	
Aykut Selcuk, 2020	sample_7	29	0.5%	-0.31 [-0.61; 0.06]	
Baday-Keskin, 2022	sample_8	88	1.6%	-0.12 [-0.32; 0.09]	
Bahar Ozdemir, 2021	sample_10	101	1.6%	-0.01 [-0.20; 0.19]	
Baykal Sahin, 2021	sample_11	98	1.6%	-0.32 [-0.48; -0.12]	
Dabek, 2020	sample_17	72	0.3%	-0.43 [-0.60; -0.22]	-
Dabek, 2020	sample_17	18	0.1%	-0.87 [-0.95; -0.67]	
Dabek, 2020	sample_17	130	0.5%	-0.52 [-0.64; -0.39]	
Dabek, 2020	sample_17	119	0.5%	-0.41 [-0.55; -0.25]	
Dabek, 2020	sample_17	27 86	0.1%	-0.20 [-0.54; 0.19]	
Dabek, 2020 Dabek, 2020	sample_17	15	0.4%	-0.56 [-0.69; -0.40] -0.66 [-0.88; -0.23]	
Demirbuken, 2016	sample_17 sample_18	99	1.6%	-0.15 [-0.34; 0.05]	
Demmelmaier, 2018	sample_10	2569	1.8%	-0.07 [-0.11; -0.03]	
Dogan, 2022	sample_20	290	1.8%	-0.06 [-0.17; 0.05]	
Donnarumma, 2017	sample_21	51	1.4%	-0.35 [-0.57; -0.08]	
Ho-A-Tham, 2022	sample_25	210	1.7%	-0.04 [-0.17; 0.10]	-
Kilinc, 2019	sample_27	200	1.7%	-0.69 [-0.76; -0.61]	
Koppenaal, 2023	sample_29	204	0.9%	-0.06 [-0.20; 0.08]	
Koppenaal, 2023	sample_29	204	0.9%	-0.03 [-0.17; 0.11]	
Marques-Sule, 2022	sample_32	117	1.6%	-0.32 [-0.47; -0.15]	
Masse-Alarie, 2016	sample_36	22	1.0%	0.09 [-0.34; 0.49]	
Ozer, 2022	sample_41	62	1.5%	-0.89 [-0.93; -0.82]	-
Ozlu, 2022	sample_42	45	1.4%	0.15 [-0.15; 0.42]	
Peres, 2023	sample_46	50	0.8%	-0.25 [-0.49; 0.03]	
Peres, 2023	sample_46	50	0.8%	0.17 [-0.11; 0.43]	_
Priore, 2020	sample_48	50	1.4%	-0.25 [-0.49; 0.03]	
Rabey, 2017	sample_49 sample_58	266	1.8%	0.07 [-0.05; 0.19]	
Suttmiller, 2022	sample_58 sample_60	126 223	1.6%	0.22 [0.05; 0.38] -0.35 [-0.46; -0.23]	
Wang , 2023 Zelle, 2016	sample_60 sample_63	487	1.7%	-0.35 [-0.46; -0.23] -0.22 [-0.30; -0.13]	
Total (95% CI)	sample_03	6439	40.0%	-0.20 [-0.30; -0.09]	-
Heterogeneity: Tau ² = 0.0658	: Chi ² = 371.71			1 ² = 91%	T
			h		
PA_outcome = Counts/	min				
Alschuler, 2011	sample_2	20	1.0%	-0.48 [-0.76; -0.05]	
Carvalho, 2017	sample_13 sample_14	119	0.6%	-0.02 [-0.20; 0.16]	
Coronado, 2021	sample_14	248	1.7%	-0.05 [-0.17; 0.08]	
Cromert, 2021	sample_16	139	1.7%	-0.13 [-0.29; 0.04]	
Helmus, 2012	sample_24	53	1.4%	-0.05 [-0.32; 0.22]	
Total (95% CI)		579	6.4%	-0.14 [-0.33; 0.05]	
Heterogeneity: Tau ² = 0.0658	; Chi* = 4.37, df	= 4 (P =	• 0.36); l* =	8%	
PA_outcome = Steps/d	-				
Alzahrani, 2021	sample_4	26	0.5%	-0.21 [-0.55; 0.19]	
Baez, 2020	sample_9	40	1.3%	0.18 [-0.14; 0.47]	
Glaviano, 2017	sample_23	20	1.0%	-0.48 [-0.76; -0.05]	
Igelstrom, 2013	sample_26	73	0.9%	-0.25 [-0.45; -0.02]	
Lotzke, 2018	sample_30	118	1.6%	-0.19 [-0.36; -0.01]	-
Miller, 2018	sample_37	52	1.4%	-0.54 [-0.71; -0.31]	
Minetama, 2022	sample_38	71	1.5%	-0.23 [-0.44; 0.00]	
Pastor-Mira, 2020	sample 44	274	1.8%	0.01 [-0.11; 0.13]	
Polaski, 2021	sample_47	38	1.3%	-0.03 [-0.35; 0.29]	
Smulligan, 2023	sample_54	23	0.5%	-0.18 [-0.55; 0.25]	
Smulligan, 2023	sample_54	23	0.5%	-0.34 [-0.66; 0.08]	
Sutcu, 2021	sample_57	20	0.7%	-0.32 [-0.67; 0.14]	
Uritani, 2020	sample_59	167	1.7%	-0.16 [-0.31; -0.01]	
Total (95% CI) Heterogeneity: Tau ² = 0.0658	ch ² = 27.04	945	14.5%	-0.18 [-0.33; -0.03]	
Heterogeneity. 1au = 0.0056	(Gin = 27.04, (1 = 12 (< 0.01), 1	- 30%	-
PA_outcome = Active t	ime				-
Assadourian, 2020	sample_5	123	1.6%	-0.02 [-0.20; 0.16]	
Carvalho, 2017	sample_13	119	0.6%	0.09 [-0.09; 0.27]	
Igelstrom, 2013	sample_26	73	0.9%	-0.11 [-0.33; 0.12]	
Marshall, 2017	sample_33	218	1.7%	-0.24 [-0.36; -0.11]	-
Marshall, 2021	sample_34	508	1.8%	-0.28 [-0.36; -0.20]	
Marshall, 2022	sample_35	393	1.8%	-0.01 [-0.11; 0.09]	
Pedler, 2018	sample_45	103	1.6%	0.14 [-0.06; 0.32]	+
Smulligan, 2023	sample_54	18	0.3%	-0.60 [-0.83; -0.18]	
Smulligan, 2023	sample_54	18	0.3%	-0.63 [-0.85; -0.23]	
Strandberg, 2022	sample_56	451	1.8%	-0.08 [-0.17; 0.01]	
Zadro, 2019 Zadro, 2019	sample_62	60		-0.18 [-0.41; 0.08]	
Zadro, 2019 Total (95% CI)	sample_62	60 2144	0.9% 14.3%	-0.12 [-0.36; 0.14]	
Total (95% CI) Heterogeneity: Tau ² = 0.0658	Chi ² = 46.84			-0.11 [-0.25; 0.03]	
			- 0.01), 1		
nounogeneny. Tuo - 0.0000					
PA_outcome = Score	sample_6	37	1.3%	-0.77 [-0.88; -0.60]	
PA_outcome = Score Aydemir, 2022	sample_12	121	1.6%	-0.05 [-0.23; 0.13]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015		119	0.6%	-0.18 [-0.35; -0.00]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017	sample 13				
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018	sample 13	53	1.4%	-0.00 [-0.27; 0.27]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007	sample 13	53 64	1.5%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07]	_ _
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011	sample_13 sample_15 sample_22 sample_28	53 64 93	1.5% 1.6%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011 Luthi, 2022	sample_13 sample_15 sample_22 sample_28 sample_31	53 64 93 433	1.5% 1.6% 1.8%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39	53 64 93 433 41	1.5% 1.6% 1.8% 1.3%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Norte, 2019	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39 sample_40	53 64 93 433 41 77	1.5% 1.6% 1.8% 1.3% 1.5%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Eliviang, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Norte, 2019 Palstam, 2014	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39 sample_40 sample_43	53 64 93 433 41 77 73	1.5% 1.6% 1.8% 1.3% 1.5% 0.9%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09] 0.03 [-0.20; 0.26]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39 sample_40 sample_43 sample_43	53 64 93 433 41 77 73 73	1.5% 1.6% 1.8% 1.3% 1.5% 0.9% 0.9%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09] 0.03 [-0.20; 0.26] -0.14 [-0.36; 0.09]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Norte, 2019 Palistam, 2014 Palistam, 2014 Palistam, 2009	sample_13 sample_15 sample_22 sample_28 sample_31 sample_40 sample_43 sample_43 sample_43 sample_50	53 64 93 433 41 77 73 73 98	1.5% 1.6% 1.8% 1.3% 1.5% 0.9% 0.9% 1.6%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09] 0.03 [-0.20; 0.26] -0.14 [-0.36; 0.09] -0.39 [-0.55; -0.21]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Elfving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Navaro-Ledesma, 2029 Palstam, 2014 Roaldsen, 2009	sample_13 sample_15 sample_22 sample_28 sample_39 sample_40 sample_43 sample_43 sample_43 sample_50 sample_51	53 64 93 433 41 77 73 73 98 460	1.5% 1.6% 1.3% 1.5% 0.9% 0.9% 1.6% 1.8%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09] -0.39 [-0.55; -0.21] -0.02 [-0.12; 0.07]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Navarro-Ledesma, 2022 Norte, 2019 Palstam, 2014 Roaldsen, 2021 Sandia, 2021 Sandia, 2021	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39 sample_40 sample_43 sample_50 sample_51 sample_52	53 64 93 433 41 77 73 73 98 460 105	1.5% 1.6% 1.3% 1.5% 0.9% 0.9% 1.6% 1.8% 1.6%	-0.00 [-0.27; 0.27] -0.31 [-0.52; -0.07] 0.10 [-0.11; 0.30] 0.06 [-0.03; 0.15] -0.06 [-0.36; 0.25] -0.31 [-0.50; -0.09] -0.39 [-0.56; 0.09] -0.39 [-0.55; -0.21] -0.02 [-0.12; 0.07] -0.57 [-0.69; -0.42]	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Navaro-Ledesma, 2029 Palistam, 2014 Roaldsen, 2009 Sandal, 2021 Sandal, 2021	sample_13 sample_15 sample_28 sample_28 sample_28 sample_39 sample_40 sample_43 sample_43 sample_51 sample_52 sample_53	53 64 93 433 41 77 73 73 98 460 105 163	1.5% 1.6% 1.8% 1.3% 1.5% 0.9% 1.6% 1.6% 1.6% 1.7%	$\begin{array}{c} -0.00 \left[0.27, 0.27 \right] \\ -0.31 \left[0.52, 0.07 \right] \\ 0.10 \left[-0.11 \right] \\ 0.30 \left[-0.31 \right] \\ 0.06 \left[-0.33 \right] \\ 0.31 \left[-0.50 \right] \\ -0.31 \left[-0.55 \right] \\ -0.31 \left[-0.55 \right] \\ -0.32 \left[-0.55 \right] \\ -0.37 \left[-0.69 \right] \\ -0.31 \left[-0.17 \right] \\ -0.31 \left[-0.1$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Cariyan, 2015 Ekinag, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Norte, 2019 Palstam, 2014 Roaldsen, 2020 Sandal, 2021 Saulicz, 2016 Sertel, 2021	sample_13 sample_15 sample_22 sample_28 sample_31 sample_39 sample_40 sample_43 sample_50 sample_51 sample_52	53 64 93 433 41 77 73 98 460 105 163 80	1.5% 1.6% 1.8% 1.5% 0.9% 1.6% 1.6% 1.6% 1.7% 1.5%	$\begin{array}{c} -0.00 \left[+0.27, \ 0.27 \right] \\ -0.31 \left[-0.52, \ 0.07 \right] \\ -0.31 \left[-0.52, \ 0.07 \right] \\ 0.06 \left[-0.36, \ 0.25 \right] \\ -0.06 \left[-0.36, \ 0.25 \right] \\ -0.31 \left[-0.50, \ -0.09 \right] \\ -0.31 \left[-0.36, \ 0.09 \right] \\ -0.38 \left[-0.55, \ -0.21 \right] \\ -0.22 \left[-0.12, \ 0.07 \right] \\ -0.22 \left[-0.12, \ 0.07 \right] \\ -0.57 \left[-0.69, \ -0.42 \right] \\ -0.36 \left[-0.54, \ -0.16 \right] \\ -0.36 \left[-0.54, \ -0.16 \right] \end{array}$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Palistam, 2014 Palistam, 2014 Roaldsen, 2009 Sandal, 2021 Sandal, 2021 Sartel, 2021 Wasiuk-Zowada, 2022 Total (95% Cf)	sample_13 sample_15 sample_28 sample_28 sample_31 sample_30 sample_40 sample_43 sample_54 sample_51 sample_52 sample_53 sample_61	53 64 93 433 41 77 73 98 460 105 163 80 2090	1.5% 1.6% 1.8% 1.5% 0.9% 1.6% 1.6% 1.8% 1.6% 1.7% 1.5% 22.6%	$\begin{array}{c} -0.00 \left[+0.27, \ 0.27 \right] \\ -0.31 \left[-0.52, \ 0.07 \right] \\ -0.01 \left[-0.11, \ 0.30 \right] \\ 0.06 \left[-0.33, \ 0.15 \right] \\ -0.06 \left[-0.36, \ 0.25 \right] \\ -0.31 \left[-0.50, \ 0.09 \right] \\ 0.33 \left[-0.20, \ 0.26 \right] \\ -0.39 \left[-0.55, \ 0.21 \right] \\ -0.20 \left[-0.14 \left[-0.36, \ 0.09 \right] \\ -0.39 \left[-0.55 \left[-0.62 \right] \right] \\ -0.25 \left[-0.69, \ 0.42 \right] \\ -0.26 \left[-0.17, \ 0.13 \right] \\ -0.36 \left[-0.54 \right] \\ -0.26 \left[-0.36, \ 0.11 \right] \end{array}$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Palistam, 2014 Palistam, 2014 Palistam, 2014 Sandia, 2021 Sandia, 2021 Sandia, 2021 Sartel, 2021 Masiuk-Zowada, 2022 Total (95% C)	sample_13 sample_15 sample_22 sample_28 sample_31 sample_30 sample_40 sample_43 sample_43 sample_50 sample_51 sample_52 sample_52 sample_61	53 64 93 433 41 77 73 98 460 105 163 80 2090	1.5% 1.6% 1.8% 1.5% 0.9% 1.6% 1.6% 1.8% 1.6% 1.7% 1.5% 22.6%	$\begin{array}{c} -0.00 \left[+0.27, \ 0.27 \right] \\ -0.31 \left[-0.52, \ 0.07 \right] \\ -0.01 \left[-0.11, \ 0.30 \right] \\ 0.06 \left[-0.33, \ 0.15 \right] \\ -0.06 \left[-0.36, \ 0.25 \right] \\ -0.31 \left[-0.50, \ 0.09 \right] \\ 0.33 \left[-0.20, \ 0.26 \right] \\ -0.39 \left[-0.55, \ 0.21 \right] \\ -0.20 \left[-0.14 \left[-0.36, \ 0.09 \right] \\ -0.39 \left[-0.55 \left[-0.62 \right] \right] \\ -0.25 \left[-0.69, \ 0.42 \right] \\ -0.26 \left[-0.17, \ 0.13 \right] \\ -0.36 \left[-0.54 \right] \\ -0.26 \left[-0.36, \ 0.11 \right] \end{array}$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Navarro-Ledesma, 2022 Navarro-Ledesma, 2029 Palstam, 2014 Roaldsan, 2009 Sandal, 2021 Sandal, 2021 Sandal, 2021 Nasiuk-Zowada, 2022 Total (95% CI) Heterogenety: Tau ² = 0.0658 PA_outcome = Kcal/dag	sample_13 sample_15 sample_22 sample_28 sample_39 sample_40 sample_40 sample_43 sample_50 sample_51 sample_52 sample_53 sample_61 t, Chi ² = 102.61,	53 64 93 433 41 77 73 98 460 105 163 80 2090 df = 15	1.5% 1.6% 1.8% 1.5% 0.9% 1.6% 1.6% 1.6% 1.7% 1.5% 22.6% (P < 0.01);	$\begin{array}{c} -0.00 \left[-0.27, \ 0.27 \right] \\ -0.31 \left[-0.52, -0.07 \right] \\ 0.10 \left[-0.11, \ 0.30 \right] \\ 0.06 \left[-0.03, \ 0.15 \right] \\ -0.06 \left[-0.30, \ 0.15 \right] \\ -0.06 \left[-0.30, \ 0.15 \right] \\ -0.01 \left[-0.50, -0.00 \right] \\ 0.03 \left[-0.55, \ 0.00 \right] \\ -0.31 \left[-0.55, \ 0.02 \right] \\ -0.39 \left[-0.55, \ 0.02 \right] \\ -0.39 \left[-0.55, \ 0.02 \right] \\ -0.36 \left[-0.55, \ 0.42 \right] \\ -0.36 \left[-0.54, \ 0.16 \right] \\ -0.36 \left[-0.54, \ 0.16 \right] \\ -0.36 \left[-0.54, \ 0.16 \right] \\ -0.36 \left[-0.54, \ 0.16 \right] \\ -0.36 \left[-0.54, \ 0.16 \right] \\ -0.24 \left[-0.36 \right] \\ -0.51 \left[$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014 Palstam, 2014 Palstam, 2014 Saudiaz, 2016 Saudaz, 2016 Saudaz, 2016 Sarda, 2021 Saudaz, 2016 Sarda, 2021 Saudaz, 2016 Sarda, 2021 Catal (95% C) = 0.0658 PA_outcome = Kcal/dag Shadema, 2020	sample_13 sample_15 sample_22 sample_22 sample_23 sample_39 sample_43 sample_43 sample_54 sample_52 sample_52 sample_61 t; Chl ² = 102.61. y sample_55	53 64 93 433 41 77 73 98 460 105 163 80 2090 df = 15	1.5% 1.6% 1.8% 1.3% 1.5% 0.9% 1.6% 1.6% 1.6% 1.5% 22.6% (P < 0.01): 1.5%	$\begin{array}{c} -0.00 \left[-0.27 \right] \left(0.27 \right) \\ -0.27 \left(0.27 \right) \\ -0.31 \left[-0.52 \left(0.07 \right) \\ -0.06 \left[-0.33 \left(1.05 \left(0.25 \right) \\ -0.06 \left[-0.36 \left(0.25 \right) \\ -0.06 \left[-0.36 \left(0.25 \right) \\ -0.08 \left[-0.55 \left(0.21 \right) \\ -0.08 \left[-0.55 \left(-0.21 \right) \\ -0.28 \left(-0.56 \left(-0.27 \right) \\ -0.24 \left[-0.36 \left(-0.27 \right) \\ -0.24 \left[-0.36 \left(-0.27 \right) \\ -0.28 \left(-0.57 \right) \\ -0.28 \left[-0.57 \right) \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ \end{array} \right]$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvalho, 2017 Coora, 2018 Elrving, 2007 Koho, 2017 Luthi, 2022 Navarro-Ledesma, 2022 Navarro-Ledesma, 2029 Palistam, 2014 Roaldsen, 2009 Palistam, 2014 Sandia, 2021 Sandia, 2021 Sandia, 2021 Sandia, 2021	sample_13 sample_15 sample_22 sample_28 sample_39 sample_40 sample_40 sample_43 sample_50 sample_51 sample_52 sample_53 sample_61 t, Chi ² = 102.61,	53 64 93 433 41 77 73 98 460 105 163 80 2090 df = 15	1.5% 1.6% 1.8% 1.3% 0.9% 0.9% 1.6% 1.8% 1.6% 1.7% 22.6% (P < 0.01): 1.5% 0.7%	$\begin{array}{c} -0.00 \left[-0.27 \right] \ 0.27$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014 Palstam, 2014 Palstam, 2014 Saudiaz, 2016 Saudaz, 2016 Saudaz, 2016 Sarda, 2021 Total (95% CI)	sample_13 sample_12 sample_22 sample_28 sample_40 sample_40 sample_40 sample_43 sample_50 sample_52 sample_61 t_Ch ² = 102.61. y sample_55 sample_57	53 64 93 433 433 77 73 98 460 105 165 165 165 165 165 460 02090 df = 15	$\begin{array}{c} 1.5\%\\ 1.6\%\\ 1.8\%\\ 1.8\%\\ 1.5\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.7\%\\ \textbf{22.6\%}\\ (P < 0.01):\\ \end{array}$	$\begin{array}{c} -0.00 \left[-0.27 \right] \left(-2.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.06 \left[-0.33 \right] \left(-0.52 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.08 \left[-0.57 \right] \left(-0.57 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.36 \left[-0.57 \right] \left(-0.67 \right) \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.58 \left[-0.57 \right] \\$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014 Palstam, 2014 Palstam, 2014 Saudiaz, 2016 Saudaz, 2016 Saudaz, 2016 Sarda, 2021 Total (95% CI)	sample_13 sample_12 sample_22 sample_28 sample_40 sample_40 sample_40 sample_43 sample_50 sample_52 sample_61 t_Ch ² = 102.61. y sample_55 sample_57	53 64 93 433 433 77 73 98 460 105 165 165 165 165 165 460 02090 df = 15	$\begin{array}{c} 1.5\%\\ 1.6\%\\ 1.8\%\\ 1.8\%\\ 1.5\%\\ 0.9\%\\ 0.9\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.7\%\\ \textbf{22.6\%}\\ (P < 0.01):\\ \end{array}$	$\begin{array}{c} -0.00 \left[-0.27 \right] \left(-2.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.06 \left[-0.33 \right] \left(-0.52 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.08 \left[-0.57 \right] \left(-0.57 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.36 \left[-0.57 \right] \left(-0.67 \right) \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.58 \left[-0.57 \right] \\$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Corrigan, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014 Palstam, 2014 Palstam, 2014 Palstam, 2014 Saudiaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Saudaz, 2016 Catal, (95% C) Heterogenetiy: Tau ² = 0.0658	sample_13 sample_25 sample_22 sample_28 sample_39 sample_40 sample_40 sample_43 sample_51 sample_51 sample_52 sample_61 ; Chi ² = 102.61, y sample_55 sample_57 ; Chi ² = 1.32, dl	53 64 93 433 41 77 73 98 460 105 163 80 2090 df = 15 61 20 81 7 = 1 (P =	1.5% 1.6% 1.8% 1.3% 0.9% 0.9% 1.6% 1.6% 1.6% 1.6% 1.5% 0.7% 22.6% (P < 0.01); 1.5% 0.7% 2.1%	$\begin{array}{c} -0.00 \left[-0.27 : 0.27 \right] \\ -0.01 \left[-0.52 : 0.07 \right] \\ -0.31 \left[-0.52 : 0.07 \right] \\ 0.06 \left[-0.33 : 0.15 \right] \\ -0.06 \left[-0.33 : 0.15 \right] \\ -0.06 \left[-0.33 : 0.25 \right] \\ -0.31 \left[-0.50 : -0.09 \right] \\ -0.35 : 0.21 \right] \\ -0.39 \left[-0.55 : -0.21 \right] \\ -0.39 \left[-0.55 : -0.21 \right] \\ -0.39 \left[-0.55 : -0.21 \right] \\ -0.36 \left[-0.54 : -0.16 \right] \\ -0.36 \left[-0.54 : -0.16 \right] \\ -0.36 \left[-0.54 : -0.16 \right] \\ -0.36 \left[-0.54 : -0.13 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.38 \left[-0.57 : -0.39 \right] \\ -0.57 : -0.38 \left[-0.57 : -0.39 \right] \\ -0.58 : -0.38 \left[-0.57 : -0.39 \right] \\ -0.58 : -0.58 : -0.58 \right] \\ -0.58 : -0.58 : -0.58 : -0.58 \right] \\ -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58 : -0.58$	
PA_outcome = Score Aydemir, 2022 Bernard, 2015 Carvaho, 2017 Carvaho, 2017 Carvaho, 2018 Eliving, 2007 Koho, 2011 Luthi, 2022 Norte, 2019 Palstam, 2014 Palstam, 2014 Palstam, 2014 Palstam, 2014 Saudiaz, 2016 Saudiaz, 2018 Saudiaz,	sample_13 sample_25 sample_22 sample_28 sample_39 sample_40 sample_40 sample_43 sample_51 sample_51 sample_52 sample_61 ; Chi ² = 102.61, y sample_55 sample_57 ; Chi ² = 1.32, dl	53 64 93 433 41 77 73 98 460 105 163 80 2090 df = 15 61 20 81 7 = 1 (P =	1.5% 1.6% 1.8% 1.3% 0.9% 0.9% 1.6% 1.6% 1.6% 1.6% 1.5% 0.7% 22.6% (P < 0.01); 1.5% 0.7% 2.1%	$\begin{array}{c} -0.00 \left[-0.27 \right] \left(-2.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.31 \left[-0.52 \right] \left(-0.77 \right) \\ -0.06 \left[-0.33 \right] \left(-0.52 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.06 \left[-0.36 \right] \left(-0.57 \right) \\ -0.08 \left[-0.57 \right] \left(-0.57 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.39 \left[-0.55 \right] \left(-0.17 \right) \\ -0.36 \left[-0.57 \right] \left(-0.67 \right) \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.24 \left[-0.36 \right] \\ -0.28 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.28 \left[-0.57 \right] \\ -0.38 \left[-0.57 \right] \\ -0.58 \left[-0.57 \right] \\$	

 $\begin{array}{l} \mbox{Heterogeneity: Tau^2 = 0.0634; Chi^2 = 564.77, df = 82 \ (P < 0.01); \ l^2 = 85\% \\ \mbox{Residual heterogeneity: Tau^2 = 0.0664; Chi^2 = 553.85, df = 77 \ (P < 0.01); \ l^2 = 86\% \\ \mbox{Test for subgroup differences: } F = 0.72, df = 5, 77 \ (P = 0.61) \end{array}$

Supplemental Figure 7. Subgroup meta-analysis: Differences by kinesiophobia measurement instrument.

Study or Subgroup	Cluster	Total	Weight	Correlation IV, Random, 95% CI	Correlation IV, Random, 95% CI
Kinesiophobia_measur	re = FABQ				
Alamam, 2019	sample_1	100	1.6%	-0.17 [-0.35; 0.03]	
Demmelmaier, 2018 Glaviano, 2017	sample_19 sample_23	2009	1.0%	-0.07 [-0.11; -0.03] -0.48 [-0.76; -0.05]	
Ho-A-Tham, 2022	sample_25	210	1.7%	-0.04 [-0.17: 0.10]	
Koppenaal, 2023	sample_29	204	0.9%	-0.06 [-0.20; 0.08]	
Koppenaal, 2023	sample_29	204	0.9%	-0.03 [-0.17; 0.11]	
Marshall, 2017 Marshall, 2021	sample_33	218 508	1.7%	-0.24 [-0.36; -0.11]	
Marshall, 2022	sample_34 sample_35	393	1.8%	-0.28 [-0.36; -0.20] -0.01 [-0.11; 0.09]	-
Palstam, 2014	sample_43	73	0.9%	0.03 [-0.20; 0.26]	
Palstam, 2014	sample_43	73	0.9%	-0.14 [-0.36; 0.09]	
Polaski, 2021	sample_47	38	1.3%	-0.03 [-0.35; 0.29]	
Rabey, 2017 Roaldsen, 2009	sample_49 sample_50	266 98	1.8% 1.6%	0.07 [-0.05; 0.19] -0.39 [-0.55; -0.21]	
Sandal, 2021	sample_50	460	1.8%	-0.02 [-0.12; 0.07]	-
Total (95% CI) Heterogeneity: Tau ² = 0.0626		5434	21.5%	-0.13 [-0.27: 0.02]	-
Kinesiophobia_measur					
Alschuler, 2011	sample_2	20	1.0%	-0.48 [-0.76; -0.05]	
Altug, 2016	sample_3	112	1.6%	-0.10 [-0.28; 0.09]	
Alzahrani, 2021	sample_4	26	0.5%	0.22 [-0.18; 0.56]	
Alzahrani, 2021 Alzahrani, 2021	sample_4 sample_4	26 26	0.5%	-0.05 [-0.43; 0.34] -0.21 [-0.55; 0.19]	
Assadourian, 2020	sample_4 sample_5	123	1.6%	-0.02 [-0.20; 0.16]	
Aydemir, 2022	sample_6	37	1.3%	-0.77 [-0.88; -0.60]	
Aykut Selcuk, 2020	sample_7	67	1.1%	-0.25 [-0.46; -0.01]	
Aykut Selcuk, 2020	sample_7	29	0.5%	-0.31 [-0.61; 0.06]	
Baday-Keskin, 2022	sample_8	88	1.6%	-0.12 [-0.32; 0.09]	
Bahar Ozdemir, 2021	sample_10	101	1.6%	-0.01 [-0.20; 0.19]	
Baykal Sahin, 2021 Bernard, 2015	sample_11 sample_12	98 121	1.6% 1.6%	-0.32 [-0.48; -0.12] -0.05 [-0.23; 0.13]	
Carvalho, 2015	sample_12 sample_13	119	0.6%	-0.18 [-0.35; -0.00]	
Carvalho, 2017	sample 13	119	0.6%	0.09 [-0.09; 0.27]	
Carvalho, 2017	sample_13	119	0.6%	-0.02 [-0.20; 0.16]	
Corrigan, 2018	sample_15	53	1.4%	-0.00 [-0.27; 0.27]	
Cromert, 2021	sample_16	139	1.7%	-0.13 [-0.29; 0.04]	+
Demirbuken, 2016	sample_18	99 290	1.6%	-0.15 [-0.34; 0.05]	
Dogan, 2022 Donnarumma, 2017	sample_20 sample_21	290 51	1.8%	-0.06 [-0.17; 0.05] -0.35 [-0.57; -0.08]	
Helmus, 2012	sample_21 sample_24	53	1.4%	-0.05 [-0.32; 0.22]	
Igelstrom, 2013	sample_24	73	0.9%	-0.25 [-0.45; -0.02]	
Igelstrom, 2013	sample_26	73	0.9%	-0.11 [-0.33; 0.12]	
Kilinc, 2019	sample_27	200	1.7%	-0.69 [-0.76; -0.61]	-
Koho, 2011	sample_28	93	1.6%	0.10 [-0.11; 0.30]	
Lotzke, 2018 Luthi, 2022	sample_30 sample_31	118 433	1.6% 1.8%	-0.19 [-0.36; -0.01] 0.06 [-0.03; 0.15]	
Masse-Alarie, 2016	sample_36	22	1.0%	0.091-0.34 0.491	
Miller, 2018	sample_37	52	1.4%	-0.54 [-0.71; -0.31]	
Norte, 2019	sample_40	77	1.5%	-0.31 [-0.50; -0.09]	
Ozer, 2022	sample_41	62	1.5%	-0.89 [-0.93; -0.82]	·
Ozlu, 2022	sample_42	45	1.4%	0.15 [-0.15; 0.42]	
Peres, 2023 Peres, 2023	sample_46	50 50	0.8%	-0.25 [-0.49; 0.03] 0.17 [-0.11; 0.43]	
Priore, 2020	sample_46 sample_48	50	1.4%	-0.25 [-0.49; 0.03]	
Sertel, 2021	sample_53	163	1.7%	-0.02 [-0.17; 0.13]	
Smulligan, 2023	sample_54	23	0.5%	-0.18 [-0.55; 0.25]	
Smulligan, 2023	sample_54	23	0.5%	-0.34 [-0.66; 0.08]	
Smulligan, 2023	sample_54	18	0.3%	-0.60 [-0.83; -0.18]	
Smulligan, 2023	sample_54	18	0.3%	-0.63 [-0.85; -0.23]	
Sutcu, 2021 Sutcu, 2021	sample_57	20 20	0.7%	-0.32 [-0.67; 0.14]	
Wasiuk-Zowada, 2022	sample_57 sample_61	80	1.5%	-0.54 [-0.79; -0.13] -0.36 [-0.54; -0.16]	
Total (95% CI) Heterogeneity: Tau ² = 0.0626		3679	50.7%	-0.23 [-0.32; -0.14]	-
		df = 43	(P < 0.01);	1 = 0078	
Kinesiophobia_measur Baez, 2020	sample 0	40	1.3%	0.18 [-0.14; 0.47]	
Baez, 2020 Marques-Sule, 2022	sample_9 sample_32	40	1.3%	-0.32 [-0.47; -0.15]	
Minetama, 2022	sample_32 sample_38	71	1.5%	-0.23 [-0.44; 0.00]	_
Navarro-Ledesma, 2022		41	1.3%	-0.06 [-0.36; 0.25]	
Pastor-Mira, 2020	sample_44	274	1.8%	0.01 [-0.11; 0.13]	
Pedler, 2018	sample_45	103	1.6%	0.14 [-0.06; 0.32]	-
Suttmiller, 2022	sample_58	126	1.6%	0.22 [0.05; 0.38]	
Zelle, 2016 Total (95% CI)	sample_63	487 1259	1.8% 12.6%	-0.22 [-0.30; -0.13] -0.04 [-0.23; 0.15]	-
Heterogeneity: Tau ² = 0.0626	i; Chi ² = 39.55, e			= 82%	
Kinesiophobia_measur	re = TSK_13	248	4.74	0.051047.000	
Coronado, 2021 Elfving, 2007	sample_14 sample_22	248	1.7% 1.5%	-0.05 [-0.17; 0.08] -0.31 [-0.52; -0.07]	
Zadro, 2019	sample_22 sample_62	60	0.9%	-0.12 [-0.36; 0.14]	-
Total (95% CI) Heterogeneity: Tau ² = 0.0626		372	4.1%	-0.16 [-0.44; 0.16]	
			3.117.1		
Kinesiophobia_measur Dabek, 2020	re = TSK_He sample_17	art 72	0.3%	-0.43 [-0.60; -0.22]	
Dabek, 2020	sample_17 sample_17	18	0.1%	-0.87 [-0.95; -0.67]	
Dabek, 2020	sample_17	130	0.5%	-0.52 [-0.64; -0.39]	-
Dabek, 2020	sample_17	119	0.5%	-0.41 [-0.55; -0.25]	-
Dabek, 2020 Dabek, 2020	sample_17 sample_17	27 86	0.1%	-0.20 [-0.54; 0.19] -0.56 [-0.69; -0.40]	
Dabek, 2020	sample_17	15	0.1%	-0.66 [-0.88; -0.23]	
Total (95% CI) Heterogeneity: Tau ² = 0.0626		467	1.9%	-0.51 [-0.78; -0.08]	
		011			
Kinesiophobia_measur Saulicz, 2016	sample_52	105	1.6%	-0.57 [-0.69; -0.42]	-
Kinesiophobia_measur		(127	1202201		
Spadema, 2020	sample_55	61	1.5%	-0.28 [-0.50; -0.03]	
Kinesiophobia_measur Strandberg, 2022	re = TSK_14 sample_56	451	1.8%	-0.08 [-0.17; 0.01]	
Kinesiophobia_measur	e = BFOMS	0			
Uritani, 2020	sample_59	167	1.7%	-0.16 [-0.31; -0.01]	-
	re = BBQ	222	1.7%	-0.35 [-0.46; -0.23]	
Kinesiophobia_measur	sample_60	223			
Kinesiophobia_measur Wang , 2023 Kinesiophobia_measur	sample_60	60			
Kinesiophobia_measur Wang , 2023 Kinesiophobia_measur Zadro, 2019	sample_60 re = TSK_12 sample_62	60	0.9%	-0.18 [-0.41; 0.08]	-
Kinesiophobia_measur Wang , 2023 Kinesiophobia_measur Zadro, 2019 Total (95% CI) Prediction interval	sample_60 re = TSK_12 sample_62	60	0.9%		

 $\begin{array}{l} \mbox{Heterogeneity: Tau^2 = 0.0634; Chr^2 = 564, 77, df = 82 (P < 0.01); l^2 = 85\%, \\ \mbox{Residual heterogeneity: Tau^2 = 0.0575; Chr^2 = 429.28, df = 72 (P < 0.01); l^2 = 83\% \\ \mbox{Test for subgroup differences: } F = 1.00, df = 10, 72 (P = 0.45) \end{array}$